Compounds and methods for targeted degradation of the androgen receptor

Bifunctional compounds targeting androgen receptors to E3 ubiquitin ligases for degradation address the specificity and efficacy issues in prostate cancer treatment, providing a novel approach for targeted protein regulation.

JP7590399B2Active Publication Date: 2024-11-26ARVINAS OPERATIONS INC

Patent Information

Application Number
JP2022210062
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-07-03
Filing Date
2022-12-27
Publication Date
2024-11-26
Estimated Expiration
2037-10-11

AI Technical Summary

Technical Problem

Current treatments for prostate cancer and other diseases involving androgen receptors lack specificity and efficacy, as existing drugs often lead to resistance and progression due to the inability to target and regulate these proteins effectively.

Method used

Development of bifunctional compounds, known as PROTACs, which recruit endogenous proteins like the androgen receptor to E3 ubiquitin ligases for targeted degradation and inhibition, utilizing a cereblon E3 ubiquitin ligase binding moiety and a protein targeting moiety linked by a chemical linker.

Benefits of technology

These compounds enable specific and tunable regulation of androgen receptors, potentially offering alternative therapeutic approaches for prostate cancer and Kennedy's disease by degrading or inhibiting target proteins effectively.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590399000414
    Figure 0007590399000414
  • Figure 0007590399000415
    Figure 0007590399000415
  • Figure 0007590399000416
    Figure 0007590399000416
Patent Text Reader

Abstract

Bifunctional compounds are provided that find utility in degrading and (inhibiting) the androgen receptor. [Solution] The present disclosure provides compounds that contain a cereblon ligand on one end that binds to an E3 ubiquitin ligase and a moiety on the other end that binds to the androgen receptor, thereby bringing the androgen receptor into proximity with the ubiquitin ligase, resulting in degradation (and inhibition) of the androgen receptor.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Patent Application No. 62 / 406,888, filed October 11, 2016, and U.S. Provisional Patent Application No. 62 / 406,888, filed July 11, 2017. This application claims priority to U.S. Provisional Patent Application No. 62 / 528,385, filed on March 3, 2014, and all of those applications. No. 60 / 699,493, filed Dec. 29, 2003, incorporated herein by reference in its entirety and for all purposes.

[0002] STATEMENT REGARDING FEDERALLY FUNDED RESEARCH This invention was funded by the National Cancer Institute under grant number 1R44CA20319 This invention was made with government support under Patent Application No. 9-01. The government has certain rights in this invention.

[0003] Incorporation by Reference U.S. Patent Application No. 14 / 686,640, filed April 14, 2015, U.S. Patent Application Publication No. 2016 / 0058 Published as U.S. Patent Application No. 14 / 792,414, filed July 6, 2015. Published as U.S. Patent Application No. 14 / 371,956, filed July 11, 2014, U.S. Patent Application No. Published as Patent Application Publication No. 2014 / 0356322. U.S. Patent Application No. 15 / 074,820, March 18, 2016 , which application was published as U.S. Patent Application Publication No. 2016 / 0272639. These patent applications are incorporated herein by reference in their entirety. Additionally, all references cited herein are incorporated by reference. It is incorporated herein in its entirety.

[0004] The present invention provides an imide-based compound, and a bifunctional compound containing the compound. and related methods for their use. The bifunctional compounds are capable of targeting ubiquitination. are useful as regulators, and in particular, are degraded and / or modified by the bifunctional compounds according to the present disclosure. The present invention is useful for a variety of polypeptides and other proteins that are inhibited by other means. In certain embodiments, the bifunctional compound inhibits cereblon E3 ubiquitin ligase (CR Cereblon E3 ubiquitin ligase binding moiety that binds to a target protein (e.g., a a target protein binding moiety that binds to the androgen receptor (androgen receptor), and optionally the cereblon binding moiety These compounds contain a linker moiety that connects the binding moiety to the target protein binding moiety. The target protein / polypeptide is brought into close proximity to the ubiquitin ligase, which then binds the protein. in a manner that affects the degradation (and inhibition) of proteins (e.g., androgen receptors) It works. [Background technology]

[0005] Most small molecule drugs bind closely and in well-defined pockets to enzymes or receptors. On the other hand, small molecules are used to detect protein-protein interactions. Targeting is notoriously difficult because of the large number of protein contacts. Due to the large surface area and shallow grooved or flat interfaces involved E3 ubiquitin ligases, of which several hundred are known in humans, It confers substrate specificity to the catalysis, and therefore has specificity for specific protein substrates and is generalizable. This makes it a more attractive therapeutic target than conventional proteasome inhibitors. The development of new drugs inevitably disrupts protein-protein interactions. However, this has proven difficult in part because of the lack of ligase activity. Specific ligands that bind to E3 ligases have been developed in recent years, including the first small molecule E3 ligase inhibitors. Since the discovery of nutrin, additional compounds targeting E3 ligases have been reported. However, much of this field is still underdeveloped.

[0006] One E3 ligase with therapeutic potential is regulated by the CRBN gene in humans. The orthologue of CRBN is Cereblon, a protein encoded by It is highly conserved from plants to humans, which underscores its physiological importance. Cereblon binds damaged DNA-binding protein 1 (DDB1), cullin ( Cullin-4A (CUL4A) and E3 ubiquitination with regulator of cullins1 (ROC1) It forms an ubiquitin ligase complex that ubiquitinates many other proteins. cereblon ubiquitinates its target protein through a mechanism that is not fully understood. The increase in fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10) levels FGF8 then mediates numerous developmental processes, such as the formation of limbs and otic vesicles. This ubiquitin ligase complex is known to be important for limb development in the embryo. The final conclusion is that in the absence of cereblon, DDB1 forms a complex with DDB2. and functions as a DNA damage-binding protein.

[0007] Thalidomide is approved for the treatment of many immunological indications and for the treatment of multiple bone diseases. It is also approved for the treatment of certain neoplastic diseases, including myeloma. Thalidomide and several of its analogs are also currently used to treat a variety of other types of cancer. The exact mechanism of thalidomide's antitumor activity is still unknown. Although the mechanism of action is still being elucidated, it is known that imides inhibit angiogenesis. Recent papers to be discussed include Lu et al. Science 343, 305 (2014) and Kronke et al. Science 343, 301 (2014).

[0008] Significantly, thalidomide and its analogs, e.g., pomolaminoide linamiode and lenalinomide are known to bind to cereblon. These agents bind to cereblon and alter the specificity of the complex, resulting in multiple myeloma. Ubiquitination of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors essential for tumor growth In fact, high expression and activity of cereblon in the treatment of multiple myeloma have been shown to be beneficial. The increased efficacy of amides is associated with

[0009] The androgen receptor (AR) is a receptor that binds to hormones such as testosterone and dihydrotestosterone. It belongs to the family of nuclear hormone receptors activated by androgens (Pharm acol. Rev. 2006, 58(4), 782-97; Vitam. Horm. 1999, 55:309-52). In the absence of Hsp90, AR is bound to heat shock protein 90 (Hsp90) in the cytoplasm. When androgen binds to AR, its conformation changes, releasing AR from Hsp90. , the nuclear localization signal (NLS) is exposed. is able to translocate into the nucleus, where it acts as a transcription factor to induce male sexual characteristics. promotes the expression of genes involved in the 02, 16(10), 2181-7). AR deficiency is a condition known as androgen deprivation, formerly known as testicular feminization syndrome. induces steroid refractoriness.

[0010] AR is involved in the development of male sexual characteristics, but in certain forms of cancer, including prostate cancer, It has also been reported that it is a gene (Endocr. Rev.2004, 25(2), 276-308). The target gene of AR activity being measured is the secreted prostate-specific antigen (PSA) protein. Current treatment regimens for prostate cancer involve blocking the androgen-AR axis in two ways: The first method relies on androgen depletion, and the second method relies on AR function. (Nat. Rev. Drug Discovery, 2013, 12,823-824). Despite the development of effective treatments, many patients develop resistance and progress with the disease. An alternative approach to treating prostate cancer involves removing the AR protein. It is a key inducer of tumorigenesis in many types of prostate cancer, and its elimination is a therapeutically beneficial response. This should result in:

[0011] There is an ongoing need for effective treatments for diseases, particularly cancer, prostate cancer, and Kennedy's disease. However, for example, transcription factors have non-specific actions and This is due to the inability to target and regulate a specific class of proteins as a whole. This remains an obstacle to the development of effective anticancer drugs. While enhancing or enhancing the activity of proteins, a wide range of protein species can be targeted and specifically regulated. Such "tunable" small molecule therapeutic agents would be highly useful as therapeutic agents. Summary of the Invention

[0012] The present disclosure describes bifunctional compounds and methods of using the same, , which functions to recruit endogenous proteins to E3 ubiquitin ligases for degradation. In particular, the present disclosure relates to bifunctional or proteolytic targeting chimeras (PROTACs). The present invention provides targeting chimeric compounds, which can be used in a variety of polypeptides and as a regulator of targeted ubiquitination of other proteins (e.g., androgen receptor). All of the polypeptides and other proteins found to be useful are disclosed herein. The compounds provided herein are decomposed and / or otherwise inhibited by bifunctional compounds. The advantage of the compounds offered is that they may have a broad range of pharmacological activity, effectively targeting all proteins. The present invention is directed to the degradation / inhibition of a target polypeptide from a protein species or family. The document describes the use of methicillin-containing compounds for the treatment or amelioration of disease states, including cancer, e.g., prostate cancer, and Kennedy's disease. Methods using effective amounts of the compounds described herein are provided.

[0013] Thus, in one aspect, the present disclosure provides novel imide-based compounds as described herein. do.

[0014] In a further aspect, the present disclosure provides bifunctional or PROTAC compounds, The compound may be an E3 ubiquitin ligase binding moiety (i.e., a compound that binds to an E3 ubiquitin ligase). ligand, or “ULM” group) and a moiety that binds to the target protein (i.e., protein Protein / polypeptide targeting ligands, or "PTM" groups), thereby targeting the target of interest. The protein / polypeptide is placed in close proximity to the ubiquitin ligase, which then catalyzes the breakdown of the protein. In a preferred embodiment, ULM exerts an anti-inflammatory (and inhibitory) effect on cereblon E3. A bifunctional compound is a biquitin ligase binding moiety (i.e., a "CLM"). The structure can be shown as follows: PTM-CLM.

[0015] the respective positions of the PTM and CLM moieties exemplified herein; and These numbers are provided as examples only and are not intended to limit the compounds in any way. As will be appreciated by those skilled in the art, the bifunctional The compounds are synthesized so that the number and position of each functional moiety can be varied as desired. It is possible.

[0016] In certain embodiments, the bifunctional compound may further comprise a chemical linker (L). In the examples, the structures of the bifunctional compounds can be shown as follows: PTM-L-CLM, where PTM is a protein / polypeptide targeting moiety, L is a chemical linker moiety, Alternatively, it is a bond that connects PTM and CLM, and CLM binds to cereblon E3 ubiquitin ligase. This is the joining part.

[0017] In a particularly preferred embodiment, the E3 ubiquitin ligase is cereblon. In certain additional embodiments, the CLM of the bifunctional compound may be, for example, an imide, an amide, a thioa, or a hydroxyl group. In an additional embodiment, the CLM comprises a hydroxyl group, such as a hydroxyl group, ... In yet further embodiments, C LM comprises a phthalimido-glutarimido group or an analog or derivative thereof. In other embodiments, the CLM is thalidomide, lenalidomide, pomalidomide, and and analogs or derivatives thereof.

[0018] In certain embodiments, the compounds described herein comprise multiple CLMs, multiple PTMs, multiple or a combination thereof.

[0019] The general structure is exemplary and each moiety may be, for example, CLM-L-PTM, and PTM-LC, respectively. It will be understood that the LMs, etc. may be spatially arranged in any desired order or configuration. cormorant.

[0020] In certain embodiments, the PTMs are AR binding moieties (ABMs). In certain embodiments, the ABM is selected from the following structures:

[0021] [ka]

[0022] During the ceremony: W 1 are aryl, heteroaryl, bicyclic, or biheterocyclic, each independently with one or more of H, halo, hydroxyl, nitro, CN, C≡CH, C 1~6 Alkyl (optionally substituted Straight chain, branched chain, e.g., one or more halo, C1~6 optionally substituted with alkoxyl), C 1~6 Alkoxy (straight or branched chain optionally substituted, e.g., optionally substituted with one or more halo) (optionally substituted), C 2~6 Alkenyl, C 2~6 substituted by alkynyl, or CF3; Y 1 , Y 2 are each independently NR Y1 ,O,S; Y 3 , Y 4 , Y 5 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , C=O, C=S, SO, SO 2、 Heteroa reel, or aryl; Q is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally with 0-6 R Q Each R is replaced by Q are independently H, C 1~6 Alkyl (optionally substituted straight or branched chain, e.g. For example, one or more halo, C 1~6 optionally substituted with alkoxyl), halogen, C 1~6 Al Coxy or two R Q The groups may contain 0 to 2 heteroatoms along with the atoms to which they are attached. forming a 3- to 8-membered ring system containing aryl groups); R 1 , R 2 , R a , R b , R Y1 , R Y2 are each independently H, C 1~6 Alkyl (optionally substituted straight chain, Branched chain, e.g., one or more halo, C 1~6 optionally substituted with alkoxyl), halogen, C1 ~6 alkoxy, cyclic, heterocyclic, or R1 , R 2 are the atoms to which they are bonded. Forming a 3-8 membered ring system containing 0-2 heteroatoms; W 2 is a bond, C 1~6 Alkyl, C 1~6 Heteroalkyl, O, C 1~6 Alicyclic, heterocyclic, aryl heteroaryl, biheterocyclic, biaryl, or biheteroaryl, each of which is Any 1 to 10 R W2 is replaced by; Each R W2 are independently H, halo, and C 1~6 Alkyl (optionally substituted straight or branched chain, e.g., one or more optionally replaced by F above), C 1~6 Heteroalkyl (optionally substituted straight or branched chain) , -OR W2A , C 3~6 Cycloalkyl, C 4~6 Cycloheteroalkyl, OC 1~3 Alkyl (optionally substituted, e.g., optionally substituted by one or more -F), C 1~6 Alicyclic (optionally substituted) heterocyclic (optionally substituted), aryl (optionally substituted), or heterocyclic aryl (optionally substituted), bicyclic heteroaryl or aryl, OH, NH2, NR Y1 R Y2 ,CN; R W2A is H, C 1~6 Alkyl (straight chain, branched chain), or C 1~6 Heteroalkyl (straight chain, branched chain), each of which is optionally a cycloalkyl, cycloheteroalkyl, aryl, heterocycle, Heteroaryl, halo, or OC 1~3 A compound substituted with alkyl.

[0023] In an additional aspect, the present disclosure provides a method for treating a rheumatoid arthritis, comprising administering to a subject an effective amount of a compound described herein or a salt form thereof, and and a pharmaceutically acceptable carrier. The therapeutic composition may be administered to a patient or The present invention relates to a method for regulating the degradation of proteins in a subject, e.g., an animal, such as a human, and for the production of the degraded proteins. The compounds can be used to treat or ameliorate symptoms or conditions that are modulated via proteins. In certain embodiments, the therapeutic compositions described herein are used to treat or prevent diseases, such as cancer. are used to degrade and / or inhibit proteins of interest for the purpose of improving In yet another aspect, the present disclosure provides a method for ubiquitinating / transducing a target protein in a cell. In certain embodiments, the method preferably comprises degrading the linker moiety. The method includes administering a bifunctional compound described herein, comprising a CLM and a PTM linked via a In this case, CLM is conjugated to a PTM, and CLM is linked to a ubiquitin pathway protein (e.g., ubiquitin ligase, preferably an E3 ubiquitin ligase such as cereblon) PTM recognizes target proteins and allows them to be ubiquitin ligated to the target proteins. When they are placed in close proximity, degradation of the target protein occurs, and the target protein This results in a reduction / inhibition of the action of the protein, leading to the regulation of protein levels. Controlling the levels of proteins that result in the development of a disease provides treatment for a symptom or condition, which acts through a target protein by reducing the level of that protein in patient cells. is adjusted accordingly.

[0024] In additional embodiments, the present disclosure provides methods for assessing (i.e., determining) the binding affinity of a CLM. In certain embodiments, the method provides a method for measuring (and / or determining) the activity of a protein. phthalimide group, phthalimide-glutarimide group, derivatized thalidomide, derivatized lena a target agent or compound having an imide moiety, such as lidomide or a derivatized pomalidomide providing an investigational agent or subject compound and binding to cereblon; and / or The test drug or compound was compared to an agent or compound known to inhibit the activity of cereblon. or compounds to compare their cereblon-binding affinity and / or cereblon-inhibitory activity. This includes:

[0025] In yet another aspect, the present disclosure provides a method for the treatment of a cancer in a subject or patient, e.g., an animal, e.g., a human. provides a method for treating or ameliorating a disease, disorder, or its symptoms, The method comprises administering to a subject an effective amount, such as a therapeutically effective amount, of a compound described herein or a salt form thereof, and a pharmaceutical and administering to a subject in need thereof a composition comprising an acceptable carrier, wherein The composition is used to treat or ameliorate a disease or disorder or a symptom thereof in a subject. It is valid.

[0026] In another aspect, the present disclosure provides methods for treating cancer in biological systems using compounds according to the present disclosure. A method for identifying the degradative effect of a protein of interest is provided.

[0027] The foregoing general description of utility is provided for illustrative purposes only and is not intended to be limiting of the scope of the present disclosure. and are not intended to limit the scope of the appended claims. Additional objects and advantages associated with the process are set forth in the claims, detailed description, and examples. For example, various aspects and embodiments of the present invention will be apparent to those skilled in the art. The embodiments can be used in many combinations, all of which are expressly set forth herein. These additional beneficial objects and embodiments are expressly contemplated within the scope of this disclosure. For purposes of explaining the background of the invention and, in certain cases, providing additional information regarding its implementation, Publications and other materials used to provide further information are incorporated by reference. do.

[0028] Where applicable, or unless specifically excluded, any of the embodiments described herein One may compare the embodiment with any one or more other embodiments, even if the embodiment is based on different aspects of the present disclosure. Even if the term is written as "combined", it is expected that combinations are possible. The foregoing general description of the present disclosure and the accompanying drawings is presented for illustrative purposes only. The present disclosure is not intended to limit the scope of the claims. Related and additional objects and advantages will become apparent from the following claims, detailed description, and examples. For example, various aspects and embodiments of the present disclosure are readily apparent to those skilled in the art. and combinations thereof, all of which are expressly contemplated by this specification. These additional beneficial objects and embodiments are expressly included within the scope of this disclosure. To explain the background of the present disclosure and, in certain cases, to provide additional details regarding implementation. Publications and other materials used in making this disclosure are incorporated by reference.

[0029] The accompanying drawings, which are incorporated in and form a part of this specification, illustrate several embodiments of the present disclosure. The drawings illustrate embodiments and, together with the written description, serve to explain the principles of the present disclosure. It is for the purpose of illustrating embodiments of the present disclosure only and is not to be construed as limiting the present invention. Further objects, features, and advantages of the present invention are set forth in the accompanying drawings, which illustrate exemplary embodiments of the present disclosure. This will become apparent from the following detailed description taken in conjunction with the drawings. [Brief explanation of the drawings]

[0030] [Figure 1A] Schematic of general principles of PROTAC function. Figure 1A: An exemplary PROTAC includes an androgen receptor targeting moiety (ABM; dark shaded rectangle), an E3 ubiquitin ligase binding moiety (CLM; light shaded triangle), such as a cereblon E3 ubiquitin ligase binding moiety, and a linker moiety (L; black line) that connects or joins the ABM and CLM (as described herein, L can be absent, a bond, or a chemical linker moiety). [Figure 1B] Figure 1B illustrates the functional applications of the PROTACs described herein. Briefly, the CLM recognizes and binds to the cereblon E3 ubiquitin ligase, and the ABM binds and recruits the androgen receptor, bringing it into close proximity with the cereblon E3 ubiquitin ligase. Typically, the E3 ubiquitin ligase, in complex with an E2 ubiquitin-binding protein, catalyzes the attachment of ubiquitin to a lysine on the target protein via an isopeptide bond (dark circle), either alone or via the E2 protein. The polyubiquitinated protein (far right) is then targeted for degradation by the cellular proteosome machinery. [Figure 2] [Figure 2-1] to [Figure 2-36] Table 2 includes exemplary compounds 1 to 75, as well as a general scheme that can be used to prepare each exemplary compound. Table 2 also includes DC50, Dmax, M / Z+, and 1H NMR data for each exemplary compound. DC50 (μM) categories (AR degradation ELISA in LNCaP and / or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. Dmax categories (AR degradation - maximum inhibition (%) AR ELISA in LNCaP and / or VCaP cells): A>50%; B<50%. [Figure 3] [Figure 3-1] to [Figure 3-169] Table 3 includes exemplary compounds 76 to 398, as well as a general scheme that can be used to prepare each exemplary compound. Table 3 also includes DC50, M / Z+, and 1H NMR data for each exemplary compound. DC50 (μM) categories (AR degradation ELISA in LNCaP and / or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. [Figure 4] [Figures 4-1] to [Figures 4-12] Table 4 includes exemplary compounds 399 to 427, as well as a general scheme that can be used to prepare each exemplary compound. Table 4 also includes the DC50, Dmax (%), M / Z+, and 1H NMR data for each exemplary compound. DC50 (μM) categories (AR degradation ELISA in LNCaP and / or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. [Figure 5] [Figures 5-1] to [Figures 5-11] Table 5 includes exemplary compounds 428 to 452. Table 5 also includes DC50, Dmax (%), M / Z+, and 1H NMR data for each exemplary compound. DC50 (μM) categories (AR degradation ELISA in LNCaP and / or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. [Figure 6] [Figure 6-1] to [Figure 6-28] Table 6 includes exemplary compounds 453 to 528. Table 6 also includes DC50, Dmax, M / Z+, and 1H NMR data for each exemplary compound. DC50 (μM) categories (AR degradation ELISA in LNCaP and / or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. Dmax categories (AR degradation - maximum inhibition (%) AR ELISA in LNCaP and / or VCaP cells): A>50%; B<50%. [Figure 7][Figure 7-1] to [Figure 7-167] Table 7 includes exemplary compounds 529 to 625. Table 7 also includes DC50, M / Z+, and 1H NMR data for each exemplary compound. DC50 (μM) categories (AR degradation ELISA in LNCaP and / or VCaP cells): A<1 nM; B: 1-10 nM; C: 10-100 nM; D: >100 nM. DETAILED DESCRIPTION OF THE INVENTION

[0031] The following is a detailed description provided to aid those skilled in the art in practicing the present invention. Those skilled in the art will be able to readily implement the present invention without departing from the spirit or scope of the present disclosure. Modifications and variations of the embodiments described herein may be made. All publications, patent applications, patents, drawings and other references are incorporated by reference in their entirety. Explicitly included.

[0032] The present disclosure provides methods for the production of E3 ubiquitin ligases by chimeric constructs (e.g., PROTACs) described herein. When the E3 ubiquitin ligase protein and the target protein are brought into close proximity, It has been reported that proteins can ubiquitinate target proteins, particularly the androgen receptor. This relates to the surprising and unexpected discovery that in the chimeric construct, the E3 ubiquitin The portion that binds to the ligase protein is the portion that binds to the androgen receptor target protein. Thus, the present disclosure provides a method for the preparation of a target molecule, such as a medicament for the treatment of a cancer. Compounds for the ubiquitination and degradation of proteins, such as the androgen receptor, Compositions containing the compounds, and related methods of use thereof, are provided (see Figures 1A and 1B).

[0033] In certain embodiments, the present disclosure relates to U.S. Patent Application Publication Nos. 2014 / 0356322A1 and 2015 / 0291562A1. No. 2016 / 0214972A1, all of which are incorporated herein by reference. is incorporated herein for the purposes of this application.

[0034] Unless otherwise defined, all technical and scientific terms used herein are It has the same meaning as commonly understood by a person skilled in the art to which this disclosure pertains. The terminology used herein is for the purpose of describing particular embodiments only and does not limit the present invention. It is not intended to determine

[0035] Where a range of values ​​is provided, unless the context clearly dictates otherwise (e.g., a certain number For groups containing carbon atoms, the respective numbers of carbon atoms within the range are provided), Each intervening value between the upper and lower limits of a range and any other specified range, to one-tenth of the unit of the lower limit It is understood that any value between or within the specified range is encompassed within the scope of the present invention. The upper and lower limits of the smaller ranges may independently be included in the smaller ranges, Included within the present invention are any specifically excluded boundary values ​​in the specified ranges. If one or both of the boundary values ​​are included, then either or both of the included boundary values ​​are excluded. The range is also included in the present invention.

[0036] The following terms are used to describe this disclosure. If not defined, the term is used in conjunction with its use in describing this invention. is given its art-recognized meaning by those of ordinary skill in the art applying the term.

[0037] As used herein, the articles "a" and "an" are used interchangeably with "a" and "an" unless the context clearly dictates otherwise. Unless otherwise indicated, the grammatical object of the article in question may be one or more (i.e., at least one) of the grammatical objects of the article. As an example, an "element" is used herein to refer to one or more means an element or elements.

[0038] As used herein in the specification and claims, "and / or" means The phrase "either or both" means "either or both" of the elements so combined. It should be understood that in some instances the elements are present in a conjugated fashion and in other instances they are present in a non-conjugated fashion. Multiple elements listed with "and / or" should be construed in the same manner. "and / or" The fact that other elements than those specifically identified by the "" clause are Thus, non-limiting examples include: When used in conjunction with open-ended language, such as "including," "A and / or B" In one embodiment, the reference to A refers only to A (optionally including elements other than B) and not to another. In some embodiments, it refers to only B (optionally including elements other than A), and in other embodiments, In this case, it refers to both A and B (and optionally includes other elements).

[0039] As used herein in the specification and claims, "or" means any of the above. It should be understood to have the same meaning as the defined "and / or." For example, When separating items within a list, "or" or "and / or" is inclusive. i.e., any one of many elements or a list of elements. Both include one, but also include more than one, and optionally include additional items not listed. For example, "one of," or "exactly one of," or when used in a claim, Only terms that clearly suggest the contrary, such as "consisting of" in refers to the inclusion of exactly one element of a list of elements. In this case, the term "or" is used in place of, for example, "either," "one of," or "one of" is exclusive only when preceded by an exclusive term such as "exclusively one of" or "exactly one of" It should not be interpreted as indicating alternatives (i.e., "one or the other, but not both"). should be interpreted as follows.

[0040] As used herein, the term "about" and the like refers to a numerical value or are subject to art-recognized practical and / or theoretical limitations related to scope. reflects the fact that there is a certain level of variation that is tolerated. Minor variations due to inherent differences in the operation of the device and / or the way measurements are taken. In accordance with the above, the term "about" typically means within a standard deviation or standard error. Used to contain a value.

[0041] In the claims and the specification, the words "comprising" and "including" "ing", "carrying", "having", "containing" , "involving," "holding," "composed of," etc. All transitional phrases in this section are open-ended, meaning including but not limited to. It should be understood that "consisting of" and "consisting essentially of" are only the transitional phrase "sisting essentially of" and a definite or semi-definite transitional phrase, respectively This is set forth in Section 2111.03 of the United States Patent Examining Guidelines.

[0042] As used herein, in the specification and claims, one or more elements With respect to a list of elements, the phrase "at least one" means any one of the elements in the list, or It should be understood to mean at least one element selected from a plurality of elements. necessarily includes at least one of every element specifically listed in the element list It does not exclude any combination of elements in the list of elements. This definition applies to the elements specifically identified in the list of elements referred to by the phrase "at least one." In addition to the elements, any element may be included, regardless of the relevance of those specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" is and one of" (or equivalently "at least one of A or B" or equivalently "A and and / or at least one of B) may, in one embodiment, be a small group containing optionally a plurality of A. In another embodiment, the element A is at least one element A, and B is not present (optionally including elements other than B). In this case, it refers to at least one B, optionally including multiple Bs, and there is no A (optionally including multiple Bs other than A). In yet another embodiment, at least one A, optionally including multiple A's, and refers to at least one B, optionally including multiple Bs (optionally including other elements).

[0043] In certain methods comprising more than one step or action described herein, The order of steps or actions is not to be construed as a sequence of steps or actions of the method unless the context indicates otherwise. The order in which they are listed is not necessarily limited to this.

[0044] The terms "co-administration" and "co-administering" or "combination therapy" refer to Simultaneous administration (two therapeutic agents) is acceptable, provided that the therapeutic agents are present at the same time, preferably in effective amounts. simultaneous administration of the therapeutic agents), and staggered administration (administration of one or more therapeutic agents at different times). (administration at a time different from that of the additional therapeutic agent). In certain embodiments, one or more of the compounds described herein are at least one of the following compounds, including, in particular, anti-cancer agents: In a particularly preferred embodiment, the compound is co-administered in combination with one or more additional bioactive agents. Co-administration results in synergistic activity and / or treatment, including anti-cancer activity.

[0045] The term "effective" when used in the context of its intended use means that such treatment or the symptoms of a condition, disorder or pathology in a subject in need of such treatment. to prevent, inhibit, ameliorate, delay or cure a condition, or to have a sufficient effect against the same It can refer to the amount / dose of active pharmaceutical ingredient that is sufficient (to relieve some, preferably all, of the symptoms) to The term effective includes, but is not limited to, all other effective amounts or concentrations. Terms such as "effective amount / dose," "pharmaceutically effective amount / dose," or "therapeutically effective amount / dose" are used. "amount / dosage" and the like, which are described or used elsewhere in this application.

[0046] The effective amount will depend on the type and severity of the disease, the composition used, the route of administration, and the mammal being treated. the type of object, the physical characteristics of the specific mammal under consideration, the concurrent treatment, and the medical technology field The exact amount can be determined using known techniques, depending on the amount of the compound, the amount of the active ingredient, and other factors that one skilled in the art will recognize. This can be ascertained by one skilled in the art (see, e.g., Lieberman, Pharmaceutical Dosage Form F). orms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Scie nce and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Will (See iams & Wilkins).

[0047] "Pharmacological composition," "therapeutic composition," "therapeutic formulation," or "pharmaceutically acceptable The term "formulation" includes, but is not limited to, any formulation that allows for effective distribution of the agents provided by the present disclosure. These refer to compositions or formulations that are best suited to the body for the desired activity. The formulation is suitable for administration to a targeted location (e.g., systemic administration).

[0048] The terms "pharmaceutically acceptable" or "pharmacologically acceptable" are used interchangeably, as appropriate. adverse reactions, allergic reactions, or other undesirable effects when administered to a substance or person It may refer to, but is not limited to, entities and compositions that do not produce a reaction.

[0049] The term "pharmaceutically acceptable carrier" or "pharmacologically acceptable carrier" refers to a pharmaceutical Any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity, etc., that are compatible with the administration of Suitable carriers include, but are not limited to, agents that delay absorption and the like. The latest edition of Remington's Pharmaceutical Sciences, a standard reference textbook The preferred carriers or diluents are: Suitable examples include, but are not limited to, water, saline, finger solutions, dextrose solutions, etc. Liposomes and non-aqueous solutions such as fixed oils, and 5% human serum albumin. Vehicles may also be used. The use of such vehicles and agents for pharmaceutically active substances Except insofar as any conventional media or agent is incompatible with the active compound, it is well known in the art. Supplementary active compounds can also be incorporated into the compositions. do.

[0050] The term "systemic administration" refers to administration, such as enteral or parenteral administration, that distributes an agent throughout the body. This refers to a route of administration in which the drug is systemically absorbed or accumulated in the bloodstream and subsequently distributed throughout the body. Suitable forms depend in part on the intended use or route of entry, e.g., oral, transdermal, or by injection. Such a form may prevent the composition or formulation from reaching the target cells. (i.e., negatively charged polymers are desirable for delivery to cells). The pharmacological composition injected into the stream must be soluble. Other factors are known in the art. known to the public, for example, toxins and forms that prevent the composition or formulation from exerting its effect. The route of administration that results in systemic absorption is not limited to These include intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary, and intramuscular. The rate of drug entry has been shown to be a function of molecular weight or size. The use of liposomes or other drug carriers containing substances can be used to treat, for example, the reticuloendothelial system (RES). Potential for drug localization in specific tissue types, such as tissues of the vascular endothelial system It can promote the binding of drugs to the surface of cells such as lymphocytes and macrophages. Liposomal formulations are also useful.

[0051] The term "local administration" refers to administration within about 10 cm of the lesion or affected area, for example. Refers to a route of administration by which an agent is delivered to an appropriate or nearby site.

[0052] As used herein, unless otherwise indicated, the term "compound" refers to the compound of interest. It refers to any specific chemical compound disclosed in this document, including tautomers, positional isomers, geometric isomers, and the like. and, where appropriate, optical isomers (enantiomers) and other stereoisomers (diastereoisomers). stereoisomers, including phenethylamines, as well as pharmaceutically acceptable salts thereof, where appropriate in the context. and derivatives (including prodrug forms). Within its use in context, the term compound The term generally refers to a single compound, but may also refer to, for example, stereoisomers and / or optical isomers of the present disclosure. enantiomers (racemic mixtures) as well as mixtures enriched in a specific enantiomer or enantiomers The term may also include other compounds that facilitate administration and localization to the site of activity. The term also refers to prodrug forms of compounds that have been modified to deliver the compound. Please note that many substituents and particularly the variables associated therewith are listed. .

[0053] The molecules described herein are intended to be stable compounds as outlined below. It is understood by the vendor.

[0054] [ka]

[0055] When is shown, both double and single bonds are present in the compound shown, and the valence The relationships are expressed or understood in the context of known rules regarding the interactions of the

[0056] As used herein, a "derivative" refers to a compound derived from a natural compound directly, through modification, or As used herein, "analog" can refer to a composition formed by partial substitution. "A compound" can refer to a composition that has a structure similar to, but not identical to, a naturally occurring compound. .

[0057] The term "ubiquitin ligase" refers to the enzyme that transfers ubiquitin to a specific substrate protein. This refers to a family of proteins that promotes degradation and targets their substrate proteins for degradation. For example, cereblon acts as a ubiquitin-binding enzyme on target proteins, either alone or in conjunction with an E2 ubiquitin-conjugating enzyme. ubiquitination of ATPases, which then target specific protein substrates for proteasomal degradation. It is an E3 ubiquitin ligase protein that targets the target. Therefore, it is complex with E2 ubiquitin-conjugating enzymes. Together or alone, E3 ubiquitin ligases mediate ubiquitination of targeted proteins. Generally, ubiquitin ligases are involved in polyubiquitination and A second ubiquitin is then added to the first, and a third ubiquitin is added to the second. Polyubiquitination marks proteins for proteasomal degradation. However, some ubiquitination events are limited to monoubiquitination, in which case In this case, only one ubiquitin is added to the substrate molecule by the ubiquitin ligase. Proteins that are typified are not targeted for proteasomal degradation but are instead catalyzed by For example, via binding to other proteins that have domains capable of binding ubiquitin. This can cause changes in the location and function of the cell. This suggests that different lysines on ubiquitin can be targeted by E3s to form chains. The most common lysine is Lys48 on the ubiquitin chain, which is involved in the proteasome. It is the lysine that is used to generate polyubiquitin, which is more easily recognized.

[0058] The terms "patient" or "subject" are used throughout this specification to refer to a patient who is receiving a composition according to the present disclosure. Therapies, including prophylactic treatments, are provided for cells, tissues, or animals, preferably, for example, humans. or domestic animals. In relation to the treatment of an infection, condition or disease specific to a dog, the term patient refers to, for example, a dog or Certain animals, including domestic animals such as cats, or agricultural animals, for example horses, cows, sheep, etc. Generally, in this disclosure, the term patient refers to a subject unless otherwise indicated or Unless otherwise implied from the context in which the term is used, it refers to a human patient.

[0059] Compounds and Compositions In one embodiment, the present disclosure provides compounds useful for regulating protein activity. The composition conforms to a defined chemical structure (preferably for E3 ubiquitin ligase alone, or complexed with E2 ubiquitin-conjugating enzymes involved in the transfer of ubiquitin to target proteins a ubiquitin pathway protein binding moiety (for a selected E3 ubiquitin ligase), and or protein targeting moieties linked or attached together via a linker, in which case wherein the ubiquitin pathway protein binding portion recognizes a ubiquitin pathway protein. The targeting moiety recognizes a target protein (e.g., the androgen receptor). The compounds may be referred to herein as PROTAC compounds or PROTACs.

[0060] In one embodiment, the present disclosure provides a method for the production of cereblon E3 ubiquitin ligase-binding moiety (CLM). In one embodiment, a compound comprising an E3 ubiquitin ligase binding moiety (ULM) is provided. wherein the CLM is attached to a chemical linker group (L) according to the following structure: L-CLM (I) where L is a chemical linker group and CLM is a cereblon E3 ubiquitin ligase binding moiety. The number and / or relative positions of moieties in the compounds described herein are for illustrative purposes only. As will be appreciated by those skilled in the art, the compounds described herein may be prepared in a variety of ways, including but not limited to, without limitation, by the use of each functional group. The radical moieties can be synthesized in any desired number and / or relative positions.

[0061] The terms ULM and CLM are used in their inclusive sense unless the context indicates otherwise. For example, the term ULM refers to molecules that bind to cereblon (i.e., CLM). Furthermore, the term CLM encompasses all possible It contains the cereblon E3 ubiquitin ligase binding domain.

[0062] In another embodiment, the present invention provides a compound that is linked via a chemical linker moiety (L) or directly. For example, a compound having two CLMs may have the following structure: It can be illustrated as: CLM-CLM (II) or CLM-L-CLM (III).

[0063] In certain embodiments, when a compound comprises multiple CLMs, the CLMs are identical. In additional embodiments, compounds comprising multiple CLMs can be linked together, either directly or via a chemical linker (L). and / or at least one PTM linked to the CLM via a CLM-binding domain. In certain additional embodiments, the compound comprising multiple CLMs further comprises multiple PTMs. In yet further embodiments, the PTMs are the same or, optionally, different. In yet a further embodiment, when the PTMs are different, each PTM binds to the same protein target. The proteins may be identical or may specifically bind to different protein targets.

[0064] In additional embodiments, the present disclosure provides a method for the preparation of a hydroxyl group-containing hydroxyl group, either directly or via a chemical linker (L), provides compounds comprising at least two different CLMs linked via both of them. For example, such a compound with two different CLMs can be illustrated as follows: CLM-CLM' (IV) or CLM-L-CLM' (V) In the formula, CLM' represents the cereblon E3 ubiquitin ligase binding moiety, which is structurally distinct from CLM. In certain embodiments, the compound comprises multiple CLMs and / or multiple CLMs'. In further embodiments, at least two different CLMs, multiple CLMs, and and / or a compound comprising multiple CLM's, either directly or via a chemical linker, or It further comprises at least one PTM linked to the CLM or CLM' via both. In any of the embodiments described herein, the compound comprising at least two different CLMs may be a compound In yet further embodiments, the PTMs are identical or In yet further embodiments, when the PTMs are different, each PTM may bind to the same protein target or may specifically bind to different protein targets In still further embodiments, the PTM itself may be a ULM or CLM (or ULM' or CL M').

[0065] In another aspect, the present disclosure provides a bifunctional or PROTAC compound, The compound binds to the cereblon E3 ubiquitin ligase binding moiety (CLM), an E3 ubiquitin ligase. The AR binding moiety (ULM) and the AR binding moiety (ABM) are the parts that bind to the target protein. i.e., protein / polypeptide targeting ligands, or "PTM" groups). In the form, the structure of the bifunctional compound can be illustrated as follows: ABM-CLM (VI), The respective positions of the ABM and CLM moieties exemplified herein, and These numbers are provided for illustrative purposes only and are not intended to limit the compounds in any way. As will be appreciated by those skilled in the art, the bifunctional The compounds are synthesized so that the number and position of each functional moiety can be varied as desired. It is possible.

[0066] In certain embodiments, compounds having the following general structure: ABM-L, wherein ABM is and L is a chemical linker moiety, e.g., a phospholipid-binding moiety as described herein. Car or optionally a bond.

[0067] In certain embodiments, the bifunctional compound further comprises a chemical linker (L). The structure of the bifunctional compound can be shown as follows: ABM-L-CLM (VII) wherein ABM is an AR-binding moiety as described herein and CLM is cereblon E3 as described herein. L is a chemical linker moiety, e.g., a linker described herein. ABM and CLM may be either a bond or optionally a bond, linking the ABM and CLM.

[0068] Furthermore, CLM binds all potential cereblon E3 ubiquitin ligase binding sites. The CLM and ABM groups may be any suitable and stable covalent group for the linker chemistry. It may be covalently attached to the linker group via a bond.

[0069] In certain embodiments, the CLM is a ligase of cereblon E3 ubiquitin ligase (CRBN). In certain embodiments, the CLM comprises a moiety that is a ligand. In certain additional embodiments, the CLM is a phthalimide group or an analog thereof. or derivatives thereof. In still further embodiments, the CLM is phthalimido-glutaric acid. In yet another embodiment, the CLM comprises an imide group or an analog or derivative thereof. from thalidomide, lenalidomide, pomalidomide, and their analogs or derivatives It includes one of the groups:

[0070] The general structure is exemplary and the individual moieties may be in any desired order or configuration, e.g. It will be understood that the CLM-L-ABM and CLM-L-ABM may be spatially arranged. In certain additional embodiments, the compound comprises multiple E3 ligase binding moieties and / or multiple Includes several ABMs.

[0071] In certain embodiments, the compounds described herein contain multiple ABMs (Ab) at the same or different positions in the AR. targeting multiple CLMs, one or more ULMs (i.e., another E3 ubiquitin ligase) The present invention also includes a moiety that specifically binds to a VHL (e.g., VHL), or a combination thereof. In any of the aspects of the described embodiments, the ABM, CLM, and ULM may be combined directly or in combination with one or more The compounds may be linked via the above chemical linkers, or combinations thereof. In embodiments, when a compound has multiple ULMs, the ULMs are linked to the same E3 ubiquitin ligator. Alternatively, each ULM may be specific for a different E3 ubiquitin ligase. In a further embodiment, when a compound has multiple ABMs, The ABMs may be the same or optionally different.

[0072] In certain embodiments, when a compound comprises multiple CLMs, the CLMs are either identical or In additional embodiments, compounds comprising multiple CLMs are directly at least one bonded to the CLM via a bond or a chemical linker (L), or both In certain additional embodiments, the compound comprising multiple CLMs further comprises: In yet further embodiments, the ABMs are the same or any combination thereof. are different.

[0073] In certain embodiments, ABM alone is capable of regulating protein activity without forming ABM-L-CLM. This provides desirable characteristics in control.

[0074] In any of the aspects or embodiments of the compounds described herein, unless otherwise indicated, Insofar as the compound is a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or Polymorphs are intended to be included.

[0075] In certain embodiments, the compounds described herein may contain multiple PTMs (same or different proteins). targeting a protein target), multiple ABMs, multiple CLMs, one or more ULMs (i.e., another E3 ubiquitin a moiety that specifically binds to a tyrosine ligase, e.g., cereblon), or a combination thereof In any of the aspects of the embodiments described herein, the PTM, ABM, CLM, and U The LM may be attached directly, via one or more chemical linkers, or a combination thereof. In additional embodiments, when a compound has multiple ULMs, those ULMs ULMs may be directed to the same E3 ubiquitin ligase, or each ULM may be directed to a different E In yet a further embodiment, the compound may specifically bind to the ubiquitin ligase. If the entity has multiple PTMs, the PTMs may bind to the same target protein, or Each PTM may specifically bind to a different target protein.

[0076] Exemplary CLM Neo-imide compounds In one embodiment, the present disclosure provides compounds useful for binding and / or inhibiting cereblon. In certain embodiments, the compound or CLM is selected from the group consisting of the following chemical structures: Select from:

[0077] [ka]

[0078] During the ceremony: W independently represents CH2, CHR, C=O, SO2, NH, and N-alkyl (optionally substituted straight chain, branched, chain); Y independently represents CH2, -C=CR', NH, N-alkyl, N-aryl, N-hetaryl, N-cyclo selected from the group consisting of alkyl, N-heterocyclyl, O and S; X and Z are each independently O, S, or H2, provided that both X and Z are not H2. Except that it won't be; G and G' are independently H, alkyl (straight or branched chain optionally substituted with R'), OH, R'O COOR, R'OCONRR", CH2-heterocyclyl optionally substituted with R', and substituted benzyl; Q1-Q4 are each independently C optionally substituted with R', N, or N-oxide; A independently represents alkyl (optionally substituted straight or branched chain), cycloalkyl (optionally substituted substituted), selected from the group consisting of Cl, H and F; R is -CONR'R", -OR', -NR'R", -SR', -SO2R', -SO2NR'R", -CR'R"-, -CR'N R'R"-, -aryl, -hetaryl, -alkyl (optionally substituted straight or branched chain), -cyclo alkyl, -heterocyclyl, -P(O)(OR')R", -P(O)R'R", -OP(O)(OR')R", -OP(O )R'R", -Cl, -F, -Br, -I, -CF3, -CN, -NR'SO2NR'R", -NR'CONR'R", -CONR'C OR", -NR'C(=N-CN)NR'R", -C(=N-CN)NR'R", -NR'C(=N-CN)R", -NR'C(=C-NO2)N R'R", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR'=CR'R", -CCR', -S (C=O)(C=N-R')R", -SF5, -R'NR'R”, (-R'O) n R”, ​​or -OCF3, but these Not limited to. R' and R'' are each independently a bond, H, alkyl (straight or branched chain), cycloalkyl , aryl, hetaryl, heterocyclyl, or -C(=O)R, each of which is optionally is replaced by; n is an integer from 1 to 10 (e.g., 1 to 4, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10);

[0079] [ka]

[0080] represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and R n contains 1 to 4 independent functional groups or atoms, one of which is optionally modified. and covalently bonded to an ABM, a chemical linker group (L), a ULM, a CLM (CLM'), or a combination thereof. are combined.

[0081] Exemplary CLM In any of the compounds described herein, the CLM may have a chemical structure selected from the group consisting of: Construction includes:

[0082] [ka]

[0083] During the ceremony: W is CH2, CHR, C=O, SO2, NH and N-alkyl (optionally substituted straight or branched chain). ru; X and Z are each independently O, S, or H2, provided that both X and Z are not H2. Except that it won't be; Y independently represents CH2, -C=CR', NH, N-alkyl, N-aryl, N-hetaryl, N-cyclo selected from the group of alkyl, N-heterocyclyl, O and S; G is H, alkyl (linear or branched), OH, R'OCOOR, R'OCONRR", CH2-heterocyclyl , heterocyclic, aryl, or benzyl, each optionally substituted with R'; Q1-Q4 are each independently C optionally substituted with R', N, or N-oxide; A independently represents C1-C6 alkyl (optionally substituted straight or branched chain), cycloalkyl (optionally substituted), substituted with), H, Cl or F; R is -CONR'R", -OR', -NR'R", -SR', -SO2R', -SO2NR'R", -CR'R"-, -CR'N R'R”-, (-CR'O) n R”, ​​-aryl, -heteroaryl, -alkyl (optionally substituted alkyl groups) -chain, branched), -cycloalkyl, -heterocyclyl, -P(O)(OR')R", -P(O)R'R", -OP (O)(OR')R", -OP(O)R'R", -Cl, -F, -Br, -I, -CF3, -CN, -NR'SO2NR'R", -NR' CONR'R", -CONR'COR", -NR'C(=N-CN)NR'R", -C(=N-CN)NR'R", -NR'C(=N-CN)R ", -NR'C(=C-NO2)NR'R", -SO2NR'COR", -NO2, -CO2R', -C(C=N-OR')R", -CR' =CR'R", -CCR', -S(C=O)(C=N-R')R", alicyclic, heterocyclic, -SF5, or -OCF3 ; R' and R'' are each independently a bond, H, N, N-oxide, alkyl (straight chain, branched chain), cycloalkyl, aryl, heteroaryl, heterocyclic, -C(=O)R, or heterocyclo Ril, each of which is optionally substituted; n is an integer from 1 to 10;

[0084] [ka]

[0085] represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and R n contains 1 to 4 independent functional groups or atoms, one of which is optionally modified. and covalently bonded to an ABM, a chemical linker group (L), a ULM, a CLM (CLM'), or a combination thereof. are combined.

[0086] In certain embodiments described herein, the CLM or ULM is selected from the group consisting of: Chemical structure including:

[0087] [ka]

[0088] During the ceremony: W is independently selected from the group consisting of CH2, C=O, NH and N-alkyl; R is H, methyl, or C1-C6 alkyl (optionally substituted straight or branched chain);

[0089] [ka]

[0090] represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and Rn contains 1 to 4 independently selected functional groups or atoms, and optionally one of is modified to include an ABM, a chemical linker group (L), a ULM, a CLM (or CLM'), or a combination thereof The resulting mixture is covalently bonded to the

[0091] As used herein, the term "independently" means that a variable that is applied independently is used to indicate that the

[0092] The term "alkyl" refers, within its context, to a straight, branched, or cyclic, fully saturated alkyl group. It is understood that the term "hydrocarbon radical" refers to a hydrocarbon radical or alkyl group, preferably C-C 10 More preferably, it is a C1-C6 or C1-C3 alkyl group, which may be optionally substituted. Examples of alkyl groups are, in particular, methyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-hexyl, Butyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methylpropyl, cyclopropyl Propyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentyl ethene cyclohexyl, cyclohexylethyl, and cyclohexyl. In certain embodiments, The alkyl group is end-capped with a halogen group (At, Br, Cl, F, or I). In some embodiments, compounds according to the present disclosure are used to covalently bind to dehalogenase enzymes. These compounds generally have a side chain (often via a polyethylene glycol group) The side chain contains a halogen substituent (often chlorine or or bromine), thereby allowing the compound containing that moiety to be easily bonded to tannic acid. Covalent bonding of proteins occurs.

[0093] The term "alkenyl" refers to straight, branched or alkyl groups containing at least one C=C bond. is a cyclic C2-C 10 (Preferably C2-C6) hydrocarbon radicals.

[0094] The term "alkynyl" refers to straight, branched or alkynyl groups containing at least one C≡C bond. or cyclic C2-C 10 (Preferably C2-C6) hydrocarbon radicals.

[0095] The term "alkylene," when used, refers to an optionally substituted -(CH) n -refers to the group ( (n is typically an integer from 0 to 6). When substituted, the alkylene group may be one of the methylene groups. and at least one C1-C6 alkyl group (including cyclopropyl or t-butyl groups) It is preferred that the aryl group contains one or more halo groups, preferably 1 to 3 halo groups, or one or two hydroxyl groups, an O—(C1-C6 alkyl) group, or any other group not otherwise disclosed herein In certain embodiments, the alkylene group may be substituted with an amino acid side chain such as urethane. or alkoxy groups (or other groups), which may further be substituted with polyethylene. ethylene glycol chains (1 to 10, preferably 1 to 6, and in most cases 1 to 4 ethylene glycol chains) The alkyl group is preferably, but not limited to, a chain of polyethylene units. The alkyl chain is substituted with one halogen group, preferably a halogen atom. In yet other embodiments, the alkylene (often methylene) group is , such as natural or unnatural amino acids, e.g., alanine, β-alanine, arginine, Asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, Lysine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine , the side chain groups of proline, serine, threonine, valine, tryptophan or tyrosine, etc. may be substituted with an amino acid side chain group of

[0096] The term "unsubstituted" shall mean substituted only with hydrogen atoms. The range of carbon atoms included means that the carbon is either absent or replaced with H. Thus, the range of carbon atoms C0-C6 includes 1, 2, 3, 4, 5, and 6 carbon atoms, and C For 0 there is an H instead of a carbon.

[0097] The terms "substituted" or "optionally substituted" refer to any one of the groups on a molecule within the context. one or more substituents at a carbon (or nitrogen) position (independent on a moiety in a compound according to the present disclosure) up to 5 substituents, preferably up to 3 substituents, often 1 or 2 substituents and may include substituents which may themselves be further substituted) independently ( (i.e., when there are multiple substituents, each substituent is independent of the other substituents), and Substituents include hydroxyl, thiol, carboxyl, cyano (C≡N), nitro (NO2), Halogen (especially on alkyl, especially methyl groups such as trifluoromethyl) is preferred 1, 2, or 3 halogens), alkyl groups (preferably C1-C 10 , more preferably C1-6), aryl (especially phenyl and substituted phenyl, e.g., benzyl or benzoyl); an oxy group (preferably C1-C6 alkyl or aryl, including phenyl and substituted phenyl); thioether (C1-C6 alkyl or aryl), acyl (preferably C1-C6 acyl) ), ester or thioester (preferably C1-C6 alkyl or aryl), alkylene esters (the attachment is on the alkylene group rather than the ester functionality, preferably is substituted with a C1-C6 alkyl or aryl group), preferably with a C1-C6 alkyl or aryl group containing alcohols, halogens (preferably F or Cl), amines (5- or 6-membered cyclic alkyls) and further including C1-C6 alkylamines or C1-C6 dialkylamines, The alkyl group may be substituted with one or two hydroxyl groups, or optionally substituted -N(C0-C6 alkyl)C(O)(O-C1-C6 alkyl) group (optionally substituted with a polyethylene glycol chain) to which may be further bonded an alkyl group containing one halogen, preferably chlorine, substituent. hydrazines, amides, which preferably contain one or two C1-C6 alkyl groups (one or including carboxamides optionally substituted with two C1-C6 alkyl groups), alkanols (preferably or C1-C6 alkyl or aryl), or alkanoic acid (preferably C1-C6 alkyl or Substituents according to the present disclosure include, for example, -SiR1R and optionally include 2R groups, where each of R and R is as otherwise described herein. and R3 is H or a C1-C6 alkyl group, preferably in this context R1, R2, R3 are C1 -C3 alkyl groups (including isopropyl or t-butyl groups). The substituent may be directly attached to the substituted moiety or may be an optionally substituted (CH2) m -of or optionally substituted -(OCH2) m -, -(OCH2CH2) m -or-(CH2CH2O) m -Through Motoi and substituted moieties (preferably in the case of aryl or heteroaryl moieties) may be bonded to, which may be substituted with any one or more of the substituents described above. alkylene group -(CH2) m -or-(CH2) n -group or, for example, the ethylene glycol groups specified above. Other chains, such as alkylene chains, may be substituted anywhere on the chain. Suitable substituents include halogen or C1-C6 (preferably C1-C3) alkyl groups, It optionally contains one or two hydroxyl groups, one or two ether groups (O-C1-C6 groups), up to three halo groups (preferably F), or at amino acid side chains as otherwise described herein; Optionally substituted amides (preferably substituted as described above) carboxamide) or urethane group (often with one or two C0-C6 alkyl substituents and the like, which may also be further substituted. In certain embodiments, alkylene The alkyl group (often a single methylene group) is substituted with one or two optionally substituted C1-C6 alkyl groups. alkyl groups, preferably C1-C4 alkyl groups, most often methyl or O-methyl groups, is replaced with an amino acid side chain as otherwise described herein. may be optionally substituted with up to 5 substituents, preferably up to 3 substituents. In the case of, the substituted moiety in this disclosure is substituted with one or two substituents.

[0098] The term "substituted," where each substituent is independent of any other substituent, means that Within the context of the use of C1-C6 alkyl, C1-C6 alkoxy, halogen, amide, carbo Sulfone, including oxamide, sulfonamide, keto, carboxy, C1-C6 ester (oxy) ester or carbonyl ester), C1-C6 keto, urethane -OC(O)-NR1R2 or -N(R 1) -C(O)-O-R1, nitro, cyano, and amine (especially C1-C6 alkylene -NR1R2, mono or or di-C1-C6 alkyl substituted amines optionally substituted with one or two hydroxyl groups Each of these groups is intended to mean the groups described above, unless otherwise indicated. Unless otherwise specified within the context, the substituents may contain from 1 to 6 carbon atoms. Preferred substituents depending on the context of use include, for example, -NH-, -NHC(O)-, -O-, =O, -(CH2) m - (wherein m and n are 1, 2, 3, 4, 5 or 6, depending on the context), -S-, - S(O)-, SO2- or -NH-C(O)-NH-, -(CH2) n OH, -(CH2) n SH, -(CH2) n COOH, C1-C6 alkyl Le, -(CH2) n O-(C1-C6 alkyl), -(CH2) n C(O)-(C1-C6 alkyl), -(CH2) n OC(O)-(C1-C6 Rukill), -(CH2) nC(O)O-(C1-C6 alkyl), -(CH2) n NHC(O)-R1, -(CH2) n C(O)-NR1R2, -(OC H2) n OH, -(CHO) n COOH, C1-C6 alkyl, -(OCH2) n O-(C1-C6 alkyl), -(CHO) n C(O)-(C1 -C6 alkyl), -(OCH2) n NHC(O)-R1, -(CHO) n C(O)-NR1R2, -S(O)2-R S , -S(O)-R S (R S teeth, C1-C6 alkyl or -(CH2) m -NR1R2 group), NO2, CN or halogens (F, Cl, Br, I, Preferably, R1 and R2 are H or C within the context. 1-C6 alkyl groups (one or two hydroxyl groups, or up to three halogen groups, preferably The term "substituted" also refers to a group of groups defined as Within the chemical context of the compound being studied and the substituents used, optionally substituted aryl groups, if any, or heteroaryl group or an optionally substituted heterocycle as otherwise described herein An alkylene group is also intended to mean a group as otherwise disclosed herein. and optionally substituted, preferably optionally substituted C1-C6 alkyl groups (methyl, ethyl or or hydroxymethyl or hydroxyethyl are preferred, and accordingly a chiral center is provided. provided), the side chain of an amino acid group as otherwise described herein, an amide group as described above, or or a urethane group, an OC(O)-NR1R2 group, where R1 and R2 are as otherwise described herein. Although the alkyl groups may be substituted with certain groups as shown, many other groups may also be used as substituents. Such optionally substituted moieties may have three or more substituents, preferably three or fewer substituents, and preferably In a compound, a group may be substituted with one or two substituents at a specific position of the molecule. When substitution is required (mainly due to valence) but substitution is not indicated, Note that unless otherwise indicated in the specification, the substituents are assumed or understood to be H. I want to be treated like that.

[0099] The term "aryl" or "aromatic" refers, in context, to a single ring (e.g., benzoate). anthracenyl, phenyl, benzyl) or fused ring (e.g., naphthyl, anthracenylphenyl) substituted (as otherwise described herein) or non-substituted with aryl, ... refers to a substituted monovalent aromatic radical and, in accordance with the present disclosure, may be any available stable ring on the Attached to the compound at the position indicated or as otherwise specified in the chemical structure presented. Other examples of aryl groups, when taken in context, include heteroaromatic ring systems, For example, imidazole, furyl, pyrrole, furanyl, thienyl, thiazole, pyridine, One or more nitrogen atoms in the ring of imidine, pyrazine, triazole, oxazole, etc. "Heteroaryl" groups containing nitrogen or sulfur atoms, or, for example, especially indole, chiral condensed ring systems such as indolizine, azaindolizine, and benzofurazan; They may be optionally substituted as described above. Among the heteroaryl groups that may be mentioned in particular are and nitrogen-containing heteroaryl groups, such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrimidine-containing heteroaryl groups. Imidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole Indoles, indoles, isoindoles, indolizines, azaindolizines, purines, indole quinoline, dihydroquinoline, tetrahydroquinoline, isoquinoline, dihydroquinoline Isoquinoline, tetrahydroisoquinoline, quinolizine, phthalazine, naphthyridine, Noxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotria azine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazolidine pyrimidine, phenanthroline, phenacene, oxadiazole, benzimidazoline pyrrolopyridines, pyrrolopyrimidines, and pyridopyrimidines; sulfur-containing aromatic heterocycles rings, such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles, such as furan; pyran, cyclopentapyran, benzofuran, and isobenzofuran; and nitrogen, Aromatic heterocycles containing two or more heteroatoms selected from among sulfur and oxygen, e.g. For example, thiazole, thiadizole, isothiazole, benzoxazole, benzothiazole , benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine , pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxa benzopyridine, furopyridine, furopyrimidine, thienopyrimidine, and oxazole. all of which may be optionally substituted.

[0100] The term "substituted aryl" refers to a group consisting of at least one aromatic ring or It refers to an aromatic carbocyclic ring consisting of multiple condensed rings, at least one of which is aromatic. In the present invention, the ring is substituted with one or more substituents. For example, the aryl group may be selected from the following: may contain substituents such as: -(CH2) n OH, -(CH2)n -O-(C1-C6) alkyl, -(CH2) n -O-(CH2) n -(C1-C6) alkyl, -(CH2) n -C(O)(C0-C6) alkyl, -(CH2) n -C(O)O(C0-C6) alkyl, -( CH2) n -OC(O)(C0-C6) alkyl, amine, mono- or di-(C1-C6 alkyl)amine The alkyl group on the amine may optionally contain one or two hydroxyl groups or up to three halo (preferably F, Cl) groups, OH, COOH, C1-C6 alkyl, preferably CH3, CF3, OMe, OCF3, NO2, or CN groups (each of which is in the ortho, meta, and / or pa positions of the phenyl ring) an optionally substituted phenyl group (which may be substituted in the para-position, preferably the para-position); The group itself is preferably substituted with a linker group attached to the ABM group, including the ULM group. and / or F, Cl, OH, COOH, CH3, CF3, OMe, OCF3, NO2, or CN groups (phenyl ring ortho-, meta-, and / or para-positions, preferably para-positions) substituted with, optionally substituted naphthyl groups, optionally substituted heteroaryl, preferably Optionally substituted isoxazoles, preferably methyl-substituted isoxazoles. optionally substituted oxazoles, including oxazole; optionally substituted thiazoles, including methyl-substituted thiazoles; Substituted thiazoles, optionally substituted isothiazoles, including methyl-substituted isothiazoles optionally substituted pyrroles including methyl-substituted pyrroles; optionally substituted imidazole, optionally substituted benzimidazole or methoxybenzoate; oximidazole, optionally substituted oximidazole or methyloximidazole optionally substituted diazole groups including methyldiazole groups, methyl-substituted triazoles Optionally substituted triazole groups containing groups, halo- (preferably F) or methyl-substituted pyrazole groups an optionally substituted pyridine group, including a lysine group or an oxapyridine group, is attached to the phenyl group by an oxygen atom), optionally substituted furan, optionally substituted benzofuran, optionally substituted dihydrobenzofuran, optionally substituted indole, Indolizine or azaindolizine (2, 3, or 4-azaindolizine), optionally substituted substituted quinolines, and combinations thereof.

[0101] "Carboxyl" means --C(O)OR, where R is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, These generic substituents have the same meaning as the corresponding group definitions defined herein.

[0102] The terms "heteroaryl" or "hetaryl" include, but are not limited to, optionally substituted heteroaryls. Quinoline (attached to the pharmacophore or any carbon atom within the quinoline ring) optionally substituted indole (including dihydroindole); optionally substituted indolizines, optionally substituted azaindolizines (2, 3, or 4-aza indolizine), optionally substituted benzimidazole, benzodiazole, benzoxazole isofuran, optionally substituted imidazole, optionally substituted isoxazole, optionally substituted substituted oxazoles (preferably methyl substituted), optionally substituted diazoles, optionally substituted triazoles, tetrazoles, optionally substituted benzofurans, optionally Substituted thiophenes, optionally substituted thiazoles (preferably methyl-substituted and / or or thiol-substituted), optionally substituted isothiazole, optionally substituted triazole silyl (preferably methyl group, triisopropylsilyl group, optionally substituted (CH2) m -OC 1-C6 alkyl group, or optionally substituted (CH2) m -C(O)-O-C1-C6 alkyl group substituted 1 , 2,3-triazole), optionally substituted pyridine (2, 3, or 4-pyridine), or It may refer to a group according to the following chemical structure:

[0103] [ka]

[0104] During the ceremony, S c is CHR SS , N.R. URE , or O; R HET is H, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably one or two hydroxyl groups or up to three halo groups (e.g., CF3) substituted with), optionally substituted O(C1-C6 alkyl) (preferably 1 or 2 alkyl hydroxyl or up to three halo groups), or optionally substituted acetyl ren group -C≡CR a wherein R a is H or a C1-C6 alkyl group (preferably a C1-C3 alkyl group) ) is an acetylene group; R SSis H, CN, NO2, halo (preferably F or Cl), optionally substituted C1-C6 alkyl aryl (preferably substituted with one or two hydroxyl groups or up to three halo groups) ), optionally substituted O—(C1-C6 alkyl) (preferably containing one or two hydroxyl groups or substituted with up to three halo groups), or optionally substituted —C(O)(C1-C6 alkyl ) (preferably substituted with one or two hydroxyl groups or up to three halo groups) ) is; R URE is H, C1-C6 alkyl (preferably H or C1-C3 alkyl), or —C(O)(C1-C6 alkyl) alkyl), each group optionally containing one or two hydroxyl groups or up to three halo groups. , preferably substituted with fluorine groups, or optionally substituted heterocycles, such as piperi idine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine azine, piperazine, etc., each of which is optionally substituted; and Y C is N or CR YC where R YC is H, OH, CN, NO2, halo (preferably Cl or F), optionally substituted C1-C6 alkyl (preferably containing one or two hydroxyl groups or is substituted with up to three halo groups (e.g., CF), optionally substituted O(C1-C6 alkyl ) (preferably substituted with one or two hydroxyl groups or up to three halo groups) , or an optionally substituted acetylenic group -C≡CR a wherein R a is H or C1-C6 and an acetylene group which is an alkyl group (preferably C1-C3 alkyl).

[0105] The terms "aralkyl" and "heteroarylalkyl" refer to aralkyl and heteroarylalkyl groups according to the definitions above. aryl or heteroaryl, respectively, and alkyl, and / or heteroalkoxy; It refers to groups containing alkyl, aryl, and / or carbocyclic and / or heterocycloalkyl ring systems.

[0106] As used herein, the term "arylalkyl" refers to any of the aryl groups defined above. An arylalkyl group refers to an aryl group as defined above appended to an alkyl group. is attached to the parent moiety through an alkyl group, where the alkyl group has 1 to 6 carbon atoms The aryl group in the arylalkyl group may be substituted as described above.

[0107] The term "heterocycle" refers to a ring containing at least one heteroatom, such as N, O, or S. It refers to a cyclic group containing aryl, which may be aromatic (heteroaryl) or non-aromatic. Thus, heteroaryl moieties are encompassed under the definition of heterocycle, depending on the context of its use. Suitable heteroaryl groups are described herein above.

[0108] Exemplary heterocycles include, among others, azetidinyl, benzimidazolyl, 1,4-benzodioxol, Xanyl, 1,3-benzodioxolyl, benzoxazolyl, benzothiazolyl, benzothiazolyl enyl, dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dioxanyl, Dioxolanil, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane furyl, homopiperidinyl, imidazolyl, imidazolinyl, imidazolidinyl, Indolinyl, indolyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isoquinolinyl Soxazolidinyl, isoxazolyl, morpholinyl, naphthyridinyl, oxazolidinyl , oxazolyl, pyridone, 2-pyrrolidone, pyridine, piperazinyl, N-methylpiperazinyl Dinyl, piperidinyl, phthalimido, succinimido, pyrazinyl, pyrazolinyl , pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinolinyl, tetra Hydrofuranyl, tetrahydropyranyl, tetrahydroquinoline, thiazolidinyl, thiazolidinyl Azolyl, thienyl, tetrahydrothiophene, oxane, oxetanyl, oxathio Ranil and Chiang are examples.

[0109] The heterocyclic group includes alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, ... Cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino , substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano No, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl, thio Aryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thio Alkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, hetero Aryloxy, heterocyclic, heterocyclooxy, hydroxyamino, alkoxyamino , nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2- Alkyl, -SO2-substituted alkyl, -SO2-aryl, oxo (=O), and -SO2-heteroaryl Such heterocyclic groups may be optionally substituted with a group selected from the group consisting of a single Examples of nitrogen heterocycles and heteroaryls include: Non-limiting examples include pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine Indoles, pyridazines, indolizines, isoindoles, indoles, indazoles, purines, Quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, Quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, Acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenon Xanthan gum, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, Indoline, morpholino, piperidinyl, tetrahydrofuranyl, etc., as well as N-alkanoic acid The term "heterocyclic" also refers to any of the heterocycles. is a benzene ring or a cyclohexane ring or another heterocyclic ring (e.g., indolyl, quinolyl) Also included are bicyclic groups fused to a ring such as quinolyl, isoquinolyl, tetrahydroquinolyl, etc.

[0110] The term "cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, 3 to 20 carbon atoms, including but not limited to cyclohexyl, cycloheptyl, etc. and monocyclic or polycyclic groups as defined herein, such as saturated monocyclic hydrocarbon groups having in the ring It means, but is not limited to, a monovalent group derived from an alkyl group or a cycloalkane. The term "substituted cycloalkyl" refers to groups such as, for example, amino, halogen, alkyl, Substituted alkyl, carbyloxy, carbylmercapto, aryl, nitro, mercapto or or sulfo, and These generic substituents refer to, but are not limited to, groups, and are intended to be construed as equivalents as defined in this description. has the same meaning as the definition of the corresponding group.

[0111] "Heterocycloalkyl" means that at least one ring carbon atom in the ring structure is N, O, or monocyclic or polycyclic alkyl substituted with a heteroatom selected from the group consisting of S or P; "Substituted heterocycloalkyl" refers to a group in which at least one ring of the ring structure is substituted with a substituted heterocycloalkyl. A monocyclic ring in which a carbon atom is replaced with a heteroatom selected from the group consisting of N, O, S, or P. or polycyclic alkyl groups, and the group is not a halogen, alkyl, substituted alkyl, carbaryl, The group consisting of ruoxy, carbylmercapto, aryl, nitro, mercapto, and sulfo Although these generic substituents are not intended to be limiting in any way, they may contain one or more substituents selected from the group consisting of: has the same meaning as the definition of the corresponding group defined in

[0112] The term "hydrocarbyl" is intended to mean a compound containing carbon and hydrogen; They may be fully saturated, partially unsaturated, or aromatic, and may contain aryl groups, alkyl groups, Includes alkenyl and alkynyl groups.

[0113] In any of the embodiments described herein, W, X, Y, Z, G, G', R, R', R'', Q1 to Q4, A and Rn are independently a linker, and / or one or more The ABM, ULM, CLM, or CLM′ group of the amide may be covalently attached to a linker that is attached to the ABM, ULM, CLM, or CLM′ group of the amide.

[0114] More specifically, non-limiting examples of CLMs include the molecules shown below, as well as the molecules shown below: "Hybrid" results from the combination of one or more of the different features exhibited in the molecule In this case, Rn is 1 to 4 independently selected functional groups or atoms. and optionally one of which is modified to include an ABM, a chemical linker group (L), U Covalently attached to the LM, CLM (or CLM') or combination thereof.

[0115] [ka]

[0116] [ka]

[0117] [ka]

[0118] [ka]

[0119] [ka]

[0120] Exemplary Linkers In certain embodiments, the compounds described herein are linked together via one or more chemical linkers (L). The antibody comprises one or more ABMs chemically linked or attached to the ULM or CLM. In certain embodiments, the linker group L is a group comprising one or more covalently linked structural units. (e.g., -A 1.. A q -, or -A q -), in which A1 is a group bonded to ABM , A q is a group attached to ULM.

[0121] In certain embodiments, the linker group L is A q - selected from; A q is a group linked to a ULM or ABM moiety; and q is an integer equal to or greater than 1, In the formula, A q is a bond, CR L1 R L2 , O, S, SO, SO2, NR L3 , SO2NR L3 ,SONR L3 ,CONR L3 , N.R. L3 C ONR L4 , N.R. L3 SO2NR L4 , CO, CR L1 =CR L2 , C≡C, SiR L1 R L2 , P(O)R L1 , P(O)OR L1 , N.R. L3 C(=NCN )NR L4 , N.R. L3 C(=NCN), NR L3 C(=CNO2)NR L4 , optionally 0 to 6 R L1 and / or R L2 Substituted with group C 3-11 Cycloalkyl, optionally 0 to 9 R L1 and / or R L2 C substituted with a group 5-13 spirocycloalkyl, optionally 0 to 6 R L1 and / or R L2 C substituted with a group 3-11 Haitai cyclocyclyl, optionally 0 to 8 R L1 and / or R L2 C substituted with group 5-13 Spiroheterosi chloroalkyl, optionally 0 to 6 R L1 and / or R L2 aryl substituted with a group, optionally 0 ~6 R L1 and / or R L2heteroaryl substituted with a group; where R L1 or R L2 are each independently optionally bonded to other groups, and optionally 0 to 4 R L5 Based on forming substituted cycloalkyl and / or heterocyclyl moieties; R L1 , R L2 , R L3 , R L4 and R L5 are each independently H, halo, or C 1~8 Alkyl, OC 1~8 Al Kill, SC 1~8 Alkyl, NHC 1~8 Alkyl, N(C 1~8 Alkyl)2, C 3~11 cycloalkyl, Aryl, heteroaryl, C 3~11 Heterocyclyl, OC 1~8 Cycloalkyl, SC 1~8 Shik Roalkyl, NHC 1~8 Cycloalkyl, N(C 1~8 cycloalkyl)2, N(C 1~8 Cycloalkane (C 1~8 alkyl), OH, NH2, SH, SO2C 1~8 Alkyl, P(O)(OC 1~8 Alkyl)(C 1~8 a Rukill), P(O)(OC 1~8 Alkyl)2, CC-C 1~8 Alkyl, CCH, CH=CH(C 1-8 alkyl), C(C1 ~8 alkyl)=CH(C 1~8 alkyl), C(C 1~8 alkyl)=C(C 1~8 alkyl)2, Si(OH)3, Si( C 1~8 alkyl)3, Si(OH)(C 1~8 Alkyl)2, COC 1~8 Alkyl, CO2H, halogen, CN, CF 3, CHF2, CH2F, NO2, SF5, SO2NHC 1~8 Alkyl, SO2N(C 1~8 Alkyl)2, SONHC 1~8 Al Kill, SON(C 1~8 alkyl)2, CONHC 1~8 Alkyl, CON(C 1~8 alkyl)2, N(C 1~8 Archi CONH(C 1~8 alkyl), N(C 1~8 alkyl)CON(C 1~8 alkyl)2, NHCONH(C 1~8 Archi le), NHCON(C 1~8 alkyl)2, NHCONH2, N(C 1~8 alkyl)SO2NH(C 1~8 alkyl), N(C1 ~8 alkyl) SO2N(C 1~8 alkyl)2, NH SO2NH(C 1~8 alkyl), NH SO2N(C 1~8 Archi (ru)2, NH SO2 NH2.

[0122] In certain embodiments, q is an integer greater than or equal to 0. In certain embodiments, q is an integer greater than or equal to 1. be.

[0123] In certain embodiments, for example, when q is greater than 2, A q is a group attached to ULM A1 and A q are linked via a linker (L) structural unit.

[0124] In certain embodiments, for example, when q is 2, A q is A1 and Combined with ULM It is the base.

[0125] In certain embodiments, for example, when q is 1, the structure of the linker group L is -A1- and A1 is a group attached to the ULM and ABM moieties.

[0126] In certain embodiments, the linker (L) has a general structure selected from the group consisting of: This includes groups represented by: -NR(CH2) n -(lower alkyl)-, -NR(CH2) n -(lower alkoxyl)-, -NR(CH2) n -(Low-level Al Coxyl)-OCH2-, -NR(CH2) n -(lower alkoxyl)-(lower alkyl)-OCH2-, -NR(CH2) n -( Cycloalkyl)-(lower alkyl)-OCH2-, -NR(CH2) n -(heterocycloalkyl)-, -NR(CH2 CH2O) n -(lower alkyl)-O-CH2-, -NR(CH2CH2O) n -(heterocycloalkyl)-O-CH2-, -NR(C H2CH2O) n -Aryl-O-CH2-, -NR(CH2CH2O) n -(heteroaryl)-O-CH2-, -NR(CH2CH2O) n -( Cycloalkyl)-O-(heteroaryl)-O-CH2-, -NR(CH2CH2O) n -(cycloalkyl)-O-a Reel-O-CH2-, -NR(CH2CH2O) n -(lower alkyl)-NH-aryl-O-CH2-, -NR(CH2CH2O) n -( (lower alkyl)-O-aryl-CH2, -NR(CH2CH2O) n -cycloalkyl-O-aryl-, -NR(CHC H2O) n-cycloalkyl-O-(heteroaryl)l-, -NR(CH2CH2)n-(cycloalkyl)-O-(heteroaryl) ring)-CH 2、 -NR(CH2CH2)n-(heterocycle)-(heterocycle)-CH2, -N(R1R2)-(heterocycle)-CH2; n may be 0 to 10; R may be H, lower alkyl; R1 and R2 may form a ring with the bond N.

[0127] In certain embodiments, the linker (L) has a general structure selected from the group consisting of: This includes groups represented by: -N(R)-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -OCH2-, -O-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -OCH2-, -O-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O-; -N(R)-(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -O-; -(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2)q -O(CH2) r -O-; -(CH2) m -O(CH2) n -O(CH2) o -O(CH2) p -O(CH2) q -O(CH2) r -OCH2-;

[0128] [ka]

[0129] During the ceremony, m, n, o, p, q, and r are each independently 0, 1, 2, 3, 4, 5, or 6; If the number is zero, there are no NO or OO bonds. R is H, methyl, or ethyl; and X is H or F.

[0130] In certain embodiments, the linker (L) comprises a group represented by the following general structure:

[0131] [ka]

[0132] In the formula, m may be 2, 3, 4, or 5. In certain embodiments, the linker (L) has a general structure selected from the group consisting of: Including groups represented by:

[0133] [ka]

[0134] [ka]

[0135] [ka]

[0136] [ka]

[0137] [ka]

[0138] [ka]

[0139] [ka]

[0140] wherein n and m are each independently 0, 1, 2, 3, 4, 5, or 6; and X is H or F. be.

[0141] In additional embodiments, the linker group comprises from about 1 to about 100 ethylene glycol units, from about 1 to about 100 ethylene glycol units, About 50 ethylene glycol units, about 1 to about 25 ethylene glycol units, about 1 to 10 ethylene glycol units, 1 to about 8 ethylene glycol units, and 1 to 6 ethylene glycol units Glycol units, optionally substituted (poly) having about 2 to 4 ethylene glycol units Ethylene glycol or interspersed with optionally substituted O, N, S, P or Si atoms In certain embodiments, the linker is an optionally substituted alkyl group such as aryl, fluoro, or cyclohexane. The alkyl group may be substituted with a phenyl, benzyl, alkyl, alkylene, or heterocyclic group. The linker may be asymmetric or symmetric in configuration.

[0142] In any of the embodiments of the compounds described herein, the linker group may be any of the groups described herein. In one embodiment, the linker is from about 1 to about 12 Ethylene glycol unit, 1 to about 10 ethylene glycol units, about 2 to 6 ethylene glycol units units, approximately 2 to 5 ethylene glycol units, and approximately 2 to 4 ethylene glycol units. It is a substituted or unsubstituted polyethylene glycol group.

[0143] In another embodiment, the present disclosure provides a compound comprising the ABM group described above, The group is attached to a target protein (e.g., androgen receptor) or polypeptide and is ubiquitous. ULM is ubiquitinated by ubiquitin ligase and then chemically linked directly to a ULM group or by ligation. ABM is chemically bonded via an anchor moiety L. Alternatively, ABM may be a ULM' group, and the ULM' group may also be a ubiquitin ligase binding moiety, which may be the same as or different from the ULM group described above. and L is bonded to the ULM group via a linker moiety or directly. minutes, which may or may not be present, and may be a combination of ULM and ABM, or a pharmaceutically acceptable salt thereof. Chemically (covalently) bonded salts, enantiomers, stereoisomers, solvates, or polymorphs Combine.

[0144] In certain embodiments, the ULM is 50 against E3 ubiquitin ligases with a concentration of less than about 200 μM exhibits activity or binds to IC 50 are well known in the art, for example, in fluorescence polarization assays. It can be determined according to any known method.

[0145] In certain additional embodiments, the bifunctional compounds described herein have a molecular weight of about 100, 50, 10, 1, Less than 0.5, 0.1, 0.05, 0.01, 0.005, 0.001 mM, or about 100, 50, 10, 1, 0.5, 0.1, 0.05 , 0.01, 0.005, 0.001 μM or less, or about 100, 50, 10, 1, 0.5, 0.1, 0.05, 0.01, 0.005 , IC<0.001nM 50 The activity of

[0146] The ULM and ABM groups can be attached via any group that is appropriate and stable for the linker chemistry. In a preferred embodiment of the present disclosure, the linker is independently Preferably, the ULM and ABM groups are amides, esters, thioesters, keto groups, carbamers, etc. The ULM and ABM groups are covalently bonded via a carbon or ether. The ULM group is inserted on either side of the ubiquitin ligase to maximize binding and degradation of the ULM group. This can provide maximum binding of the ABM group to the target protein. In such cases, the linker may comprise an optionally substituted alkyl on the ULM and / or ABM group, It may be bonded to an alkylene, alkene or alkyne group, an aryl group or a heterocyclic group. stomach.

[0147] Exemplary Androgen Binding Moieties (ABMs) In another aspect, the present disclosure provides AR binding moieties (ABMs), which are specific In aspects and embodiments of the present invention, the linker and / or ULM is linked to a will be done.

[0148] In any of the compounds described herein, the ABM binds to the androgen receptor (AR). A variety of androgen receptor binding compounds have been reported in the literature. Testosterone, dihydrotestosterone, and metribolone (methyltriethoxybenzone) also known as nolon or R1881), as well as e.g. bicalutamide, enzalutamide androgen derivatives, such as non-steroidal compounds such as benzodiazepines, benzodiazepines, and benzocaine. For manufacturers, these androgen receptor binding compounds are ABMs in PROTAC compounds. It will be recognized that there are many documents that could be used as part of the Although not yet determined, GF Allan et. al, Nuclear Receptor Signaling, 2003, 1, e009; R. H. Bradbury et. al, Bioorganic & Medicinal Chemistry Letters, 2011 5442-5445; C Guo et. al, Bioorganic & Medicinal Chemistry Letters, 2012 2572-2578; PK Po utiainen et. al, J. Med. Chem. 2012, 55, 6316 - 6327 A. Pepe et. al, J. Med. Che m. 2013, 56, 8280 - 8297; ME Jung et al, J. Med. Chem. 2010, 53, 2779-2796 and the like, which are incorporated herein by reference.

[0149] In certain embodiments, the ABM is selected from, but not limited to, the structures shown below: The dashed line indicates the linker moiety or point of attachment of ULM:

[0150] [ka]

[0151] During the ceremony: W 1 are aryl, heteroaryl, bicyclic, or biheterocyclic, each independently with one or more of H, halo, hydroxyl, nitro, CN, C≡CH, C 1~6 Alkyl (optionally substituted Straight chain, branched chain, e.g., one or more halo, C 1~6 optionally substituted with alkoxyl), C 1~6 Alkoxy (straight or branched chain optionally substituted, e.g., optionally substituted with one or more halo) (optionally substituted), C 2~6 Alkenyl, C 2~6 substituted by alkynyl, or CF3; Y 1 , Y 2 are each independently NR Y1 ,O,S; Y 3 , Y 4 , Y 5 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , C=O, C=S, SO, SO2, heteroa Reel, or aryl; Q is a 3-6 membered ring with 0-4 heteroatoms, optionally 0-6 R Q Each R is replaced by Q are independently H, C 1~6 Alkyl (straight or branched chain, optionally substituted, e.g., with one or more halo groups) , C 1~6 optionally substituted with alkoxyl), halogen, C 1~6 Alkoxy or or two R Q The groups are 3-8 membered rings containing 0-2 heteroatoms along with the atoms to which they are attached. form a system); R 1 , R 2 , Ra , R b , R Y1 , R Y2 are each independently H, C 1~6 Alkyl (optionally substituted straight chain, Branched chain, e.g., one or more halo, C 1~6 optionally substituted with alkoxyl), halogen, C1 ~6 alkoxy, cyclic, heterocyclic, or R 1 , R 2 are the atoms to which they are bonded. Forming a 3-8 membered ring system containing 0-2 heteroatoms; W 2 is a bond, C 1~6 Alkyl, C 1~6 Heteroalkyl, O, aryl, heteroaryl, fatty cyclic, heterocyclic, biheterocyclic, biaryl, or biheteroaryl, each of which is optionally 1 to 10 R W2 is replaced by; Each R W2 are independently H, halo, and C 1~6 Alkyl (optionally substituted straight or branched chain, e.g., one or more Optionally replaced by F above), -OR W2A , C 3-6 Cycloalkyl, C 4-6 cycloheteroalkyl , C 1-6 Alicyclic (optionally substituted), heterocyclic (optionally substituted), aryl (optionally substituted), substituted), or heteroaryl (optionally substituted), bicyclic heteroaryl or is aryl, OC 1-3 Alkyl (optionally substituted), OH, NH2, NR Y1 R Y2 , CN; and Beauty R W2A is H, C 1~6 Alkyl (straight chain, branched chain), or C 1~6 Heteroalkyl (straight chain, branched chain), each of which is optionally a cycloalkyl, cycloheteroalkyl, aryl, heterocycle, Heteroaryl, halo, or OC 1~3 It is substituted by alkyl.

[0152] In any of the embodiments described herein, W 2 may contain one or more ULM groups or is covalently attached to a CLM group, or one or more UL groups as described herein. It is covalently attached to a linker that is attached to the M group or the CLM group.

[0153] In certain embodiments, W 1 teeth,

[0154] [ka]

[0155] In the formula, each R 22 are independently halo, H, optionally substituted alkyl, haloalkyl, cyano, or nitro; and Each R 23 are independently H, halo, CF3, optionally substituted alkyl, alkoxy, haloalkoxy The substituents are aryl, cyano, or nitro.

[0156] In certain additional embodiments, W 1 is selected from the group consisting of:

[0157] [ka]

[0158] In certain embodiments, the ABM comprises a structure selected from the following structures shown below: During the ceremony,

[0159] [ka]

[0160] indicates the point of attachment of the linker or ULM:

[0161] [ka]

[0162] During the ceremony: R Q2 is H, halogen, CH3 or CF3; R Q3 is H, halo, hydroxyl, nitro, CN, C≡CH, C 1~6 Alkyl (straight chain, branched chain) , optionally one or more halo, C 1~6 substituted by alkoxyl), C 1~6 Alkoxyl (straight chain , branched chain, optionally substituted with one or more halo), C 2~6 Alkenyl, C 2~6 Alkini le, or CF3; Y 3 , Y 4 , Y 5 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , C═O, heteroaryl, or is aryl; R Y1 , R Y2 are each independently H or C 1~6 Alkyl (straight or branched chain, optionally with one or more Haro, C 1~6 alkoxy, cyclic or heterocyclic); and R Q are each independently H, C1-C6 alkyl (linear or branched, optionally with one or more halo, or or C 1~6 substituted by alkoxyl) or two R Q But they are combined Together with the atom(s) to be bonded, they form a 3- to 8-membered ring system containing 0-2 heteroatoms.

[0163] In certain embodiments, each R Q is independently H or CH. In another embodiment, R Q3 teeth , CN.

[0164] In certain embodiments, the ABM comprises a structure selected from the following structures shown below: During the ceremony,

[0165] [ka]

[0166] indicates the point of attachment of the linker or ULM:

[0167] [ka]

[0168] During the ceremony: R Q2 is H, halogen, CN, CH3 or CF3; and R Q3 is H, halo, hydroxyl, nitro, CN, C≡CH, C 1~6 Alkyl (straight chain, branched chain, Optionally one or more halo, C 1~6 substituted by alkoxyl), C 1~6 Alkoxyl (straight chain, Branched chain, optionally substituted with one or more halo), C 2~6 Alkenyl, C 2~6 Alkynyl , or CF3; Y 3 , Y 4 , Y 5 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , C═O, heteroaryl, or is aryl; and R Y1 , R Y2 are each independently H or C 1~6 Alkyl (straight or branched chain, optionally with one or more Haro, C 1~6 alkoxy, cyclic or heterocyclic); and X is N or C.

[0169] In certain embodiments, R Q3 is CN. In certain additional embodiments, the ABM comprises the structure shown below, where the dashed line represents the linker: -Indicating the attachment point of the moiety or ULM or CLM:

[0170] [ka]

[0171] [ka]

[0172] Each R 22 are independently H or -CN; Each R 23 are independently H, halo, C1-C6 alkyl (optionally substituted straight or branched chain), C1- C6 alkoxy, or -CF3; Y 3 is a bond or O; Y 4 is a bond or NH; Y 5 is a bond, C=O, C1-C6 heteroaryl, or C1-C6 aryl; R 1 , R 2 are each independently H or C1-6 alkyl (optionally substituted straight or branched chain, e.g., If there are more than one halo, or C 1~6 optionally substituted with alkoxyl); W 2 is a bond, C 1~6 Aryl, C1-6 heteroaryl, C 1~6 Alicyclic or C1-6 heterocyclic , biheterocyclic, biaryl, or biheteroaryl, each optionally containing 1 to 10 R W2 to is substituted by; and Each R W2 are independently H or halo; and

[0173] [ka]

[0174] represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific. In any of the embodiments described herein, W 2 may contain one or more ULM groups or is covalently attached to a CLM group, or one or more UL groups as described herein. It is covalently attached to a linker that is attached to the M group or the CLM group.

[0175] In certain additional embodiments, W 1 is selected from the group consisting of:

[0176] [ka]

[0177] In any aspect or embodiment described herein, W 2 is from the group consisting of Selected:

[0178] [ka]

[0179] In certain embodiments, the ABM is selected from, but not limited to, the structures shown below: The dashed line indicates the linker moiety or point of attachment of ULM:

[0180] [ka]

[0181] [ka]

[0182] Each R 22 are independently H or -CN; Each R 23 are independently H, halo, or -CF3; Y 1 , Y 2 are each independently O or S; R 1 , R 2 are each independently H or a methyl group; W 2 is a bond, C 1~6 aryl, or heteroaryl, each of which may have one, two, or three R W2 is replaced by; and Each R W2 are independently H, halo, and C 1~6 alkyl (optionally substituted with one or more F), OC 1~ 3 alkyl (optionally substituted with one or more -F).

[0183] In any of the embodiments described herein, W 2 may contain one or more ULM groups or is covalently attached to a CLM group, or one or more UL groups as described herein. It is covalently attached to a linker that is attached to the M group or the CLM group.

[0184] In certain additional embodiments, W 1 is selected from the group consisting of:

[0185] [ka]

[0186] In certain additional embodiments, W 2 teeth

[0187] [ka]

[0188] is selected from the group consisting of: In certain embodiments, the ABM is selected from the group consisting of:

[0189] [ka]

[0190] [ka]

[0191] [ka]

[0192] [ka]

[0193] [ka]

[0194] [ka]

[0195] In certain embodiments, the ABM comprises the following structure:

[0196] [ka]

[0197] In the formula, W 1 are aryl or heteroaryl, each independently containing one or more of H, halo, Droxyl, nitro, CN, C≡CH, C 1~6 Alkyl (straight or branched chain, optionally with one or more halides) Ro, C 1~6 substituted by alkoxyl), C 1~6 Alkoxy (linear or branched chain, optionally 1 (substituted by more than one halo), C 2~6 Alkenyl, C 2~6 Alkynyl, or CF3 be replaced; Y 3 , Y 4 , Y 5 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , C=O, C=S, SO, SO 2、 Heteroa reel, or aryl; Q is a 4-membered alicyclic ring with 0-2 heteroatoms, optionally 0-6 R Q is replaced by Each R Q are independently H, C 1~6 Alkyl (straight or branched chain, optionally with one or more halo, C 1~6 Arco substituted with hydroxyl) or two R Q The groups, together with the atoms to which they are attached, are Forming a 3-8 membered ring system containing two heteroatoms); R Y1 , R Y2 are independently H, C 1~6 Alkyl (straight or branched chain, optionally containing one or more halo groups) , C1~6 substituted by alkoxyl); W 2 is a bond, C 1~6 Alkyl, C 1~6 Heteroalkyl, O, C 1~6 Alicyclic, heterocyclic, aryl aryl, biheterocyclic, biaryl, or biheteroaryl, or heteroaryl; Each optionally contains 1, 2, or 3 R W2 is replaced by; and Each R W2 are independently H, halo, and C 1-6 Alkyl (straight or branched chain, optionally substituted with one or more F) (substituted), C 1-6 heteroalkyl (straight chain, branched chain, optionally substituted), -OR W2A OC 1-3 alkyl (optionally substituted with one or more -F), C 3-6 Cycloalkyl, C 4-6 Shik heteroalkyl (optionally substituted), C 1-6 Alkyl (optionally substituted), C 1-6 Alicyclic Formula (optionally substituted), heterocyclic (optionally substituted), aryl (optionally substituted) ), heteroaryl (optionally substituted), bicyclic heteroaryl (optionally substituted) , bicyclic aryl, OH, NH2, NR Y1 R Y2 , or CN; and R W2A is H, C 1~6 Alkyl (straight chain, branched chain), or C 1~6 Heteroalkyl (straight chain, branched chain), each of which is optionally a cycloalkyl, cycloheteroalkyl, aryl, heterocycle, Heteroaryl, halo, or OC 1~3 It is substituted by alkyl.

[0198] In an additional aspect, the present disclosure provides an androgen receptor binding compound comprising the structure: Provide:

[0199] [ka]

[0200] In the formula, W 1 is aryl, heteroaryl, bicyclic or biheterocyclic; each independently one or more of H, halo, hydroxyl, nitro, CN, C≡CH, C 1~6 Alkyl ( Straight chain, branched chain, optionally with one or more halo, C 1~6 substituted by alkoxyl), C 1~6 Al Coxyl (straight or branched chain, optionally substituted with one or more halo), C 2~6 Alkenyl, C 2~6 substituted by alkynyl, or CF3; Y 1 , Y 2 are each independently NR Y1 , O, or S; Y 3 , Y 4 , Y 5 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , C=O, C=S, SO, SO2, He is heteroaryl, or aryl; Q is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally 0 ~6 R Q Each R is replaced by Q are independently H, C 1~6 Alkyl (straight or branched chain, optionally with one or more Upper halo, C 1~6 substituted with alkoxyl) or two R Q The groups are those that bond together with the atoms to be bonded form a 3-8 membered ring system containing 0-2 heteroatoms); R 1 , R 2 , R a , R b , R Y1 , R Y2 are each independently H, C 1~6 Alkyl (straight chain, branched chain, One or more halos, C 1~6 optionally substituted with alkoxyl) or R 1 , R 2 is that together with the atom to which they are attached form a 3-8 membered ring system containing 0-2 heteroatoms); W 2 is a bond, C 1~6 Alkyl, C 1~6 Heteroalkyl, O, C 1~6 Alicyclic, heterocyclic, aryl, biheterocyclic, biaryl, or biheteroaryl, or heteroaryl; each optionally containing 1, 2, or 3 R W2 is replaced by; Each R W2 are independently H, halo, and C 1-6 Alkyl (straight or branched chain, optionally containing one or more F substituted by), C 1-6 heteroalkyl (straight chain, branched chain, optionally substituted), -OR W2A , O.C. 1-3 alkyl (optionally substituted with one or more -F), C 3-6 Cycloalkyl, C 4- 6Cycloheteroalkyl, C 1-6 Alkyl (optionally substituted), C 1-6 Alicyclic (optionally substituted) heterocyclic (optionally substituted), aryl (optionally substituted), or heterocyclic aryl (optionally substituted), bicyclic heteroaryl or aryl, OH, NH2, N R Y1 R Y2, CN; and R W2A is H, C 1~6 Alkyl (straight chain, branched chain), or C 1~6 Heteroalkyl (straight chain, branched chain), each of which is optionally a cycloalkyl, cycloheteroalkyl, aryl, heterocycle, Heteroaryl, halo, or OC 1~3 It is substituted by alkyl.

[0201] In certain embodiments, the androgen receptor binding moiety has the structure:

[0202] [ka]

[0203] [ka]

[0204] Each R 22 are independently H or -CN; Each R 23 are independently H, halo, or -CF3; Y 3 is a bond or O; Q is a 4-membered ring, optionally containing 0 to 4 R Q Each R is replaced by Q are independently H or methyl ; Y4 is a bond or NH; Y5 is a bond, C=O, or C=S; Each W 2 are independently a bond, C1-6 aryl or heteroaryl, each of which is 1, 2 or 3 of W2 and each R W2 are independently H, halo, or one or two hetero atoms. A 6-membered alicyclic ring containing a heteroatom or a 5-membered alicyclic ring containing one, two, or three heteroatoms is an aromatic ring.

[0205] In certain additional embodiments, W 2 teeth,

[0206] [ka]

[0207] In any of the embodiments described herein, W 2 may contain one or more ULM groups or is covalently attached to a CLM group, or one or more UL groups as described herein. It is covalently attached to a linker that is attached to the M group or the CLM group.

[0208] In certain additional embodiments, W 1 teeth,

[0209] [ka]

[0210] In certain embodiments, the androgen binding moiety has the following structure:

[0211] [ka]

[0212] In the formula, W 1 is aryl, independently substituted by one or more halo, CN; Y 3 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , where C=O; Q is a 5-membered aromatic ring having 1 or 2 heteroatoms; R Y1 , R Y2 are independently H, C 1-6 It is alkyl (straight chain, branched chain); W 2 is a bond, aryl, or heteroaryl, each of which may optionally occur 1, 2, or 3 times; R W2 is replaced by; and Each R W2 are independently H, halo, and C 1~6 alkyl (optionally substituted with one or more F), OC 1~ 3 alkyl (optionally substituted with one or more -F).

[0213] In any of the embodiments described herein, W 2 may contain one or more ULM groups or is covalently attached to a CLM group, or one or more UL groups as described herein. It is covalently attached to a linker that is attached to the M group or the CLM group.

[0214] In certain embodiments, W 1 teeth,

[0215] [ka]

[0216] In the formula, each R 22 is independently halo or CN; and Each R 23 are independently H or halo.

[0217] In certain additional embodiments, W 1 is selected from the group consisting of:

[0218] [ka]

[0219] In certain additional embodiments, Q is

[0220] [ka]

[0221] In certain additional embodiments, W 2 teeth

[0222] [ka]

[0223] In certain additional embodiments, (Y 3 ) 0-5 teeth

[0224] [ka]

[0225] In certain embodiments, the ABM is selected from, but not limited to, the structures shown below: The dashed line indicates the linker moiety or point of attachment of ULM:

[0226] [ka]

[0227] [ka]

[0228] Each R 22 are independently H or -CN; Each R 23 are independently H, halo, or -CF3; Y 1 , Y 2 are each independently O or S; Y 3 , Y 4 , Y 5 are each independently a bond, O, or NR Y2 , C.R. Y1 R Y2 , C=O, C=S, SO, or SO2 ru; R 1 , R 2 are each independently H or a methyl group; W 2 is a bond, C 1~6 aryl, or heteroaryl, each of which may have one, two, or three R W2 is replaced by; and Each R W2 are independently H, halo, and C 1~6 alkyl (optionally substituted with one or more F), C 3-6 Cycloalkyl, C 4-6 Cycloheteroalkyl, OC 1-3 Alkyl (optionally with one or more -F) is replaced).

[0229] In any of the embodiments described herein, W 2 may contain one or more ULM groups or is covalently attached to a CLM group, or one or more UL groups as described herein. It is covalently attached to a linker that is attached to the M group or the CLM group.

[0230] In certain additional embodiments, W 1 is selected from the group consisting of:

[0231] [ka]

[0232] In certain additional embodiments, W2 is

[0233] [ka]

[0234] In certain embodiments, the ABM comprises the structure shown below, where the dashed line represents the linker moiety: Or to indicate the attachment point of ULM or CLM:

[0235] [ka]

[0236] [ka]

[0237] Each R 22 are independently H or -CN; Each R 23 are independently H, halo, or -CF3; Y 3 is a bond or O; Y 4 is a bond or NH; Y 5 is a bond, C=O, C1-C6 heteroaryl, or C1-C6 aryl; R 1 , R 2 are each independently H or C1-C6 alkyl (straight or branched chain, with one or more B or C 1-6 optionally substituted with alkoxyl); W 2 is a bond, C 1~6 Aryl, C1-6 heteroaryl, C 1~6 Alicyclic or C1-6 heterocyclic Each of these formulas is an arbitrary value of 1 to 10 R W2 is replaced by; and Each R W2 are independently H or halo; and

[0238] [ka]

[0239] represents a bond that can be stereospecific ((R) or (S)) or non-stereospecific. In any of the embodiments described herein, W 2may contain one or more ULM groups or is covalently attached to a CLM group, or one or more UL groups as described herein. It is covalently attached to a linker that is attached to the M group or the CLM group.

[0240] In certain additional embodiments, W 1 is selected from the group consisting of:

[0241] [ka]

[0242] In certain additional embodiments, W 2 teeth,

[0243] [ka]

[0244] In certain embodiments, the androgen receptor binding compound of the ABM is selected from the group consisting of: Selected: trans-2-chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile ; cis-2-chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile; trans 6-amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl] [tributyl]pyridazine-3-carboxamide; trans tert-butyl N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl] chlorobutyl]carbamate; trans 4-amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl] [tributyl]benzamide; trans 5-amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl] [tributyl]pyrazine-2-carboxamide; trans 2-amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl] [tributyl]pyrimidine-5-carboxamide; 4-Methoxy-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl thylcyclobutyl]benzamide; trans 1-(2-hydroxyethyl)-N-[3-(3-chloro-4-cyanophenoxy)-2,2, 4,4-Tetramethylcyclobutyl]-1H-pyrazole-4-carboxamide; trans 6-amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl] [tributyl]pyridine-3-carboxamide; trans 4-[(5-hydroxypentyl)amino]-N-[3-(3-chloro-4-cyanopheno (oxy)-2,2,4,4-tetramethylcyclobutyl]benzamide; and trans tert-butyl 2-({5-[(4-{[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl- (tetramethylcyclobutyl)carbamoyl}phenyl)aminopentyl}oxy)acetate; and N-((1r,3r)-3-(4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-methylbenzyl Zuamide.

[0245] The term "hydrocarbyl" is intended to mean a compound containing carbon and hydrogen; They may be fully saturated, partially unsaturated, or aromatic, and may contain aryl groups, alkyl groups, Includes alkenyl and alkynyl groups.

[0246] The term "unsubstituted" shall mean substituted only with hydrogen atoms. The range of carbon atoms included means that the carbon is either absent or replaced with H. Thus, the range of carbon atoms C0-C6 includes 1, 2, 3, 4, 5, and 6 carbon atoms, and C For 0, there is an H in place of the carbon. "Substituted" or "Optionally substituted" The term refers to one or more substituents (as defined in this application) at any carbon (or nitrogen) position on a molecule within the context. Up to five independent substituents, preferably up to three substituents, on the moieties in the compounds according to the formula A group, often one or two substituents, may contain substituents which may themselves be further substituted. ) are meant to be independently selected (i.e., when there are multiple substituents, each substituent is a separate substituent). (independent of substituents), and the substituents are hydroxyl, thiol, carboxyl , cyano (C≡N), nitro (NO2), halogen (especially alkyl, especially e.g. trifluoromethyl) alkyl groups (preferably 1, 2, or 3 halogens on a methyl group, such as methyl, C1-C 10 , more preferably C1-6), aryl (especially phenyl and substituted phenyl, e.g. benzyl or benzoyl), alkoxy groups (preferably C1-C6 alkyl or aryl), phenyl and substituted phenyl), thioethers (C1-C6 alkyl or aryl ), acyl (preferably C1-C6 acyl), ester or thioester (preferably C1-C6 alkyl or aryl) and alkylene ester (the bond is not an ester functional group) , on an alkylene group, preferably substituted with a C1-C6 alkyl or aryl group; Preferably containing C1-C6 alkyl or aryl, halogen (preferably F or Cl) amines (including 5- or 6-membered cyclic alkylene amines, C1-C6 alkylamines or C1-C6 Further included are dialkylamines, wherein the alkyl groups are substituted with one or two hydroxyl groups. or an optionally substituted —N(C0-C6 alkyl)C(O)(O-C1-C6 alkyl) group (polyethylene glycol). The ethylene glycol chain may be optionally substituted with one halogen, preferably chlorine, substituent. further bonded to an alkyl group containing the hydroxyl group), hydrazine, amide, which is preferably one or more or two C1-C6 alkyl groups (carboxyl optionally substituted with one or two C1-C6 alkyl groups) an alkanol (preferably C1-C6 alkyl or aryl), or an alkanol and those substituted with glycerol (preferably C1-C6 alkyl or aryl). Substituents according to the present disclosure may include, for example, -SiR1R2R3 groups, where each of R1 and R2 is is as otherwise described herein, and R3 is H or a C1-C6 alkyl group, In this context, preferably R1, R2, and R3 are C1-C3 alkyl groups (isopropyl or t-butyl groups). Each of the above groups may be directly attached to the substituted moiety, or The substituents are optionally substituted (CH2) m - or optionally substituted -(OCH2) m -,-( OCH2CH2) m -or-(CH2CH2O) m -group to a substituted moiety (preferably aryl or In the case of heteroaryl moieties, they may be bonded to any of the above-mentioned substituents. The alkylene group may be substituted with one or more of -(CH2) m -or-(CH2) n -Base or example Other chains, such as the ethylene glycol chains identified above, may be substituted anywhere on the chain. Preferred substituents on the alkylene group include halogen or C1-C6 (preferably (e.g., C1-C3) alkyl groups, which optionally contain one or two hydroxyl groups, one or or two ether groups (O-C1-C6 groups), up to three halo groups (preferably F), or substituted with amino acid side chains as otherwise described herein, and optionally substituted amides. (preferably a carboxamide substituted as described above) or a urethane group (often and one or two C0-C6 alkyl substituents, which may also be further substituted. In certain embodiments, an alkylene group (often a single methylene group) can have one or more are two optionally substituted C1-C6 alkyl groups, preferably C1-C4 alkyl groups, in most cases and optionally substituted with a methyl or O-methyl group, or an amino acid side chain as otherwise described herein. In this disclosure, a moiety in a molecule may optionally have up to five substituents, preferably up to three. In most cases, the substituted moieties in this disclosure may be substituted with one or more substituents. or two substituents.

[0247] The term "substituted," where each substituent is independent of any other substituent, means that Within the context of the use of C1-C6 alkyl, C1-C6 alkoxy, halogen, amide, carbo Sulfone, including oxamide, sulfonamide, keto, carboxy, C1-C6 ester (oxy) ester or carbonyl ester), C1-C6 keto, urethane -OC(O)-NR1R2 or -N(R 1) -C(O)-O-R1, nitro, cyano, and amine (especially C1-C6 alkylene -NR1R2, mono or or di-C1-C6 alkyl substituted amines optionally substituted with one or two hydroxyl groups Each of these groups is intended to mean the groups described above, unless otherwise indicated. Unless otherwise specified within the context, the substituents may contain from 1 to 6 carbon atoms. Depending on the context of use, preferred substituents include, for example, -NH-, -NHC(O)-, -O-, =O, -(CH2 ) m - (wherein m and n are 1, 2, 3, 4, 5 or 6, depending on the context), -S- , -S(O)-, SO2- or -NH-C(O)-NH-, -(CH2) n OH, -(CH2) n SH, -(CH2) n COOH, C1-C6 Al Kill, -(CH2) n O-(C1-C6 alkyl), -(CH2) n C(O)-(C1-C6 alkyl), -(CH2) n OC(O)-(C1-C6 alkyl), -(CH2) n C(O)O-(C1-C6 alkyl), -(CH2) n NHC(O)-R1, -(CH2) n C(O)-NR1R2, -( OCH2) n OH, -(CHO) n COOH, C1-C6 alkyl, -(OCH2) n O-(C1-C6 alkyl), -(CHO) n C(O)-( C1-C6 alkyl), -(OCH2) n NHC(O)-R1, -(CHO) n C(O)-NR1R2, -S(O)2-R S , -S(O)-R S (R S teeth , C1-C6 alkyl or -(CH2) m -NR1R2 group), NO2, CN or halogens (F, Cl, Br, I R1 and R2 may each be H or Cl depending on the context. is a C1-C6 alkyl group (containing one or two hydroxyl groups or up to three halogen groups, preferably The term "substituted" also applies to the definition. Within the chemical context of the compound being studied and the substituents used, optionally substituted aryl groups are also or heteroaryl group or an optionally substituted heteroaryl group as otherwise described herein. An alkylene group is also intended to mean a cyclic group, as otherwise disclosed herein. and preferably an optionally substituted C1-C6 alkyl group (methyl, ethyl, or hydroxymethyl or hydroxyethyl, and the chiral center is provided), the side chain of an amino acid group as otherwise described herein, an amide group as described above, or a urethane group, an OC(O)-NR1R2 group, where R1 and R2 are as otherwise described herein. Although the alkyl groups may be substituted with certain groups as described above, many other groups may also be used as substituents. Various optionally substituted moieties may have three or more substituents, preferably three or fewer substituents, and preferably Preferably, the compound may be substituted with one or two substituents. If a substitution is required (mainly due to valence) but no substitution is indicated, the context of the substitution Unless otherwise indicated in the specification, the substituents are to be considered or understood to be H. Please be careful.

[0248] Exemplary AR-PROTAC Compounds As noted above, in certain embodiments, the present disclosure provides a compound comprising at least one ABM group as described herein. , a linker, and a bifunctional PROT comprising at least one ULM (or CLM) group. Provided is an AC compound.

[0249] In certain embodiments, the compounds are compounds 1-625 (i.e., compounds 1-625 shown in Figures 2, 3, 4, and 5, respectively). , 6, and 7, the chemical structures of which are set forth in Tables 2, 3, 4, 5, 6, and 7, and their The compound is selected from the group consisting of salts and polymorphs.

[0250] In additional embodiments, the compound is selected from the group consisting of: 4-{3-[4- ({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H- isoindole-4-yl]-4,7,10-trioxa-1-azadodecan-12-yl}oxy) phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl} -2-(trifluoromethyl)benzonitrile (1); 4-(3-{4-[2-(2-{[2-(2,6-diox Isopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl -(4,4-dimethyl-5-oxo-2-sulfanilic acid) 4-{3-[ 4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H -isoindol-4-yl]-4,7,10,13,16-pentaoxa-1-azaoctadecane-18 -yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazoline 4-[3-(4-{2-[2-(2 -{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-i [isoindol-4-yl]amino}ethoxy)ethoxy]ethoxy}phenyl)-4,4-dimethyl -5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl ) benzonitrile (4); 4-[3-(4-{3-[2-(2-{[2-(2,6-dioxopiperidin-3-yl )-1,3-Dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)eth Oxy]propoxy}phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazo Lysin-1-yl]-2-(trifluoromethyl)benzonitrile (5); 4-{3-[4-({1-[2- (2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindo (4-yl)-4,7,10-trioxa-1-azatetradecane-14-yl}oxy)phenyl yl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-( Trifluoromethyl)benzonitrile (6); 4-{3-[4-({1-[2-(2,6-dioxopiperidinyl Indol-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]-4,7,10 -trioxa-1-azatridecan-13-yl}oxy)phenyl]-4,4-dimethyl-5-o {2-(trifluoromethyl)benzoxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzo Nitrile (7); 4-(3-{4-[(1-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1,3- Dioxo-2,3-dihydro-1H-isoindol-4-yl}-4,7,10-trioxa-1-a (Zadodecan-12-yl)oxy]phenyl}-4,4-dimethyl-5-oxo-2-sulfanil 4-(3-( ... 4-[(1-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydrido (1H-isoindol-4-yl)-4,7,10-trioxa-1-azadodecan-12-yl Oxy]phenyl}-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidine-1 -yl)-2-(trifluoromethyl)benzonitrile (9); 4-[3-(4-{3-[3-(2-{[2-( 2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindo (4-yl)amino}ethoxy)propoxy]propoxy}phenyl)-4,4-dimethyl-5 -Oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzyl 4-{4,4-dimethyl-3-[4-({1-[2-(3-methyl-2,6-dioxopyridine 1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)- 4,7,10-trioxa-1-azatridecan-13-yl}oxy)phenyl]-5-oxo-2- Sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile ( 11); 4-[3-(4-{4-[(5-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo -2,3-dihydro-1H-isoindol-4-yl]amino}pentyl)oxy]phenyl}f (phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]- 2-(Trifluoromethyl)benzonitrile (12); 4-{[5-(3-{[2-(2,6-dioxopiperidine Indol-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino }propoxy)pentyl]oxy}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-Tetramethylcyclobutyl]benzamide (13); 4-{3-[4-({1-[2-(2,6-di Oxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl (1,4,7,10-tetraoxatridecan-13-yl)oxy)phenyl]-4,4-dimethyl -5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl )benzonitrile (14); 6-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo So-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl ]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo butyl]pyridine-3-carboxamide (15); 6-{4-[2-(3-{[2-(2,6-dioxopiperidine Indol-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino }propoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanopropanol] (phenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (16); 4 -(3-{4-[1-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-yl]oxy}ethyl)-1H-1,3-benzodiazole-5- 4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidine-1-ylphenyl 4-{[5-(3-{[2-(2,6-dioxo-2-yl)benzonitrile (17); Isopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl 1r,3r)-3-(3-chloro-N-[(1r,3r)-3-propoxy-pentyl]amino}-3-fluoro-N-[(1r,3r)-3-(3-chloro- 4-Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (18); 6-[4 -(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-i [(1r,3r)-3-(3-chloro-4-indol-4-yl)oxy]ethyl)piperazin-1-yl]-N-[ ... (4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carbohydrate Voxamide (19); 6-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxamide So-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl ]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo butyl]pyridine-3-carboxamide (20); 6-(4-{3-[2-(2,6-dioxopiperidine -3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]propyl}piperidine 1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetraazine-1-yl tetramethylcyclobutyl]pyridine-3-carboxamide (21); 6-{4-[2-(2-{[2-(2,6 -Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-4 -yl]oxy}ethoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro- 4-Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxa 4-{4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3 -Dihydro-1H-isoindol-4-yl]oxy}ethyl)piperazin-1-yl]butyl }-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetrahydrofuran tetramethylcyclobutyl]benzamide (23); 6-{4-[2-(3-{[2-(2,6-dioxopiperidine Indol-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]amino }propoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanopropanol] (phenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (24); 6 -{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-diox 2,3-Dihydro-1H-isoindol-4-yl]amino}propoxy)ethyl]piperazine {(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-4-phenyl-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-4-phenyl-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl- Methylcyclobutyl]pyridine-3-carboxamide (25); 4-(6-{4-[2-(2,6-dioxo Isopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl yl]piperazin-1-yl}hexyl)-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl) 4-{3-[4-(4-methyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide (26); -(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H -isoindol-4-yl]amino}propyl)piperazin-1-yl]propyl}-N-[(1r ,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyano 4-[5-(3-{[2-(2,6-dioxopiperidin-3-yl) -1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)pe N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl cyclobutyl]benzamide (28); 6-{4-[2-(3-{[2-(2,6-dioxopiperidine-3- yl)-5-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]a {amino}propoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyano (2,2,4,4-tetramethylcyclobutyl)pyridine-3-carboxamide (29) 4-(4-{4-[2-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3- Dihydro-1H-isoindol-5-yl}oxy)ethyl]piperazin-1-yl}butyl -N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo butyl]benzamide (30); 4-(4-{4-[2-({2-[(3S)-2,6-dioxopiperidine-3- yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}oxy)ethyl]piperidine 1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-Tetramethylcyclobutyl]benzamide (31); 4-{4-[4-(2-{[2-(2,6-diox (isopiperidin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoin N-[(1r,3r)-3-(3-(2 ... Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (32) 6-{4-[5-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro 1H-isoindol-4-yl)(oxy)pentyl)piperazin-1-yl}-N-[(1r, 3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine Zine-3-carboxamide (33); 4-(4-{4-[2-({2-[(3S)-2,6-dioxopiperidine -3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}oxy)e butyl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy 6-{4-[5-({2-[(3S)- 2,6-Dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindole -5-yl}oxy)pentyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4- Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (35); 4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-5-fluoro-1,3-dioxo xo-2,3-dihydro-1H-isoindol-4-yl]piperazin-1-yl}butyl)-N -[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl 4-{4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-5- Fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl 1r,3r)piperazin-1-yl]butyl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy) -2,2,4,4-tetramethylcyclobutyl]benzamide (37); 6-(4-{6-[2-(2,6-di- 1-oxo-2,3-dihydro-1H-isoindol-4-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl hexyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy) -2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (38); 4-(4-{4- [2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1,3-dioxo-2,3-dihydro 1H-isoindol-5-yl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3 -chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (3 9); 4-(6-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro- 1H-isoindol-5-yl]piperazin-1-yl}hexyl)-N-[(1r,3r)-3 -(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamine 6-{4-[5-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo -2,3-Dihydro-1H-isoindol-5-yl}oxy)pentyl]piperazin-1-yl }-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo Butyl]pyridine-3-carboxamide (41); 6-[4-(5-{[2-(2,6-dioxopiperidine -3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentyl -N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclo(yl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclo(yl)] ... Butyl]pyridine-3-carboxamide (42); 4-[4-(5-{[2-(2,6-dioxopiperidine -3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentyl -N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclo(yl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclo(yl)] ... butyl]benzamide (43); 4-(5-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3 -Dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}pene (1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl 4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)- 1,3-Dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}bu (1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl 4-(6-{4-[2-(2,6-dioxopiperidin-3-yl)- 6-Fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-trimethyl-1-phenyl-1-yl]hexyl] -tetramethylcyclobutyl]benzamide (46); 4-(4-{[2-(2,6-dioxopiperidinyl (indol-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}butyrate (1r,3r)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl 4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-ol]benzamide (47); xo-2,3-dihydro-1H-isoindol-4-yl]oxy}pentyl)-N-[(1r,3r)- 3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzal 4-[3-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-di Hydro-1H-isoindol-4-yl]oxy}ethoxy)propyl]-N-[(1r,3r)-3-( 3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide ( 49); 4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro 1r,3r)-3-(3-chloro-1H-isoindol-4-yl]oxy}ethoxy)butyl]-N-[( ... (4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (50); 4-[5-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H -isoindol-4-yl]oxy}ethoxy)pentyl]-N-[(1r,3r)-3-(3-chloro -4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (51); 4-[ 6-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-i N-[(1r,3r)-3-(3-chloro-4-isoindol-4-yl]oxy}ethoxy)hexyl]-N ... Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (52); N-[(2R) -1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl yl]-5-{[4-(4-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-di Hydro-1H-isoindol-4-yl]amino}butyl)piperazin-1-yl]methyl}-1 H-Pyrazole-3-carboxamide (53); 4-(4-{6-[2-(2,6-dioxopiperidine-3 -yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]hexyl}piper 1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetraazine-1-yl tetramethylcyclobutyl]benzamide (54); 4-(3-{[2-(2,6-dioxopiperidine-3 -yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}propyl) -N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo Butyl]benzamide (55); N-[(2R)-1-[3-(3-chloro-4-cyanophenyl)-1H-pi 2,6-dioxopiperidine-5-yl-[(3-[(4-[(2-(2,6-dioxopiperidine-1-yl)propan-2-yl]-5-((3-[(4-[(2-(2,6-dioxopiperidine-1-yl)propan-2-yl)propan-2-yl]-5-((3-[(4-[(2-(2,6-dioxopiperidine-1-yl) 3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine- 1-yl}propoxy)methyl]-1H-pyrazole-3-carboxamide (56); 4-[4-(3-{[ 2-(2,6-Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindo 1H-1,2,3-triazol-1-yl]-N-[(1r,3r)- 3-(3-chloro-4-cyanophenoxy)cyclobutyl]benzamide (57); 6-[4-(6-{[2 -(2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro -1H-isoindol-5-yl]amino}hexyl)piperazin-1-yl]-N-[(1r,3r) -3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridin N-3-carboxamide (58); N-[(2R)-1-[3-(3-chloro-4-cyanophenyl)-1H- Pyrazol-1-yl]propan-2-yl]-5-({3-[4-(2-{[2-(2,6-dioxopipene Lysin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amine (methyl)-1H-pyrazole-3-carboxamide 4-[4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2 ,3-Dihydro-1H-isoindol-4-yl]oxy}pentyl)-1H-1,2,3-triazo [(1r,3r)-3-(3-chloro-4-cyanophenoxy)cyclobutyl]benzyl 6-{4-[2-(4-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3 -Dioxo-2,3-dihydro-1H-isoindol-4-yl}butoxy)ethyl]piperazine {(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-4-phenyl-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-4-phenyl-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl- methylcyclobutyl]pyridine-3-carboxamide (62); 6-{4-[2-(4-{2-[(3R)-2, 6-Dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindole -N-[(1r,3r)-3-(3-chloro-4-yl)-4-yl]butoxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-yl)butoxy] ... -Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamine 6-(4-{2-[(5-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo xo-2,3-dihydro-1H-isoindol-4-yl}pentyl)oxy]ethyl}piperazine N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzoyl]-N ... 6-(4-{2-[(5-{2-[(3R)-2 ,6-Dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindole (1r,3r)-3-(3-chloro-4-yl)-N-[(1r,3r)-3-(3-chloro-4-yl)-pentyl]oxy]ethyl}piperazin-1-yl] (4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carbohydrate Voxamide (65); 4-(4-{2-[(5-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1, 3-Dioxo-2,3-dihydro-1H-isoindol-4-yl}pentyl)oxy]ethyl} Piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4 -tetramethylcyclobutyl]benzamide (66); 4-(4-{2-[(5-{2-[(3R)-2,6-di Oxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindole-4 -yl}pentyl)oxy]ethyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro- 4-Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (67); 4-(4 -{6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-iso indol-5-yl]hexyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4 -cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (68); 4-(3- {4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-i (1r,3r)-3-(3-chloroisoindol-5-yl)piperazin-1-yl}propyl)-N-[(1r,3r)-3-(3-chloroisoindol-5-yl)piperazin-1-yl]propyl] -4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (69); 4-[ 6-(4-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1 H-isoindol-5-yl}piperazin-1-yl)hexyl]-N-[(1r,3r)-3-[4- Ano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]ben amide (70); 4-[6-(4-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1-oxo -2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl)hexyl]-N-[ (1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethy 6-[4-(6-{[2-(2,6-dioxopiperidine-3-yl] (yl)-5-fluoro-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy} hexyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy) -2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (72); 6-[4-(6- {[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydr 1r,3r )-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridin 4-[6-(4-{2-[(3S)-2,6-dioxopiperidine-3-yl] yl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}piperazin-1-yl) Hexyl]-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4 ,4-tetramethylcyclobutyl]benzamide (74); and 4-[6-(4-{2-[(3R)-2,6- Dioxopiperidin-3-yl]-3-oxo-2,3-dihydro-1H-isoindole-5- yl}piperazin-1-yl)hexyl]-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl) N-((1r,3 methyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (75); r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(6-((2 -(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)amino )hexyl)piperazin-1-yl)nicotinamide (76); N-((1r,3r)-3-(3-chloro-4-cyano) Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidine (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4 -tetramethylcyclobutyl)-6-(4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)piperidin-4-yl)ethyl)piperazin-1-yl)nicotine Amide (78); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl (4-(2-((5-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindo N-((1r, 3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(( 5-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl) Oxy)ethyl)piperazin-1-yl)benzamide (80); N-((1r,3r)-3-(3-chloro-4-cyano)benzamide (81) (2,6-dioxopiperidine)-2,2,4,4-tetramethylcyclobutyl (1,3-dioxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzoate (81); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzoate (82); (4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisopropyl)-4-(6-( ... N-((indolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)hexyl)benzamide (82); 1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((1R, 4R)-5-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Oxy)pentyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)nicotinamide (83); N- ((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4- (5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)pentane N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-methyl-piperazin-1-yl)benzamide (84); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-methyl- (Ci)-2,2,4,4-tetramethylcyclobutyl)-4-(1-(5-((2-(2,6-dioxopiperidin-3-yl) )-1,3-Dioxoisoindolin-5-yl)oxy)pentyl)-1,2,3,6-tetrahydropyridin N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl)-4-(5-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxo N-((1r,3r)-isoindolin-5-yl)piperazin-1-yl)pentyl)benzamide (86); 3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(4-(2-((R )-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl )pentyl)benzamide (87); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- tetramethylcyclobutyl)-4-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro- 1-Oxoisoindolin-5-yl)piperazin-1-yl)hexyl)benzamide (88); N-((1 r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4- (2-(2,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-hydroxybenzoyl)benzamide (89); (Ci)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(6-((2-(2,6-dioxopiperidin-3-yl )-6-Fluoro-1-oxoisoindolin-5-yl)oxy)hexyl)piperazin-1-yl)di Cotinamide (90); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl (cyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoin N-((1r,3r)-3-( ... 3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-((2-(2,6- Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-4-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxo Isoindolin-5-yl)piperidin-1-yl)hexyl)benzamide (93); N-((1r,3r)-3- (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6- Dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-1-yl)hexyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-2,2,4,4-tri ... (4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)-4-(5-( ... soindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)pentyl)benzamide (95); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-( 4-(5-((2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)oxy)pe N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-methyl-2-(2-methyl-1-phenyl)piperazin-1-yl)nicotinamide (96); ... (2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidine-3- (yl)-1,3-dioxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)butyl Benzamide (97); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl (4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindole)-4-(5-( ... N-((1r,3r)-5-yl)-3,6-dihydropyridin-1(2H)-yl)pentyl)benzamide (98); -3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(1-(5-((2-( 2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl )piperidin-4-yl)benzamide (99); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-tetramethylcyclobutyl)-4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1- Oxoisoindolin-5-yl)oxy)pentyl)-1H-1,2,3-triazol-1-yl)benz Amide (100); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl 4-(6-((1S,4S)-5-(2-((R)-2,6-dioxopiperidin-3-yl)-1-oxoisopropyl)- 2,5-diazabicyclo[2.2.1]heptan-2-yl)hexyl)benzamide ( 101); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl yl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)o N-((1r,3r)-3-(3-hydroxy)pentyl)-1H-1,2,3-triazol-1-yl)nicotinamide (102); -chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-di (Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoyl N-isoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)butyl)benzamide (104); -((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4 -(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy) Piperidin-1-yl)propyl)-1H-1,2,3-triazol-1-yl)benzamide (105); N-(( 1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3 -(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)a Zetidin-1-yl)propyl)-1H-1,2,3-triazol-1-yl)benzamide (106); N-((1r ,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-( 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1H-1,2,3 -triazol-4-yl)ethyl)piperazin-1-yl)nicotinamide (107); N-((1r,3r)-3- (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(3-(1-(2-(2 ,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1H-1,2,3-triazol-1H-iodo N-((1r,3r)-3-(3-chloro-4-yl)propyl)piperazin-1-yl)nicotinamide (108); N-((1r,3r)-3-(3-chloro-4-yl)propyl)piperazin-1-yl)nicotinamide (108); 4-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)- (1,3-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)hexadecyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-2,2,4,4-tri ... tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1, 3-Dioxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide (110); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-( 4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxa N-((1r,3r)-3-(3-chloro-4-cyano)propyl)piperazin-1-yl)nicotinamide (111); N-((1r,3r)-3-(3-chloro-4-cyano) (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(1-(5-((2-(2,6-dioxopiperidine 1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl ) Nicotinamide (112); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrahydrofuran Methylcyclobutyl)-6-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Indolin-5-yl)oxy)propyl)piperidin-4-yl)nicotinamide (113); N-((1r, 3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3r)-3-(3-chloro-2-methyl-2-pyridyl)oxy)pentyl)piperazin-1-yl)nicotinamide (114); -4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-((2-(2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperazine-1- N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-2,2,4,4-tri ... tetramethylcyclobutyl)-4-((3S)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)oxy)pentyl)-3-(hydroxymethyl)piperazine-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzamide (116); Methylcyclobutyl)-6-(4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisopropyl Indolin-5-yl)oxy)azetidin-1-yl)propyl)-1H-1,2,3-triazol-1-yl N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy) -2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidin-3-yl)-1, 3-Dioxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide (118); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-( 3-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-yl)propyl)nicotinamide (119); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy) -2,2,4,4-tetramethylcyclobutyl)-6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1, 3-Dioxoisoindolin-5-yl)piperazin-1-yl)propyl)nicotinamide (120); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-( 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2 ,2,4,4-tetramethylcyclobutyl)-6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)nicotinamide (12 2); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pi N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2-(2-chloro-2-phenyl-2-pyridin-1-yl)butyl)nicotinamide (123); ... (2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidine-3- yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)butyl)nicotinamide ( 124); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl yl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-3-yl) N-((1r,3r)-3-(4-cyano-3-methylphenyl)-4-pyrazine-1-yl)butyl)nicotinamide (125); (2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidine-3- yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinic acid N-((1r,3r)-3-(3,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclohexyl amide (126) butyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5 -yl)oxy)pentyl)piperazin-1-yl)nicotinamide (127); N-((1r,3r)-3-(3-chlor- 4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(5-(3-((2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)- 1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2, 4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotine Amide (129); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl (4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline) N-((1r,3r)-3-(3-chloro-5-yl)oxy)piperidin-1-yl)butyl)nicotinamide (130); 4-(2-(4-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl) N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-methyl-piperidin-1-yl)nicotinamide (131); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-methyl- (2,2,4,4-tetramethylcyclobutyl)-2-(4-(5-((2-(2,6-dioxopiperidine-3- yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)pyrimidin Zine-5-carboxamide (132); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl)-4-(2-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo (xoisoindolin-5-yl)piperazin-1-yl)propoxy)ethyl)-3,5-difluorobenzyl N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl cyclobutyl)-4-((3S,5R)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo (isoindolin-5-yl)oxy)pentyl)-3,5-dimethylpiperazin-1-yl)benzamide ( 134); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (2,6-dioxopiperidin-3-yl)-6-(2-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) (butyl)oxy)butyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)nicotinamide ( 135); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)-6-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) (butyl)oxy)butyl)-4,6-dihydropyrrolo[3,4-c]pyrazol-5(1H)-yl)nicotinamide ( 136); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)-6-(5-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) (butyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl)nicotinamide ( 137); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (2,6-dioxopiperidin-3-yl)-6-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) )piperazin-1-yl)pentyl)nicotinamide (138); N-((1r,3r)-3-(3-chloro-4-cyano) Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-((S)-2,6-dioxopiperidine (3-indolin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperazin-1-yl)hexyl ) Nicotinamide (139); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrahydrofuran Methylcyclobutyl)-6-(6-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1- Oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide (140); N-(( 1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(9 -(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1-oxa- 4,9-Diazaspiro[5.5]undecan-4-yl)ethyl)benzamide (141); N-((1r,3r)-3-(3 -chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(4-((2-(2,6- Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyano)pyrimidine-5-carboxamide (142); Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(3-((2-(2,6-dioxopiperidinyl) (1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl) Pyrimidine-5-carboxamide (143); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2 ,4,4-tetramethylcyclobutyl)-2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)oxy)ethyl)piperazin-1-yl)pyrimidine-5-carboxylate Voxamide (144); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl cyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo phosphon-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamine N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethyl- (tetramethylcyclobutyl)-6-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo N-((R)-1-(3-isoindolin-5-yl)piperazin-1-yl)propyl)nicotinamide (146); -(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((4-(4-(2-( 2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-yl N-((1r,3r)-3-(3-chloro-2-methyl-2-phenyl)butoxy)methyl)-1H-pyrazole-3-carboxamide (147); ... -4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(9-(2-(2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1-oxa-4,9-diazaspiro[ 5.5]undecan-4-yl)propyl)benzamide (148); N-((1r,3r)-3-(4-cyano-3-methyl)benzamide (148) (4-(2-(2,6-dioxopiperidine)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidine) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidin Zine-5-carboxamide (150); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- tetramethylcyclobutyl)-6-(4-(5-((2-((S)-2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinamide (15 1); N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl) -6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl )piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide (152); N-((1r,3r)-3-( 4-Cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-( 4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin N-((1r,3r)-3-(3-perazin-1-yl)ethyl)piperidin-1-yl)nicotinamide (153); Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-di Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-3- N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2-oxopiperazin-1-yl)nicotinamide (154); ... (2,2,4,4-tetramethylcyclobutyl)-2-(4-(4-(3-((2-(2,6-dioxopiperidine -3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)butyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyano)pyrimidine-5-carboxamide (155); Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(3-(3-((2-(2,6-dioxopiperidine (3-indolin-1,3-yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)propyl )piperazin-1-yl)pyrimidine-5-carboxamide (156); 2-chloro-4-(3-(4-(5-(4-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1- (yl)pentyl)-3-fluorophenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzal 2-chloro-4-(5-(4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxamide (158); Soyisoindolin-5-yl)piperazin-1-yl)pentyl)-3-fluorophenyl)-8-oxo -6-Thioxo-5,7-diazaspiro[3.4]octan-7-yl)benzonitrile (159); N-((1r,3r) -3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2 -(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl )ethyl)piperidin-1-yl)nicotinamide (160); N-((1r,3r)-3-(3,4-dicyanophenone) 2-(4-(2-(2,6-dioxopiperidine-3- yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-pyrimidine-5-carboxamide (161); 2,2,4,4-tetramethylcyclobutyl)-6-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)nicotinamide (1 62); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl )-6-(7-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7 -diazaspiro[3.5]nonan-2-yl)nicotinamide (163); N-((1r,3r)-3-(3-chloro-4-chlorophenyl)-nicotinamide (163); (anhydrophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(2-(5-((2-(2,6-dioxopipe Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)-2,6-dihydropyridin N-((1r,3r)-3-(3-chloro-4- Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(3-(2-((2-(2,6-dioxopyrrolidone) Peridine-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)azetidin-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-pyrimidine-5-carboxamide (165); 2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1, 3-Dioxoisoindolin-5-yl)oxy)butyl)piperazin-1-yl)-2,6-difluoro Benzamide (166); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl (cyclobutyl)-2-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoin (1,4-Diazepan-1-yl)pyrimidine-5-yl)piperidin-4-yl)methyl Voxamide (167); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl cyclobutyl)-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo phosphon-5-yl)oxy)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)benzyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl amide (168) 4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole (5-phenyl)oxy)propyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)benzoate N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl methyl ester (169) 4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisopropyl)- N-((1r,3R)-3-(3-isoindolin-5-yl)piperazin-1-yl)ethyl)benzamide (170); Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((1R,4R)-5-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,5-diazabi Cyclo[2.2.1]heptan-2-yl)ethyl)benzamide (171); N-((1r,3r)-3-(3-chloro-4- Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopipene Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carbonyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3,5-difluoro N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzamide (173); tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-diox Soyisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide (174); N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (1R,4R)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole (2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)piperidin-1-yl)benzyl N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzoate (175) (4-(((1S,4S)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo)-4-(4-(((1S,4S)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo) Isoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)piperidin N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4 -tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Xoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluoro Benzamide (177); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzamide (4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxobutyl)-4-( ... Xoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)piperidine-1 -yl)benzamide (178); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy)- tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-fluoronicotinamide Chloramic acid amide (179); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl (4-((4-(2-(2,6-dioxopiperidin-3-yl)-4-fluoro-1,3-dioxobutyl)-4-fluoro-1,3-dioxopiperidin-3-yl) Xoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamido N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl) butyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (1 81); N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl )-4-((3R)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisopropyl N-(2 ... -((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4 -((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pipera N-((1r,3r)-3-(4-cyano-3-methyl)cyclohexyl)benzamide (183); N-((1r,3r)-3-(4-cyano-3-methyl)cyclohexyl)benzamide (183); (4-((4-(2-(2,6-dioxopipene)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopipene) Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo hexyl)benzamide (184); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro -3-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benz Amide (185); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl 4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisopropyl) Indolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (186); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4- (4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisoindoline-5- N-((1r,3r)-3-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide (187); (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2 ,6-dioxopiperidin-3-yl)-6-fluoro-3-oxoisoindolin-5-yl)piperazine N-((1r,3r)-3-(3-chloro-4- Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(2-(4-(2-(2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)a Zetidin-1-yl)benzamide (189); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2, 2,4,4-tetramethylcyclobutyl)-4-(4-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1 ,3-Dioxoisoindolin-5-yl)oxy)azetidin-1-yl)ethyl)piperidin-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzamide (190); Methylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Indolin-5-yl)piperazin-1-yl)methyl)azepan-1-yl)pyrimidine-5-carboxamide N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl 4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline- 5-yl)piperazin-1-yl)cyclohexyl)benzamide (192); N-((1r,3R)-3-(3-chloro 2-(2-(2,4-cyanophenoxy)-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((3S,5R)-4-(3-((2-(2, 6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)- 3,5-Dimethylpiperazin-1-yl)nicotinamide (193); N-((1r,3R)-3-(3-chloro-4-cyano) (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S,5R)-4-(3-((2-(2,6-dioxo Isopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethyl N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-3-(ethylpiperazin-1-yl)benzamide (194); ... (Ci)-2,2,4,4-tetramethylcyclobutyl)-2-((3S,5R)-4-(3-((2-(2,6-dioxopiperidinyl) (3-indolin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethylpipera N-((1r,3r)-3-(3-chloro-4-cyanobenzofuran-1-yl)pyrimidine-5-carboxamide (195); N-((1r,3r)-3-(3-chloro-4-cyanobenzofuran-1-yl)pyrimidine-5-carboxamide (195); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1s,3S)-3-(((2-(2,6-dioxopyrrolidinyl) Peridine-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)methyl)cyclobutyl)pi N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2, 2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)-2-fluorobenzamide (1 97); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl )-4-(4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl N-((piperazin-1-yl)azetidin-1-yl)piperidin-1-yl)benzamide (198); 1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R) -3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pi N-((1-pyrrolidin-4-yl)methyl)(methyl)amino)pyrrolidin-1-yl)benzamide (199); r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)- 3-(((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine Lysin-4-yl)methyl)(methyl)amino)pyrrolidin-1-yl)benzamide (200); N-((1r, 3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3- (((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine N-((1r,3)-4-yl)(methyl)amino)methyl)pyrrolidin-1-yl)benzamide (201); ... R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((2S,6 R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6- Dimethylpiperazin-1-yl)ethyl)benzamide (202); N-((1r,3r)-3-(3-chloro-4-methylphenyl)benzamide (anhydrophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidine (1,3'-biazetidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)- N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2, 4,4-tetramethylcyclobutyl)-4-(4-(2-(((1r,3r)-3-((2-(2,6-dioxopiperidine-3- (yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)ethyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)piperazin-1-yl)benzamide (204); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)piperazin-1-yl)benzamide (204); 4-(1-(2-((2-(2,6-dioxopiperidine-3- yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)azetidin-3-yl)piperazine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4 -tetramethylcyclobutyl)-4-(2-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)azetidin-3-yl)piperazin-1-yl)ethyl)benzalkonium N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl 2-(2R,6R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)-4-(2-( ... N-((1r ,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-3 -((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pipera N-((1r,3S)-3-(3-chloro- 4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-((2S,6S)-4-(2-(2,6-di Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6-dimethylpiperazine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-tetramethylcyclobutyl)-4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1, 3-Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)benzyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzoate (210) cyclobutyl)-4-(3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoin N-((2- ... (1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-( 2-(4-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-6,7-dihydro-5H-pyrrolo[3,4- b]pyrazin-2-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide (212); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4- (4-((4-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxoisoindoline- 5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (213); N-((1r,3r) -3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-( 2,6-Dioxopiperidin-3-yl)-4-fluoro-1-oxoisoindolin-5-yl)piperazine N-((1r,3S)-3-(3-chloro-4- Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-((4aR,6R,8aS)-6-(4-(2-(2,6 -dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl) Octahydroisoquinolin-2(1H)-yl)nicotinamide (215); N-((1r,3r)-3-(3-chloro- 4-Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(2-(((1r,3r)-3-((2-(2 ,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutene N-((1r,3r)-3-(3 -chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6- Dioxopiperidin-3-yl)-4-fluoro-1,3-dioxoisoindolin-5-yl)oxy N-((1r,3R)-3-(3-chloro-4-cyanopropyl)piperazin-1-yl)benzamide (217); N-((1r,3R)-3-(3-chloro-4-cyanopropyl)piperazin-1-yl)benzamide (217); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((1r,3R)-3-((4-(2-(2,6-dioxopyrrolidinyl) (Peridine-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- tetramethylcyclobutyl)-4-((1s,3S)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-1, 3-Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclobutyl)benzamido N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl butyl)-6-((4aR,6S,8aR)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl Indolin-5-yl)piperazin-1-yl)octahydroisoquinolin-2(1H)-yl)nicotine Amide (220); N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl cyclobutyl)-6-((4aR,6R,8aR)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)octahydroisoquinolin-2(1H)-yl)nico Chinamide (221); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl Cyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo (Phosphorin-5-yl)piperazin-1-yl)piperidin-1-yl)pyridazine-3-carboxamide (222 ); N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)- 4-((3R)-3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3r)-3-(3-chloro)piperazin-1-yl)pyrrolidin-1-yl)benzamide (223); ... 4-(4-(1-(2-(2,6-dioxa-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)- ... Isopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)pipera N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-4-((3R)-3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-5-yl)piperazine-1-carbonyl)pyrrolidin-1-yl)benz Amide (225); N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl chlorobutyl)-4-((3R)-3-(4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo Xoisoindolin-5-yl)piperazine-1-carbonyl)pyrrolidin-1-yl)benzamide (226); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutane 4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisopropyl) N-(2 ... -((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4 -(((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindole N-((1r, 3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(2-(( 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl (3R)-N-(1-(4-(((1r, 3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl phenyl)piperidin-4-yl)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)-N-methylpyrrolidine-3-carboxamide (230); N-((1r,3r)-3-( 3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2, 6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pipera N-((1r,3R)-ethyl)piperidin-1-yl)pyridazine-3-carboxamide (231); N-((1r,3R)-ethyl)piperidin-1-yl)pyridazine-3-carboxamide (231); )-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((2S,4R,6R )-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin Perazin-1-yl)methyl)-2,6-dimethylpiperidin-1-yl)pyrimidine-5-carboxamine N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexane (2S,4S,6R)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)- (indolin-5-yl)piperazin-1-yl)methyl)-2,6-dimethylpiperidin-1-yl)pyrimidin N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-5-carboxamide (233); tetramethylcyclobutyl)-2-((2S,6S)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2,6-dimethylpiperidine-1 -yl)pyrimidine-5-carboxamide (234); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy) 3-((2-(2,6-dioxopiperidine-3- yl)-1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl)propyl)azeti N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-6-(7-((3-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)piperidin-1-yl)methyl)octahydro-2H-pyrido[1,2- a]pyrazin-2-yl)nicotinamide (236); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy) (1r,3r)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidine (3-indolin-1,3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)methyl)(methyl N-((1r,3r)-3-(3-chloro-4-cyano)amino)piperidin-1-yl)benzamide (237); Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((1'-(2-(2,6-dioxopiperidine- 3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidin]-4-yl)amino)be N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzolamide (238); (4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)-4-( ... N-(2 ... -((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4 -((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5- (Isopropyl)amino)methyl)piperidin-1-yl)benzalkonium N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl (1S,4S,5R)-5-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo (isoindolin-5-yl)piperazin-1-yl)methyl)-2-azabicyclo[2.2.1]heptan-2-yl N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)pyrimidine-5-carboxamide (241); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)pyrimidine-5-carboxamide (241); -2,2,4,4-tetramethylcyclobutyl)-2-((1S,4S,5S)-5-((4-(2-(2,6-dioxopiperidinyl) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)-2-azabicyclo[2.2.1]dione Cyclo[2.2.1]heptan-2-yl)pyrimidine-5-carboxamide (242); N-((1r,3r)-3-(3- Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-di Oxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazine -1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide (243); N-((1r,3R)-3- (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-((2-(( 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl N-((1r,3R)-3-(3-chloro-4-methylamino)pyrrolidin-1-yl)benzamide (244); N-((1r,3R)-3-(3-chloro-4-methylamino)pyrrolidin-1-yl)benzamide (244); -cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3R)-3-(3-((2-(2,6-di- 1,3-dioxoisoindolin-5-yl)oxy)azetidin-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-pyrrolidin-1-yl)benzamide (245); ... (Ci)-2,2,4,4-tetramethylcyclobutyl)-4-(5-(2-((2-(2,6-dioxopiperidin-3-yl )-1,3-Dioxoisoindolin-5-yl)oxy)ethyl)hexahydropyrrolo[3,4-c]pyrro N-((1r,3r)-3-(4-cyano-3-methylphenoxy)-2, 2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidin Zine-5-carboxamide (247); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl)-4-(4-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxo N-((1r,3r)-isoindolin-5-yl)piperazin-1-yl)butyl)benzamide (248); 3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-((R )-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl )butyl)benzamide (249); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl)-4-(6-(4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxo N-((1r,3r)isoindolin-5-yl)piperazin-1-yl)hexyl)benzamide (250); )-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(4-(2-( (R)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-yl N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenyl)hexyl)benzamide (251); N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenyl)hexyl)benzamide (252); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(5-((2-(2,6-dioxopiperidine- 3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)benzoate N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4 -tetramethylcyclobutyl)-4-(6-((2S,6R)-4-(2-(2,6-dioxopiperidin-3-yl)-1, 3-Dioxoisoindolin-5-yl)-2,6-dimethylpiperazin-1-yl)hexyl)benzal N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl 4-((3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline- 5-yl)-3,6-dihydropyridin-1(2H)-yl)ethyl)oxetan-3-yl)methyl)benzal N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetrafluoroethylene (254) tetramethylcyclobutyl)-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)ethyl)piperazin-1-yl)benzamide (255); N-((1r ,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-((1S ,4S)-5-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-2,5 -diazabicyclo[2.2.1]heptan-2-yl)hexyl)benzamide (256); N-((1r,3r)-3- (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-((2-(2,6 -dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2 ,4,4-tetramethylcyclobutyl)-4-(6-((1R,4R)-5-(2-((S)-2,6-dioxopiperidine-3- (yl)-1-oxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanobenzamide (258); tetramethylcyclobutyl)-4-(6-((1R,4R)-5-(2-((R)-2,6-dioxopiperidin-3-yl)-1 -oxoisoindolin-5-yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)hexyl Benzamide (259); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzamide (3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisopropyl)-4-( ... Benzamide (5-indolyl)piperazin-1-yl)ethyl)oxetan-3-yl)methyl) 260); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (2-(2,6-dioxopiperidin-3-yl)-6-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3r)-3-(3-chloro-)oxy)ethyl)piperidin-4-yl)nicotinamide (261); N-((1r,3r)-3-(3-chloro-) 4-Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(1-(4-((2-(2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperidine-4- N-((1r,3r)-3-((5-cyano-6-methylpyridin-2-yl)oxy)nicotinamide (262); N-((1r,3r)-3-((5-cyano-6-methylpyridin-2-yl)oxy)nicotinamide (262); (Ci)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-(2,6-dioxopiperidin-3-yl )-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)nicotinic acid N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl (4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline -5-yl)oxy)pentyl)piperazin-1-yl)pyrazine-2-carboxamide (264); N-((1 r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5- ((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pe N-((1r,3r)-3-(3-chlorophenyl)piperazin-1-yl)pyridazine-3-carboxamide (265); N-((1r,3r)-3-(3-chlorophenyl)piperazin-1-yl)pyridazine-3-carboxamide (265); 2-(2,6-dioxa-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(2,6-dioxa-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) Isopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-1-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)oxy)pentyl)piperidin-4-yl)-1H-pyrazole-4- Carboxamide (267); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy Methylcyclobutyl)-1-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Indolin-5-yl)oxy)pentyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl (1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline -5-yl)oxy)butyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxamide (269); N -((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2 -(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pipera N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-(3-chloro-4-cyanophenoxy)-3-(2-methyl-1-yl)ethyl)benzamide (270); )-2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-((R)-2,6-dioxopiperidin-3-yl) (I)-6-fluoro-3-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotine Amide (271); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl 6-(6-(4-(2-((R)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisopropyl) N-((1r,3r)-isoindolin-5-yl)piperazin-1-yl)hexyl)nicotinamide (272); 3-(4-cyano-3-(trifluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)- 4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2-pyridin-1-yl)propyl)benzamide (273); (2,2,4,4-tetramethylcyclobutyl)-6-(4-(4-(2-(2,6-dioxopiperidine-3- (yl)-1,3-dioxoisoindolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)butyl Nicotinamide (274); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrahydrofuran Methylcyclobutyl)-1'-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl (indolin-5-yl)oxy)pentyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxylate Ruboxamide (275); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)-6-(5-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl) (indolin-5-yl)oxy)pentyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-2(4H)-yl) Nicotinamide (276); N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl) (2,6-dioxopiperidin-3-yl)-5-((3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)propan-2-yl) Indolin-5-yl)piperazin-1-yl)propoxy)methyl)-1H-pyrazole-3-carboxamide N-((R)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propanamide (277); (pan-2-yl)-5-((4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo Phosphorus-5-yl)oxy)butyl)piperazin-1-yl)methyl)-1H-pyrazole-3-carboxamine N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexane (2R)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole (5-phenyl)oxy)pentyl)-2-(hydroxymethyl)piperazin-1-yl)nicotinamide (2 79); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl )-1'-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)o (oxy)pentyl)-1',2',3',6'-tetrahydro-[2,4'-bipyridine]-5-carboxamide (280) N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6 -(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)o N-((1r,3r)-3-(3-oxy)pentyl)-2-oxopiperazin-1-yl)nicotinamide (281); Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(1-(4-((2-(2,6-di Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-4-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)oxy)propyl)piperidin-4-yl)benzamide (283) N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4 -(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine) N-((1r,3r)-3-(3-chloro-4-chlorophenyl)-3-hydroxypropyl)benzamide (284); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2-((R)-2,6-dioxopyrrolidone) 1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazine-1- N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-2,2,4,4-tri ... tetramethylcyclobutyl)-6-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)ethyl)azetidin-1-yl)nicotinamide (286); N-(( 1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-(4 -((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy) (ethyl)azetidin-1-yl)nicotinamide (287); 4-(3-(4-(5-(4-(2-(2,6-dioxopipene Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl)-3- Fluorophenyl)-4,4-dimethyl5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluorophenyl) Fluoromethyl)benzonitrile (288);N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2 ,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-Dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridine Dazin-3-carboxamide (289); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4 -tetramethylcyclobutyl)-5-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrazine- 2-Carboxamide (290); N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazole-1- yl)propan-2-yl)-5-(1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)propoxy)ethyl)-1H-pyrazole-3-carboxylate Voxamide (291); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethicone (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-5-((3S)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo (isoindolin-5-yl)oxy)pentyl)-3-(hydroxymethyl)piperazin-1-yl)picolin N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl cyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo phosphon-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl) butyl)-6-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3r)-3-(3 -chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(9-(2-(2,6-di ... (1,3-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,9-diazaspiro[5.5] undecane-3-yl)pyrimidine-5-carboxamide (295); N-((1r,3R)-3-(3-chloro-4-phenyl)- (2-((1R,4R)-5-(2-(2,6-dioxaphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-( ... (isopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-2,5-diazabiphenyl Cyclo[2.2.1]heptan-2-yl)ethyl)benzamide (296); N-((1r,3r)-3-(3-chloro-4 -cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopyrrolidinyl)- 1,3-dioxoisoindolin-5-yl)oxypropyl)piperazine-1- N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,6-difluorobenzamide (297); (Ci)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(5-((2-(2,6-dioxopiperidin-3-yl )-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)-2,6-difluoro N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzamide (298); tetramethylcyclobutyl)-4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)butyl)piperazin-1-yl)-2-fluorobenzamide (2 99); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl )-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Piperazin-1-yl)methyl)piperidin-1-yl)-4-(trifluoromethyl)pyrimidine-5- Carboxamide (300); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy Methylcyclobutyl)-3'-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl) (indolin-5-yl)piperazin-1-yl)methyl)-[1,1'-biphenyl]-4-carboxamide (30 1); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Piperazin-1-yl)methyl)piperidin-1-yl)-3-(trifluoromethyl)benzamide ( 302); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl yl)-3'-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3R)piperazin-1-yl)ethyl)-[1,1'-biphenyl]-4-carboxamide (303); N-((1r,3R)piperazin-1-yl)ethyl)-[1,1'-biphenyl]-4-carboxamide (303); )-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S,5R)-4 -(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine) Lysin-4-yl)ethyl)-3,5-dimethylpiperazin-1-yl)benzamide (304); N-((1r,3 r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-((4-(2 -(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1- N-((1r,3r)-3-(3 -chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(2-(4-(2-(2,6 -dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl) Ethyl)piperidin-1-yl)pyrimidine-2-carboxamide (306); N-((1r,3r)-3-(3-chloro 4-((1-(2-(2,6-dioxa-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxa-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) Isopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidine-4- N-((1r,3r)-3-(3-chloro-4-chlorophenyl)methyl)piperazin-1-yl)benzamide (307); N-((1r,3r)-3-(3-chloro-4-chlorophenyl)methyl)piperazin-1-yl)benzamide (307); (2,6-dioxopiperidine)-4-(3-(4-(2-(2,6-dioxopiperidine)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidine) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)azetidin-1-yl )benzamide (308); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl (4-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxobutyl)- (isoindolin-5-yl)oxy)azetidin-1-yl)ethyl)piperazin-1-yl)benzamido N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl butyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5 -yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-methylpyrimidine-5-carbox N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl)amide (310); 2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole) methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5- Carboxamide (311); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy Methylcyclobutyl)-4-(2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)ethyl)piperazin-1-yl)ethyl)benzamide (312); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-3' -(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine) N-((1r,3R)-3-((1,1'-biphenyl)-4-carboxamide)-(1,1'-biphenyl)-4-carboxamide (313); N-((1r,3R)-3-(( 3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S,5R)-4-(4-( (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl N-((1r,3r)-3-(3-chloro-4- Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopyrrolidone) (Peridine-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)methyl)piperidine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2 ,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazin-1-yl)benz Amide (316); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl cyclobutyl)-6-((3S)-4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl) (Hydroxy)pentyl)-3-(hydroxymethyl)piperazin-1-yl)nicotinic acid N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl (4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline) -5-yl)oxy)butyl)piperazin-1-yl)-4-fluoronicotinamide (318); N-((1r,3 r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1- N-((1r,3r)-3-(3-chloro-4-cyanobenzoyl)ethyl)-2,6-difluorobenzamide (319); N-((1r,3r)-3-(3-chloro-4-cyanobenzoyl)ethyl)-2,6-difluorobenzamide (319); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(3-((2-(2,6-dioxopiperidine- 3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)azetidin-1-yl)benzoate N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzoate (320) cyclobutyl)-4-((3S)-3-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Indolin-5-yl)piperidin-4-yl)methoxy)pyrrolidin-1-yl)benzamide (321 ); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)- 4-(4-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3R)-3-(pyrrolidin-3-yl)methyl)piperazin-1-yl)benzamide (322); 3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((3R)-1-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidine-3- N-((1r,3r)-3-(3-chloro-4-chlorophenyl)methyl)piperazin-1-yl)benzamide (323); N-((1r,3r)-3-(3-chloro-4-chlorophenyl)methyl)piperazin-1-yl)benzamide (323); (2,6-dioxopiperidine)-3-(4-(2-(2,6-dioxo-2,6-diphenyl)-2,2,4,4-tetramethylcyclobutyl)- (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)butyl)benzamine N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl butyl)-4-((3R)-3-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo N-(phosphoric acid-5-yl)piperidin-4-yl)methoxy)pyrrolidin-1-yl)benzamide (325); (1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-((3R ,5R)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Oxy)propyl)-3,5-dimethylpiperazin-1-yl)pyrimidine-5-carboxamide (326) N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4 -((3R)-3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3S)-3-((1r,3S)-piperazin-1-yl)methyl)pyrrolidin-1-yl)benzamide (327); 3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-((3S)-3-((4-(2- (2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pi N-((1r,3r)-3-(3-chloro-2-methyl-1-pyrrolidin-1-yl)benzamide (328); 4-((2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-( ... (1-oxopiperidin-3-yl)-1-oxoisoindolin-4-yl)butyl)piperazin-1-yl)benzyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzolamide (329); (cyclobutyl)-4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoin N-((1r,3r)-3-(3-chloro-5-yl)azetidin-3-yl)propyl)benzamide (330); N-((1r,3r)-3-(3-chloro-5-yl)azetidin-3-yl)propyl)benzamide (330); 4-((2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-( ... (1,3-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)butyl)piperazine-1-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzamide (331); Methylcyclobutyl)-3-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Indolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)cyclobutane-1-carboxamide Voxamide (332); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethicone (cyclobutyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoin (5-methyl-piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamine N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl) butyl)-4-((3R)-3-((((1r,3R)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)pyrrolidin-1-yl N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachlorobenzamide (334); Methylcyclobutyl)-4-(4-(((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-diox Soyisoindolin-5-yl)pyrrolidin-3-yl)methoxy)piperidin-1-yl)benzaminium N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl butyl)-4-(4-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo N-(phosphoric acid-5-yl)pyrrolidin-3-yl)methoxy)piperidin-1-yl)benzamide (336); (1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-( (((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) (methyl)oxy)cyclobutyl)(methyl)amino)methyl)azetidin-1-yl)benzamide (337 ); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)- 4-((3S)-3-((((1r,3S)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoin (5-yl)oxy)cyclobutyl)(methyl)amino)methyl)pyrrolidin-1-yl)benz Amide (338); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl chlorobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole (5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-fluoronicotinamide ( 339); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl 4-(4-((((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoyl) (isoindolin-5-yl)pyrrolidin-3-yl)methyl)(methyl)amino)piperidin-1-yl)benzyl N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzolamide (340); cyclobutyl)-4-(4-((((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3 -dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)(methyl)amino)piperidinyl N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4 -tetramethylcyclobutyl)-6-((4aR,6S,8aS)-6-(4-(2-(2,6-dioxopiperidin-3-yl) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)octahydroisoquinoline -2(1H)-yl)nicotinamide (342); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2 ,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-furan (fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1- N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2-yl)-3-fluorobenzamide (343); ,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)piperidin-1-yl)benzamide ( 344); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl 4-(4-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisopropyl)- ... Indolin-5-yl)pyrrolidin-3-yl)methyl)piperazin-1-yl)benzamide (345); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6- (4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindoline- 5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide (34 6); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) (piperazin-1-yl)methyl)piperidin-1-yl)-3-(2-(2-methoxyethoxy)ethoxy)benzyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzoate (347); (4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindole)-4-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindole) N-((1r, 3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-( 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-4 -yl)oxy)piperidin-1-yl)benzamide (349); N-((1r,3r)-3-(3-chloro-4-cyano)benzamide (349); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((1-(2-(2,6-dioxopiperidine (1,3-dioxoisoindolin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperazine N-((1r,3r)-3-(3-chloro-4-cyanophenone)-4-fluoronicotinamide (350); N-((1r,3r)-3-(3-chloro-4-cyanophenone)-4-fluoronicotinamide (350); Oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((1-(2-(2,6-dioxopiperidin-3-yl) (I)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)methyl)azetidin-1-yl )benzamide (351); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl (4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl) (Phendolin-5-yl)piperazin-1-yl)methyl)-3,6-dihydropyridin-1(2H)-yl)benz Amide (352); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl chlorobutyl)-4-((1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline -5-yl)-[1,4'-bipiperidin]-4-yl)oxy)benzamide (353); N-((1r,3r)-3-(3- Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-di Oxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazine -1-yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide (354); N-((1r,3r)-3-(4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2 -(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1- N-((1r,3r)-3-(4-cyano-3-(trimethylsilyl)methyl)piperidin-1-yl)benzamide (355); ... Fluoromethyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-di (Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-methyl-piperidin-1-yl)benzamide (356); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-3-methyl- Oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(6-(2-((2-(2,6-dioxopiperidin-3-yl) (I)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)-2-azaspiro[3.3]heptane-2 -yl)benzamide (357); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy)- tetramethylcyclobutyl)-2-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)propyl)piperazin-1-yl)-4,6-dimethylpyrimidine- 5-Carboxamide (358); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl- (tetramethylcyclobutyl)-5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Soyindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carboxamide (359); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl)-6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) (1-chloro)oxy)propyl)piperazin-1-yl)pyridazine-3-carboxamide (360); 2-chloro —N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4- (4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine) 2-chloro-N-((1r,3r)-3 -(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2, 6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pipera N-((1r,3r)-3-(3-chloro-)-2-(2-methyl-4-piperidin-1-yl)benzamide (362); ... 4-Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazine- 1-yl)pyrimidine-2-carboxamide (363); N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)methyl)pyrimidine-2-carboxamide (363); Methyl)phenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(2,6-dioxopyrrolidone) 1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazine-1- N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-2,2,4,4-tri ... tetramethylcyclobutyl)-2-((3S,5S)-4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)oxy)propyl)-3,5-dimethylpiperazin-1-yl)pi Rimidine-5-carboxamide (365); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2, 4,4-tetramethylcyclobutyl)-4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)oxy)ethoxy)propyl)benzamide (366); N-((1r, 3r)-3-(3-chloro-4-cyanophenoxy)cyclobutyl)-4-(4-(4-((2-(2,6-dioxopiperidine 1H-1,2,3-triazole-3-yl-1-oxoisoindolin-4-yloxybutyl 1-yl)benzamide (367); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl- tetramethylcyclobutyl)-6-(4-(2-((5-(2-((R)-2,6-dioxopiperidin-3-yl)-1-ol (xoisoindolin-4-yl)pentyl)oxy)ethyl)piperazin-1-yl)nicotinic acid amine N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl) butyl)-4-(4-(2-((5-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisoindole (2S)-1-(4-phenyl-4-yl)pentyl)oxy)ethyl)piperazin-1-yl)benzamide (369); -(((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamate bamoyl)phenyl)-N-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo Phosphorin-5-yl)piperazin-1-yl)butyl)-N-methylpyrrolidine-2-carboxamide (370); (2R)-1-(4-(((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo butyl)carbamoyl)benzyl)-N-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxo) N-methylpyrrolidine-2-carboxylate (2S)-1-(4-(((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetra ... Methylcyclobutyl)carbamoyl)benzyl)-N-(2-(4-(2-(2,6-dioxopiperidine-3- yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)-N-methylpyrrolidine -2-Carboxamide (372); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrahydrofuran (2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)-4-( ... N-((1r,3r)-3-(3-isoindolin-5-yl)oxy)ethoxy)ethyl)benzamide (373); Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(2,6-di Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)pyrro Lysin-3-yl)-1H-pyrazole-4-carboxamide (374); N-((1r,3r)-3-(3-chloro-4-phenylindole) (anhydrophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(2-(3-(4-(2-(2,6-dioxopyrrolidinyl)- (peridin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy) Ethyl)-1H-pyrazole-4-carboxamide (375); 4-(3-(4-(4-(5-((2-(2,6-dioxopyrazole 1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazine-1- 5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)phenyl)-4,4-dimethyl (376); 2-chloro-4-(3-(4-(4-(5-((2-(2,6-dioxopiperidine) 1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl )phenyl)-4,4-dimethyl5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile ( 377; 4-(5-(4-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole phenyl)-8-oxo-6-thioxo-5,7-diphenyl)-5-yl)oxy)pentyl)piperazin-1-yl)phenyl) Azaspiro[3.4]octan-7-yl)-2-(trifluoromethyl)benzonitrile (378); N-(( R)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-((2- (2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy) Ethoxy)ethoxy)methyl)-1H-pyrazole-3-carboxamide (379); N-((1r,3r)-3-(3- Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-(4-(2-(2,6-di (Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl) N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenanthroline)picolinamide (380); Oxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-(4-(2-(2,6-dioxopiperidin-3-yl) (I)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propyl)picolinamide (381); 4-(3-(6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo phosphon-5-yl)oxy)pentyl)piperazin-1-yl)pyridin-3-yl)-4,4-dimethyl-5-oxo (2-Thioxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (382) ; 4-(3-(4-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5 -yl)oxy)butyl)piperazine-1-carbonyl)-3-fluorophenyl)-4,4-dimethyl5- Oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (38 3); N-((1r,3S)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -4-(2-((1S,4S)-5-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5 -yl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)ethyl)benzamide (384); 4-(5- (((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) carbamazepine bamoyl)pyridin-2-yl)-1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)pentyl)-1-methylpiperazin-1-ium (385); 4-(3-(2 -((5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pi Perazin-1-yl)pentyl)oxy)phenyl)-4,4-dimethyl 5-oxo-2-thioxoimida Zolidin-1-yl)-2-(trifluoromethyl)benzonitrile (386); 4-(3-(2-((6-(4-(2-( 2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-yl (hexyl) hexyl) oxy) phenyl)-4,4-dimethyl 5-oxo-2-thioxoimidazolidin-1-yl N-((1r,3r)-3-(3-chloro-4-cyano)benzonitrile (387); Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidinyl) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine -1-yl)-2-fluorobenzamide (388); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy) )-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl)- 1,3-Dioxoisoindolin-4-yl)oxy)propyl)piperazin-1-yl)benzamide (389); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutane 4-(2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) N-((1r,3r)-3-(3-chloro-4-cyano)azetidin-3-yl)ethyl)benzamide (390); Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidinyl) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine -1-yl)-2,6-difluorobenzamide (391); N-((1r,3r)-3-(3-chloro-4-cyanophenone) Oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(3-((2-(2,6-dioxopiperidin-3-yl) (I)-1-oxoisoindolin-4-yl)oxy)propyl)piperazin-1-yl)benzamide (392); 4-(3-(2-(2-(4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl) 5-indolin-4-yl)piperidin-4-yl)methyl)piperazin-1-yl)ethyl)phenyl)-4,4- Dimethyl 5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzodi Tolyl (393); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl 4-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole) N-((1r,3r)-3-(3-chloro- 4-Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azetidin-3-yl)methyl)pi N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2-chloro-4-phenyl-2-pyridin-1-yl)benzamide (395); ,2,4,4-tetramethylcyclobutyl)-1-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)-1H-pi N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-1-(1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-4-yl)-1H-pi N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-tetramethylcyclobutyl)-4-(2-(dimethylamino)ethoxy)-6-(4-((4-(2-(2,6-di Oxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazine -1-yl)methyl)piperidin-1-yl)nicotinamide (398); N-((1s,4s)-4-(3-chloro-4- Cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinic N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-( (4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine N-((1r,4r)-4-(3-chloro- 4-cyanophenoxy)cyclohexyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1 ,3-Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzyl N-((1s,4s)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-( (4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine N-((1r,4r)-4-(3-chloro-4- Cyanophenoxy)cyclohexyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidin N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexane 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5- yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamide (404); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dichloro-4-cyanophenoxy)cyclohexyl) (1,3-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl N-((1r,4r)-4-(3-chloro-4- Cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6- Fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1 -yl)pyridazine-3-carboxamide (406); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy) (cyclohexyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-di Oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidin N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-carboxamide (407); 1,3-dioxoisoinyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoin (5-methyl-piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamine N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(4-(2-(2 ,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-yl N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)-3-chloro-4-piperidin-1-yl)benzamide (409); (Ci)cyclohexyl)-4-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl) N-((1r,4 r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(1-(2-(2,6-dioxopiperidine) (1,3-dioxoisoindolin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)piperazine-1-yl N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)pyridazine-3-carboxamide (411); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)pyridazine-3-carboxamide (411); Cyclohexyl)-2-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoin (4-amino-5-yl)piperidin-4-yl)piperazin-1-yl)pyrimidine-5-carboxamide 12); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(4-(2-(2,6- Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl) Piperidin-1-yl)pyridazine-3-carboxamide (413); N-((1r,4S)-4-(3-chloro-4-chlorophenyl)pyridazine-3-carboxamide (413); (2-(2,6-dioxopiperidin-3-yl)-2-((3S)-3-((4-(2-(2,6-dioxopiperidin-3-yl)- 1,3-Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pyrrolidin-1-yl)piperazin-1-yl Rimidine-5-carboxamide (414); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclo[3.2.1.2.2.3.1.2 ...1.2.1. hexyl)-6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline -5-yl)oxy)ethyl)piperazin-1-yl)pyridazine-3-carboxamide (415); N-((1 r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(2-((2-(2,6-dioxopyrrolidone) 1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazine-1-yl N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)benzamide (416); -2-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Oxy)ethyl)piperazin-1-yl)pyrimidine-5-carboxamide (417); N-((1r,4r)-4- (3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(3-((2-(2,6-dioxopiperidine -3-yl)-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pi Rimidine-5-carboxamide (418); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)-4-methyl (4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisopropyl) Indolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (419); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-5-(4-(2-((2-(2,6-dichloro-4-cyanophenoxy)cyclohexyl) 1,3-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethyl)piperazine N-((1r,4r)-4-(3-chloro-4-cyanophenanthren-1-yl)pyrazine-2-carboxamide (420); N-((1r,4r)-4-(3-chloro-4-cyanophenanthren-1-yl)pyrazine-2-carboxamide (420); 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo- (isoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)picolinamide (4 21); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(2-((2-(2,6- Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy Ethyl)piperazin-1-yl)-5-fluoronicotinamide (422); N-((1r,4r)-4-(3-chloro -4-cyanophenoxy)cyclohexyl)-5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)- 6-Fluoro-1,3-dioxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl) Pyrazine-2-carboxamide (423); N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl) 2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline) phosphon-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-5-carboxamine N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(4-(2-(4-(2 -(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1- N-((1r,4r)-4-(3-chloro-4-chlorophenyl)ethyl)piperidin-1-yl)benzamide (425); N-((1r,4r)-4-(3-chloro-4-chlorophenyl)ethyl)piperidin-1-yl)benzamide (425); (2-(2,6-dioxopiperidin-3-yl)-1,3-diphenyl)-5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-diphenyl)- Oxoisoindolin-5-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carbo N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-( 2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pipera N-((1r,3r)-ethyl)piperidin-1-yl)pyridazine-3-carboxamide (427); N-((1r,3r)-ethyl)piperidin-1-yl)pyridazine-3-carboxamide (427); )-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(5-((2- (1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)ox N-((1r,3r)-3-(3-chloro-4-((1r,3r)-pentyl)piperazin-1-yl)nicotinamide (428); ... (anhydrophenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(1-methyl-2,6-dihydro- 1,3-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidine N-((1r,3r)-3-(3-chloro-4-thiazolinone)-1H-pyrazole-4-carboxamide (429); N-((1r,3r)-3-(3-chloro-4-thiazolinone)-1H-pyrazole-4-carboxamide (429); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(1-methyl-2,6-dioxo Isopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperidin N-((1r,3r)-3-(3-chloro-4-cyano)-1H-pyrazole-3-carboxamide (430); N-((1r,3r)-3-(3-chloro-4-cyano)- Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-1-(1-(4-((2-(1-methyl-2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)butyl)pyrrolidine-3- N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-1H-pyrazole-4-carboxamide (431); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-1H-pyrazole-4-carboxamide (431); (2,2,4,4-tetramethylcyclobutyl)-1-(1-(5-((2-(1-methyl-2,6-dioxopipene Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)pyrrolidin-3-yl N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-1H-pyrazole-4-carboxamide (432); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-1H-pyrazole-4-carboxamide (432); oxy)-2,2,4,4-tetramethylcyclobutyl)-1-(2-(3-(4-(2-(1-methyl-2,6-dioxopiperidine Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propoxy) N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-1H-pyrazole-4-carboxamide (433); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)- (2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(1-methyl-2,6-dioxopipene Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazine-1-yl N-((1r,3r)-3-(4-cyano-3-(trifluoromethyl)phenoxy ... )-2,2,4,4-tetramethylcyclobutyl)-5-(4-(5-((2-(1-methyl-2,6-dioxopiperidine -3-yl)-1,3-dioxoisoindolin-5-yl)oxy)pentyl)piperazin-1-yl)pi Cholinamide (435); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl ethylcyclobutyl)-5-(3-(4-(2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-diox Soyisoindolin-5-yl)piperazin-1-yl)propyl)picolinamide (436); 6-(4-(4 -((2-(1-butyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Oxy)butyl)piperazin-1-yl)-N,N-dimethylpyridazine-3-carboxamide (437); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-( 4-(4-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5- N-((1r,3)-oxy)butyl)piperazin-1-yl)pyrimidine-5-carboxamide (438); N-((1r,3)-oxy)butyl)piperazin-1-yl)pyrimidine-5-carboxamide (438); r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2 -(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine N-((1r,3r)-3-(3-chloro-2-pyridin-1-yl)methyl)piperidin-1-yl)benzamide (439); (4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(1-methyl-2 ,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-yl (3-(5-(4-((1-(4-(( (1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carba phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoin (2-yl)-2,6-dioxopiperidin-1-yl)methyl methyl carbonate (441); ( 3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl (chlorobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3 (-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl ethyl carboxylate Carbonate (442); (3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4, 4-Tetramethylcyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)pipera (1,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl Chill isopropyl carbonate (443); (3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl) (chlorobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3 -dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl (tetrahydro (3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4 -Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidine (4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-di Oxopiperidin-1-yl)methyl (2-acetamidoethyl)carbamate (445); (3-(5-(4 -((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl (phenyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-diox Soyisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl (2-(2-aminoacetamide) (3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyano Phenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl)phenyl)piperidine-4- yl)methyl)piperazin-1-yl)-1,3-dioxoisoindolin-2-yl)-2,6-dioxopip (peridin-1-yl)methyl (2-((S)-2-aminopropanamido)ethyl)carbamate (447); (3-(5-(4-((1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl Cyclobutyl)carbamoyl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1 ,3-dioxoisoindolin-2-yl)-2,6-dioxopiperidin-1-yl)methyl (2-((S)-2 -amino-3-methylbutanamido)ethyl)carbamate (448); (3-(5-(4-((1-(4-(((1r,3r )-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamoyl) Phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindoline- 2-yl)-2,6-dioxopiperidin-1-yl)methyl (2-((S)-2-((S)-2-amino-3-methylbutyric acid) (3-(5-(4-((1-(4-(((1 r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carbamo yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1,3-dioxoisoindo (2,5,8,11-tetraoxatrideca)methyl (2-yl)-2,6-dioxopiperidin-1-yl 2-chloro-4-(3-(3-fluoro-4-(5-(4-(2-(1-methyl-2 ,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-yl (phenyl)pentyl)phenyl)-4,4-dimethyl5-oxo-2-thioxoimidazolidin-1-yl)benzo 2-chloro-4-(5-(3-fluoro-4-(5-(4-(2-(1-methyl-2,6-dioxopyrrolidone) (peridin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)pentyl) (phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)benzonitrile (452); 4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2, 3-Dihydro-1H-isoindol-4-yl]-4,7,10-trioxa-1-azadodecane- 12-yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazo Lysin-1-yl}-2-(trifluoromethyl)benzonitrile (453); 4-(3-{4-[2-(2 -{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-i 4,4-dimethyl-5-oxo-indol-4-yl]amino}ethoxy)ethoxy]phenyl}- (2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzodi Tolyl (454); 4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxopiperidin-3-yl)-1,3-dioxopiperidin-3-yl 2,3-Dihydro-1H-isoindol-4-yl]-4,7,10,13,16-pentaoxa-1 -Azaoctadecan-18-yl}oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfonyl {phenylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile (455 4-[3-(4-{2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo -2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethoxy]ethoxy} Phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl] -2-(trifluoromethyl)benzonitrile (456); 4-[3-(4-{2-[2-(2-{[2-(2,6 -Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindole -4-yl]amino}ethoxy)ethoxy]ethoxy}phenyl)-4,4-dimethyl-5-oxo -2-Sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonite 4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxa [so-2,3-dihydro-1H-isoindol-4-yl]-4,7,10-trioxa-1-azate (ladecane-14-yl)oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfanilide 4-{3- [4-({1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1 H-isoindol-4-yl]-4,7,10-trioxa-1-azatridecan-13-yl}o 4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidine-1- yl}-2-(trifluoromethyl)benzonitrile (459); 4-(3-{4-[(1-{2-[(3R)-2 ,6-Dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindole (4,7,10-trioxa-1-azadodecan-12-yl)oxy]phenyl}-4, 4-Dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl) (fluoromethyl)benzonitrile (460); 4-(3-{4-[(1-{2-[(3S)-2,6-dioxopipene Lysin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-4, 7,10-trioxa-1-azadodecan-12-yl)oxy]phenyl}-4,4-dimethyl-5- Oxo-2-sulfanylideneimidazolidin-1-yl)-2-(trifluoromethyl)benzene Zonitrile (461); 4-[3-(4-{3-[3-(2-{[2-(2,6-dioxopiperidin-3-yl) (1,3-Dioxo-2,3-dihydro-1H-isoindol-4-yl)amino}ethoxy)pro (poxy)propoxy}phenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimida Zolidine-1-yl]-2-(trifluoromethyl)benzonitrile (462); 4-{4,4-dimethyl 3-[4-({1-[2-(3-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxo -2,3-Dihydro-1H-isoindol-4-yl]-4,7,10-trioxa-1-azatride (can-13-yl)oxy)phenyl]-5-oxo-2-sulfanylideneimidazolidine-1 -yl}-2-(trifluoromethyl)benzonitrile (463); 4-[3-(4-{4-[(5-{[2-( 2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindo (4-yl)amino}pentyl)oxy]phenyl}phenyl)-4,4-dimethyl-5-oxy [2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzodi Tolyl (464); 4-{[5-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo -2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)pentyl]oxy} -N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo butyl]benzamide (465); 4-{3-[4-({1-[2-(2,6-dioxopiperidin-3-yl )-1-Oxo-2,3-dihydro-1H-isoindol-4-yl]-1,4,7,10-tetraoxo (satridecan-13-yl)oxy)phenyl]-4,4-dimethyl-5-oxo-2-sulfani 6- Imidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile (466); [4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H- isoindole-4-yl]amino}ethyl)piperazin-1-yl]-N-[(1r,3r)-3-(3- Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxylate Ruboxamide (467); 6-{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}propoxy)ethyl]pi Perazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl]pyridine-3-carboxamide (468); 4-(3-{4-[1-(2-{ [2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindo] (1H-1,3-benzodiazol-5-yl)phenyl}-4,4 -Dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2- (Trifluoromethyl)benzonitrile (469); 4-{[5-(3-{[2-(2,6-dioxopiperidine Indol-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino }propoxy)pentyl]amino}-3-fluoro-N-[(1r,3r)-3-(3-chloro-4-cyano phenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (470); 6-[4-(2-{[ 2-(2,6-Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindo N-[(1r,3r)-3-(3-chloro-4-yl]oxy}ethyl)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-yl]oxy}ethyl] ... -Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamine 6-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3 -dihydro-1H-isoindol-4-yl]amino}ethyl)piperazin-1-yl]-N-[ (1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl] Pyridine-3-carboxamide (472); 6-(4-{3-[2-(2,6-dioxopiperidine-3- yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl]propyl}piperazine -1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl 6-{4-[2-(2-{[2-(2,6-di Oxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl -N-[(1r,3r)-3-(3-chloro-4-(2-yl)oxy}ethoxy)ethyl]piperazin-1-yl}- ... Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (474); 4-{4-[4-(2-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3- Dihydro-1H-isoindol-4-yl]oxy}ethyl)piperazin-1-yl]butyl} -N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetrahydrofuran tetramethylcyclobutyl]benzamide (475); 6-{4-[2-(3-{[2-(2,6-dioxopipene Lysin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]amine N-[(1r,3r)-3-(3-chloro-4-cyano)-4-(2-methyl-2-propoxy)ethyl]piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyano) Phenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (476); 6-{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxopiperidin-3-yl] 2,3-Dihydro-1H-isoindol-4-yl]amino}propoxy)ethyl]pipera {(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl ... 4-(6-[4-[2-(2,6-dichloromethylcyclobutyl]pyridine-3-carboxamide (477); (1,3-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindole-5- yl]piperazin-1-yl}hexyl)-N- [(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethy 4-(3-[4-(3-{[2-(2,6-dioxopiperidine -3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}p (1r,3r)-3-[4-cyano-3-(trifluoromethyl)piperazin-1-yl]propyl]-N-[( ... 4-[(2,2,4,4-tetramethylcyclobutyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide (479); 5-(3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H -isoindol-4-yl]amino}propoxy)pentyl]-N-[(1r,3r)-3-(3-chloro (b)-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (480); 6-{4-[2-(3-{[2-(2,6-dioxopiperidin-3-yl)-5-fluoro-1,3-diox 2,3-Dihydro-1H-isoindol-4-yl]amino}propoxy)ethyl]piperazine {(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-4-phenyl-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl-4-phenyl-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl- Methylcyclobutyl]pyridine-3-carboxamide (481); 4-(4-{4-[2-({2-[(3S)- 2,6-Dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindole -5-yl}oxy)ethyl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro -4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (482); 4 -(4-{4-[2-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1- Oxo-2,3-dihydro-1H-isoindol-4-yl}oxy)ethyl]piperazine-1- yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4- Tetramethylcyclobutyl]benzamide (483); 4-{4-[4-(2-{[2-(2,6-dioxopyrrolidone (Peridin-3-yl)-7-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindole -N-[(1r,3r)-3-(3-chloro-4-yl]amino}ethyl)piperazin-1-yl]butyl}- ... (b)-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (484); 6-{4-[5-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydrido 1r,3r-1H-isoindol-4-yl}oxy)pentyl]piperazin-1-yl}-N-[(1r,3r )-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridin 4-(4-{4-[2-({2-[(3S)-2,6-dioxopiperidine -3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}oxy)e butyl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy 6-{4-[5-({2-[(3S) -2,6-dioxopiperidin-3-yl]-1-oxo- 2,3-Dihydro-1H-isoindol-5-yl}oxy)pentyl]piperazin-1-yl} -N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo butyl]pyridine-3-carboxamide (487); 4-(4-{4-[2-(2,6-dioxopiperidine -3-yl)-5-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl yl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy) -2,2,4,4-Tetramethylcyclobutyl]benzamide (488); 4-{4-[4-(2-{[2-(2,6 -Dioxopiperidin-3-yl)-5-fluoro-1,3-dioxo-2,3-dihydro-1H- Isoindol-4-yl]amino}ethyl)piperazin-1-yl]butyl}-N-[(1r,3r)- 3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzal 6-(4-{6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3- Dihydro-1H-isoindol-4-yl]hexyl}piperazin-1-yl)-N-[(1r,3r) -3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridin 4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-4 -Fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine -1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy] tetramethylcyclobutyl]benzamide (491); 4-(6-{4-[2-(2,6-dioxopiperidinyl Indol-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazine N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-trimethyl-1-phenyl-1-yl]hexyl] -Tetramethylcyclobutyl]benzamide (492); 6-{4-[5-({2-[(3S)-2,6-di 1,3-dioxo-2,3-dihydro-1H-isoindole-5-oxopiperidin-3-yl yl}oxy)pentyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyano Phenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (493) 6-[4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-yl]oxy}pentyl)piperazin-1-yl]-N-[(1r,3r)-3 -(3-chloro-4-cyanophenoxy)cyclobutyl]pyridine-3-carboxamide (494) 4-[4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro- 1H-isoindol-4-yl]oxy}pentyl)piperazin-1-yl]-N-[(1r,3r)-3 -(3-chloro-4-cyanophenoxy)cyclobutyl]benzamide (495); 4-(5-{4-[2 -(2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoin 1r,3r)-3-(3-chloro-4-(2-(2-chloro-5-yl)piperazin-1-yl)pentyl)-N-[(1r,3r)-3-(3-chloro-4-(2-chloro-5-yl)piperazin-1-yl]pentyl] ... 4-( ... -[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-iso indol-5-yl]piperazin-1-yl}butyl)-N-[(1r,3r)-3-(3-chloro-4- Cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (497); 4-(6- {4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-di Hydro-1H-isoindol-5-yl]piperazin-1-yl}hexyl)-N-[(1r,3r)- 3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzal 4-(4-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro- N-[(1r,3r)-3-(3-chloro-4-isoindol-4-yl]oxy}butyl]-N-[(1r,3r)-3-(3-chloro-4-isoindol-4-yl]oxy] ... -cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (499); 4-(5 -{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoyl N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2-(2-phenyl-4-yl)oxy]pentyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy) 4-[3-(2-{[2-(2, 6-Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-4 -yl]oxy}ethoxy)propyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy 4-[4-(2-{[2-(2,6 -Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-4 -yl]oxy}ethoxy)butyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy) -2,2,4,4-tetramethylcyclobutyl]benzamide (502); 4-[5-(2-{[2-(2,6-di Oxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl -N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-(1r,3r)-oxy}ethoxy)pentyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-Tetramethylcyclobutyl]benzamide (503); 4-[6-(2-{[2-(2,6-di 1-oxo-2,3-dihydro-1H-isoindol-4-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl Oxy}ethoxy)hexyl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2 ,4,4-tetramethylcyclobutyl]benzamide (504); N-[(2R)-1-[3-(3-chloro- 4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl]-5-{[4-(4-{[2 -(2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoin (4-yl)amino}butyl)piperazin-1-yl]methyl}-1H-pyrazole-3-carboxylate Ruboxamide (505); 4-(4-{6-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo hexyl-2,3-dihydro-1H-isoindol-5-yl)hexyl}piperazin-1-yl)- N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutane] 4-(3-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo So-2,3-dihydro-1H-isoindol-4-yl]oxy}propyl)-N-[(1r,3r)-3 -(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamine N-[(2R)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole-1-yl] propan-2-yl]-5-[(3-{4-[2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}propionate 4-[4-(3-{[2-(2,6-di ... 1-oxo-2,3-dihydro-1H-isoindol-4-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-yl Oxy}propyl)-1H-1,2,3-triazol-1-yl]-N-[(1r,3r)-3-(3-chloro -4-Cyanophenoxy)cyclobutyl]benzamide (509); 6-[4-(6-{[2-(2,6-di- (xopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoyl N-[(1r,3r)-3-(3-chloro-2-(2-phenyl-5-yl)amino}hexyl]piperazin-1-yl]-N ... (4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carbo N-[(2R)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole] -1-yl]propan-2-yl]-5-({3-[4-(2-{[2-(2,6-dioxopiperidine-3- yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethyl) Piperazin-1-yl]propoxy}methyl)-1H-pyrazole-3-carboxamide (511); 4-[4-(5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1 H-isoindol-4-yl]oxy}pentyl)-1H-1,2,3-triazol-1-yl]- N‐[(1r,3r)‐3‐(3‐chloro‐4‐cyanophenoxy)cyclobutyl]benzamide (512); 4-[4-(6-{[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1 H-isoindol-4-yl]oxy}hexyl)-1H-1,2,3-triazol-1-yl]- N‐[(1r,3r)‐3‐(3‐chloro‐4‐cyanophenoxy)cyclobutyl]benzamide (513); 6-{4-[2-(4-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3 -Dihydro-1H-isoindol-4-yl}butoxy)ethyl]piperazin-1-yl}-N -[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl 6-{4-[2-(4-{2-[(3R)-2,6-dioxopipene Lysin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}butanoate oxy)ethyl]piperazin-1-yl}-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy 6-(4-)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (515); {2-[(5-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2,3-dihydro 1H-isoindol-4-yl)pentyl)oxy]ethyl}piperazin-1-yl)-N -[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl 6-(4-{2-[(5-{2-[(3R)-2,6-dioxopyridine-3-carboxamide (516); peridin-3-yl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}peridin-3-yl N-[(1r,3r)-3-(3-chloro-4-cyano)-N- ... Phenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3-carboxamide (517); 4-(4-{2-[(5-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1,3-dioxo-2, 3-Dihydro-1H-isoindol-4-yl}pentyl)oxy]ethyl}piperazine-1- yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl] 4-(4-{2-[(5-{2-[(3R)-2,6-dioxopiperidine 1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}pentyl )oxy]ethyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanopheno 4-(4-{6-[2-(2,6 -Dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-5 -yl]hexyl}piperazin-1-yl)-N-[(1r,3r)-3-(3-chloro-4-cyanophen 4-(3-{4-[2-(2 ,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindole (1r,3r)-3-(3-chloro-4-cyano)-N-[(1r,3r)-3-yl-5-yl]piperazin-1-yl}propyl]-N-[( ... phenoxy)-2,2,4,4-tetramethylcyclobutyl]benzamide (521); 4-[6-(4-{2 -[(3S)-2,6-Dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoyl N-[(1r,3r)-3-[4-cyano-3-(4-cyano-2-(2-(4-cyano-3-(4-cyano-2 ... (Trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]benzamide (522); 4-[6-(4-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3- Dihydro-1H-isoindol-5-yl}piperazin-1-yl)hexyl]-N-[(1r,3r) -3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclo butyl]benzamide (523); 6-[4-(6-{[2-(2,6-dioxopiperidin-3-yl)-5 -Fluoro-1-oxo-2,3-dihydro-1H-isoindol-4-yl]oxy}hexyl 1r,3r)piperazin-1-yl]-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4 ,4-Tetramethylcyclobutyl]pyridine-3-carboxamide (524); 6-[4-(6-{[2-( 2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H -isoindol-5-yl]oxy}hexyl)piperazin-1-yl]-N-[(1r,3r)-3- (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyridine-3 -carboxamide (525); 4-[6-(4-{2-[(3S)-2,6-dioxopiperidin-3-yl] (-3-oxo-2,3-dihydro-1H-isoindol-5-yl)piperazin-1-yl)hexa Sil]-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4- Tetramethylcyclobutyl]benzamide (526); 4-[6-(4-{2-[(3R)-2,6-dioxo Piperidin-3-yl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}piperidine 4-cyano-3-(trifluoromethyl)-N-[(1r,3r)-3-[4-cyano-3-(trifluoromethyl)-2-pyridyl-1-yl]-hexyl] ... N-((1r,3r)-3-(3 -chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6- Dioxopiperidin-3-yl)-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin rac-N-((2-methyl-6-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (528); (1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-( (4-(2-(2,6-dioxopiperidin-3-yl)-4-methylene-1-oxo-1,2,3,4-tetrahydro- Soquinolin-6-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (529); rac-N-(1-(4-(((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl) (2-(2,6-dioxopiperidine-3-yl)-1-(2-(2,6-dioxopiperidine-3-yl)-2 ... -yl)-1,3-dioxoisoindolin-5-yl)-N-methylpiperidine-4-carboxamide (5 30); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -6-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindole (5-phenyl)oxy)propyl)piperazin-1-yl)pyridazine-3-carboxamide (531); ac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)- 5-(4-(3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindole Benzene-5-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carboxamide (532); rac -N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(3-((2-(2,6-dichloro-4-cyanophenoxy)cyclohexyl) 1,3-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy)pro rac-N-((1r,4r)-4-(3-cyclohexyl)piperazin-1-yl)pyrimidine-5-carboxamide (533); 2-(4-(2-(2,6-dioxopiperidine-3-yl)-4-(2-(4-cyanophenoxy)cyclohexyl)- ... yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)ethyl)piperazin Lysin-1-yl)pyrimidine-5-carboxamide (534); rac-N-((1r,3r)-3-(3-chloro-4-phenyl)- (anhydrophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopipe Lysin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl ethyl)piperidin-1-yl)-4-(2-(2-methoxyethoxy)ethoxy)nicotinamide (535); rac-N-((1r,4R)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-4-(2-((2R,6R)-4-(2 -(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,6-dimethyl Piperazin-1-yl)ethyl)benzamide (536); rac-N-((1r,3r)-3-(3,4-dicyanophenoxy) (2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidine-3- yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl rac-N-((1r,3r)-3-(4-cyano-2-methylphenoxy)-2,2,4,4-tetramethyl- tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (5 38); rac-N-((1r,3r)-3-(2,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Piperazin-1-yl)methyl)piperidin-1-yl)benzamide (539); rac-N-((1r,3r)-3- (4-cyano-2,6-dimethylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1- rac-N-((1r,3r)-3-(4-cyano-3-yl)methyl)piperidin-1-yl)benzamide (540); Methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxo Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)pi N-((1r,4r)-4-(4-cyano-3-methylphenoxy)-peridin-1-yl)benzamide (541); cyclohexyl)-5-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo Isoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidine -1-yl)pyrazine-2-carboxamide (542); rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy) (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-4-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo)cyclohexyl) Isoindolin-5-yl)thio)ethyl)piperazin-1-yl)benzamide (543); rac-N-(( 1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(3 -((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindoline-5-yl (1-methyl)oxy)propyl)piperazin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide (5 44); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6,7-difluoro-1,3-dioxoisoin (5-indoline)piperazin-1-yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine -5-carboxamide (545); rac-2-chloro-4-(((1r,4r)-4-(5-(4-((4-(2-(2,6-dioxopyrrolidone) (Peridine-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperazine Lysin-1-yl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)oxy)benzonitrite aryl (546); rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-( 2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pipera rac-N-((1r,4r)-4-(3- Chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopipene Lysin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl rac-N-((1r,4r)-4-(4-cyclohexyl)piperidin-1-yl)pyridazine-3-carboxamide (548); 2-(2,6-dioxopiperidin-3-yl)-4-(2-(2,6-dioxo-3-methylphenoxy)cyclohexyl)-6-(4-( ... (I)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine rac-N-((1r,3r)-3-(4-cyano-3-methyl)pyridazine-3-carboxamide (549); (4-((2-(2,6-dioxopiperidine)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidine) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine rac-N-((1r,3r)-3-((5-cyano-6-methylpyridin-2-yl)benzamide (550); (4-(2-(2,6-dioxopiperidine)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidine) -3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1 -yl)benzamide (551); rac-N-((1r,3r)-3-((5-cyanopyridin-2-yl)oxy)-2,2 ,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benz Amide (552); rac-N-((1r,3r)-3-(3,4-dicyanophenoxy)-2,2,4,4-tetramethylcyclohexyl (4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline) -5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide ( 553); rac-N-((1r,3r)-3-((5-cyano-6-methylpyridin-2-yl)oxy)-2,2,4,4-tetramethylpyridin-2-yloxy) Methylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Indolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carbo rac-N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethicone (1R,4R,5S)-5-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2-cyclobutyl)- (Xoisoindolin-5-yl)piperazin-1-yl)methyl)-2-azabicyclo[2.2.1]hepta rac-N-((1r,3r)-3-((5-cyano-3-methyl)pyrimidine-5-carboxamide (555); 4-((4-(2-(2,6-diphenylpyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-( ... (Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl rac-N-((1r,3r)-3-((5-cyanopyrimidine) -2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidine Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine rac-N-((1r,3r)-3-(4-cyano-3,5-dimethylphenoxy)-3-(4-methyl-3-phenylpropan-1-yl)benzamide (557); (4-((4-(2-(2,6-dioxopiperidin-3-yl)methyl)-2,2,4,4-tetramethylcyclobutyl )-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl) Benzamide (558); rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl )-5-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Piperazin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide (559); rac-N-((1r, 4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-(4-(2-(2,6-dioxopipene) Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)piperidine-1- rac-N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2-methyl-2-pyrimidine-5-carboxamide (560); (2,2,4,4-tetramethylcyclobutyl)-2-((1R,4R,5R)-5-((4-(2-(2,6-dioxopyrrolidin-2-yl) 2-( ... Azabicyclo[2.2.1]heptan-2-yl)pyrimidine-5-carboxamide (561); rac-N-((1r ,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-((2- ((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)e (methyl)amino)pyrrolidin-1-yl)benzamide (562); rac-N-((1r,3R)-3-(3-chloro- 1R,3S)-3-((2-( 2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclopentadiene rac-N-((1r,3r)-3-((6-cyano-5-methyl)benzamide (563); pyridin-3-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-diphenylpyrid ... (Oxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl rac-N-((1r,3r)-3-((6-cyano-5-(trifluoromethyl)piperidin-1-yl)benzamide (564); (4-fluoromethyl)pyridin-3-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4- (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine- 1-yl)methyl)piperidin-1-yl)benzamide (565); rac-N-((1r,3r)-3-(3-chloro-4 -cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(3-((4-(2-(2,6-dioxopyrrolidinyl)- (Peridine-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azeta rac-N-((1r,4r)-4-(3-chloro-4-thiazin-1-yl)pyrazine-2-carboxamide (566); (phenoxy)cyclohexyl)-5-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-di Oxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyrazine- 2-Carboxamide (567); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy)-2,2,4,4-tetrachloro-4-cyanophenoxy tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoisopropyl) Indolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide (568); rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-(2-((2-(2,6- Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)oxy rac-N-((1r,4r)-4-(3-chloro-N-ethyl)piperazin-1-yl)-4-fluoronicotinamide (569); 4-((2-(2,6-dioxopiperidin-3-yl)-4-cyanophenoxy)cyclohexyl)-6-(4-( ... (I)-7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperazine rac-N-((1r,3r)-3-(3-chloro-4-thiazolinone)-1-yl)pyridazine-3-carboxamide (570); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidine (7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl rac-N-((1r,3r)-3-(4-cyano)-3-pyrimidine-5-carboxamide (571); (3-methylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxo- Isopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazine-1- yl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide (572); ra cN-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6 -(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pi Perazin-1-yl)methyl)azetidin-1-yl)pyridazine-3-carboxamide (573); rac-N -((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-2-(3-((4-(2-(2,6-dioxo- (isopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl Azetidin-1-yl)pyrimidine-5-carboxamide (574); rac-N-((1r,4r)-4-(4-cyano-3 -methylphenoxy)cyclohexyl)-2-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1, 3-Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)pyridine rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2 ,4,4-tetramethylcyclobutyl)-6-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-furan (fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1- rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2-methyl-2-pyridazine-3-carboxamide (576); Oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl) (I)-7-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperazine rac-N-((1r,3r)-3-(3-chloro-4-thiazolinone)-1-yl)pyridazine-3-carboxamide (577); (phenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidine (3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine-1 -yl)pyrimidine-5-carboxamide (578); rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy) (2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl) Piperidin-1-yl)pyrazine-2-carboxamide (579); rac-N-((1r,4r)-4-(3-chloro-4- Cyanophenoxy)cyclohexyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidine-3 -yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino (1r,3r)-3-((1r,3r)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide (580); (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6 -dioxopiperidin-3-yl)-4,6-difluoro1,3-dioxoisoindolin-5-yl)piperidine (1-pyridinyl)methyl)piperidin-1-yl)-4,6-dimethylpyrimidine-5-carboxamide (581); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl butyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridazine-3-carboxylate Ruboxamide (582); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrachloro ... Methylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3- Dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-4-(2- Morpholinoethoxy)nicotinamide (583); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy) (1r,3r)-2,2,4,4-tetramethylcyclobutyl)-2-(3-((((1r,3r)-3-((2-(2,6-dioxopiperidine (3-indolin-1,3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl )amino)methyl)azetidin-1-yl)pyrimidine-5-carboxamide (584); rac-N-((1r,3 r)-3-((5-cyano-6-ethylpyridin-2-yl)oxy)-2,2,4,4-tetramethylcyclobutyl )-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Piperazin-1-yl)methyl)piperidin-1-yl)benzamide (585); N-((1r,3r)-3-(3- Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-6-(3-((((1r,3r)-3-( (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclohexyl (isopropyl)amino)methyl)azetidin-1-yl)pyridazine-3-carboxamide rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl chlorobutyl)-4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)methyl)azetidin-1-yl)benzamide (5 87); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutene 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-yl) rac-N-((1r,3 yl)piperidin-4-yl)methyl)piperidin-4-yl)benzamide (588); r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(((1-( 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-4 -yl)oxy)methyl)pyrrolidin-1-yl)benzamide (589); rac-N-((1r,3r)-3-(3-c 4-(((1-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) 6-fluoro-3-oxoisoindolin-5-yl)piperidin-4-yl (1r,3r)-3-(3-chloro-4-methyl)piperazin-1-yl)benzamide (590); (anhydrophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((1-(2-(2,6-dioxopipe Lysin-3-yl)-6-fluoro-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl )piperazin-1-yl)benzamide (591); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenone) Oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl) (I)-4,6-difluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperazin-1-yl Peridine-1-yl)pyridazine-3-carboxamide (592); rac-2-chloro-4-(((1r,4r)-4-(5- (4'-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-1- Methyl-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1-methyl-1H-imidazo rac-N-((1r,4r)-4-(3-chloro-2-yl)cyclohexyl)oxy)benzonitrile (593); -4-cyanophenoxy)cyclohexyl)-6- (4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxoisoindole (5-phenyl-1-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide (594); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl 2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4,6-difluoro-1,3-dioxo Isoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxylate Ruboxamide (595); rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl) -4-(3-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) Piperazin-1-yl)methyl)azetidin-1-yl)benzamide (596); rac-N-((1r,3r)-3- (3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-((((1r,3r)- 3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy) Cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyrazine-2-carboxamide Mido (597); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethyl cyclobutyl)-2-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindo phosphon-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)pyrimidine-5-carboxamine rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexyl 4-(2-(2,6-dioxopiperidin-3-yl)-7-fluoro-1,3-dioxoisopropyl)-6-(4 ... Indolin-5-yl)piperazin-1-yl)piperidin-1-yl)pyridazine-3-carboxamine rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl cyclobutyl)-6-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo isoindoline-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidine-1 -yl)pyridazine-3-carboxamide (600); rac-N-((1r,4r)-4-(3-chloro-4-cyanophenoxy) (2-(2,6-dioxopiperidin-3-yl)-1,3 -dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl) Piperidin-1-yl)picolinamide (601); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy) (2,2,4,4-tetramethylcyclobutyl)-6-(6-(4-(2-(2,6-dioxopiperidine-3- yl)-6-fluoro-1-oxoisoindolin-5-yl)piperazin-1-yl)hexyl)nicotinic acid rac-2-chloro-4-(((1r,4r)-4-(2-(4-(3-((4-(2-(2,6-dioxopiperidine) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)azetidine -1-yl)phenyl)-1H-imidazol-5-yl)cyclohexyl)oxy)benzonitrile (6 03); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexane ethyl)-1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5- (1-yl)piperazin-1-yl)methyl)cyclohexyl)-1H-pyrazole-3-carboxamide (60 4); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclohexane (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl )oxy)propyl)-1H-pyrazole-3-carboxamide (605); rac-N-((1r,4r)-4-(3-chloro 1-(4-((2-(2,6-dioxopiperidin-3-yl)-4-cyanophenoxy)cyclohexyl)-1-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4-cyanophenoxy)cyclohexyl) )-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)-1H- Pyrazole-3-carboxamide (606); 3-chloro-5-(5-(4-(1-((1-(2-(2,6-dioxopipene Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidine (4-yl)-3-fluorophenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa 3-chloro-5-(5-(4-(4-((4-(2-(2,6-dioxopiperidine) (1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine (phenyl)-8-oxo-6-thioxo-5,7- Diazaspiro[3.4]octan-7-yl)picolinonitrile (608); rac-N-((1r,3r)-3-(3-c 4-(((4-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dichloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) 1-oxopiperidin-3-yl)-3-methyl-1-oxoisoindolin-5-yl)piperazin-1-yl rac-N-((1r,3r)-3-(3-chloro-4-cyano)methyl)piperidin-1-yl)benzamide (609); Phenoxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidinyl) (3-indolin-3-yl)-1-methyl-3-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperazin Lysin-1-yl)benzamide (610); rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy) -2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-4 -fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidine- 1-yl)pyridazine-3-carboxamide (611); 3-chloro-5-(5-(4-(4-((4-(2-(2,6-dioxo) (isopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl Piperidin-1-yl)-3-fluorophenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4] Octan-7-yl)picolinonitrile (612); 3-chloro-5-(5-(4-(1-((1-(2-(2,6-dioxo) Piperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)pi (4-(4-(2-Hydroxy-2-phenyl)-2,4-dioxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)phenyl 5-(4-((1-(2-(4-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazo[3,4 ... (3-yl)phenoxy)ethyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6 -dioxopiperidin-3-yl)isoindoline-1,3-dione (614); rac-N-((1r,3r)-3-(3- Chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-( (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclohexyl (isopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide rac-N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylsilyl 4-(5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindole) (5-phenyl)piperazine-1-carbonyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl) Benzamide (616); rac-N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylbenzoate (1r,4R)-4-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dihydroxybenzoyl)-1-( ... Oxoisoindolin-5-yl)piperidin-4-yl)(methyl)amino)cyclohexyl)-1H- Pyrazole-3-carboxamide (617); 5-(4-((1-(4-(6,7-dihydro-5H-pyrrolo[1,2-a]imide (3-phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-(2,6-dioxol-3-yl) ... rac-N-((1r,3r)-3-(3-chloro-N-isopiperidin-3-yl)isoindoline-1,3-dione (618); rac-N-((1r,3r)-3-(3-chloro-N-isopiperidin-3-yl)isoindoline-1,3-dione 1r,3r)-3-((2-( 2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutene (isopropyl)amino)methyl)azetidin-1-yl)pyrazine-2-carboxamide (61 9); N-((1r,3R)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl) -1-((1R,4R)-4-((((1r,3R)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoiso Indolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)cyclohexyl )-1H-pyrazole-3-carboxamide (620); N-((1r,3r)-3-(4-cyano-3-methoxyphenoxy) oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopipe Lysin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl N-((1r,3r)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide (621); N-((1r,3r) -3-(4-cyano-3-methylphenoxy)-2,2,4,4- tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)- 1,3-Dioxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl N-((1r,3r)-3-(4-cyano-3-yl)pyrimidine-5-carboxamide (622); N-((1r,3r)-3-(4-cyano-3-yl)pyrimidine-5-carboxamide (622); ,5-dimethylphenoxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((((1r,3r)-3-((2-( 2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutene (isopropyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide ( 623); N-((1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl yl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperidin-3-yl) N-((1r,4r)-4-(perazin-1-yl)methyl)piperidin-1-yl)benzamide (624); and N-((1r,4r)-4- (3-chloro-4-cyanophenoxy)cyclohexyl)-2-(4-((((1r,3r)-3-((2-(2,6-dioxo Piperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)cyclobutyl)(isopropyl 1-amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide (625).

[0251] In another embodiment, the present disclosure provides a library of compounds. The library comprises a plurality of compounds, wherein each compound has the formula ABM-L-ULM, where ULM is a ubiquitin a ubiquitin pathway protein binding moiety (preferably an E3 ubiquitin as otherwise disclosed herein) CLM is a CTL ligase moiety, and ABM is an AR protein binding moiety; In this case, the ABM is linked to the ULM (preferably via a linker moiety), and In some cases, the ubiquitin pathway protein binding moiety is a ubiquitin pathway protein, particularly an E3 Recognizes ubiquitin ligase.

[0252] References herein to pharmaceutically acceptable salts, particularly acid addition salts, of the compounds of the present disclosure, where applicable, are included. Also included are compositions containing base addition salts.

[0253] The term "pharmaceutically acceptable salt" is used throughout this specification when referring to the Used to describe one or more salt forms of the compounds described herein, the salts are , which exhibits increased solubility of the compound in the gastric juices of the patient's gastrointestinal tract, and which enhances the dissolution and bioavailability of the compound. Pharmaceutically acceptable salts include, where applicable, pharmaceutically acceptable salts. Suitable salts include those derived from various inorganic or organic bases and acids. Among many other acids and bases known in the pharmaceutical art, potassium and sodium alkali metals such as sodium, alkaline earth metals such as calcium and magnesium, and ammonium salts. Sodium and potassium salts include: Particularly preferred as neutralized salts of phosphates according to the present disclosure.

[0254] used to prepare pharmaceutically acceptable acid addition salts of the above-mentioned base compounds useful in the present disclosure. The acids to be added include non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, For example, among many other acids, hydrochlorides, hydrobromides, hydroiodides, nitrates, sulfuric acid salts, Acid salts, bisulfates, phosphates, superphosphates, acetates, lactates, citrates, percitrates, Tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharin nitrate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate , p-toluenesulfonate, and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxybenzoyl) Examples of acids that form α-3-naphthoic acid include:

[0255] Pharmaceutically acceptable base addition salts are pharmaceutically acceptable salts of compounds or derivatives according to the present disclosure. The pharmaceutically acceptable salt forms of the present compounds which are acidic in nature may also be used to form the pharmaceutically acceptable salt forms of the present compounds. Chemical bases that can be used as reagents to prepare acceptable base salts with such compounds are Such non-toxic base salts include, but are not limited to, those which form toxic base salts. for example, alkali metal cations (e.g., potassium and sodium) and alkaline earth metals. pharmaceutically acceptable cations such as metal cations (e.g., calcium, zinc, and magnesium); Base salts derived from thiones, ammonium or water-soluble amine addition salts, e.g., N-methyl Tilglucamine (meglumine), lower alkanolammonium salts, and others Examples of pharmaceutically acceptable base salts of organic amines include:

[0256] composition In another aspect, the present disclosure provides compounds described herein, including salts thereof, and pharmaceutically acceptable salts thereof. In certain embodiments, the composition comprises a composition comprising a carrier as described herein. A therapeutic or pharmaceutical composition comprising an effective amount of a compound as described above and an acceptable carrier. do.

[0257] The compounds in the pharmaceutical compositions of the present disclosure that can be combined with carrier materials to form a single dosage form. The amount of the compound will vary depending on the host and disease being treated, and the particular mode of administration. The dosage ranges from 0.1 mg / kg to 1000 mg / kg of body weight per day, depending on the efficacy of the drug. The toxicity and therapeutic efficacy of such compounds are evaluated using standard methods in cell cultures or experimental animals. Useful pharmaceutical procedures, such as LD50 (lethal dose for 50% of the population) and ED50 (lethal dose for 50% of the population) The relationship between toxicity and therapeutic effect can be determined by the procedure for determining the therapeutically effective dose. The dose ratio of LD50 to ED50 is the therapeutic index and can be expressed as LD50 / ED50. Compounds that exhibit toxic side effects can be used, but are not effective in non-diseased cells. To minimize potential damage and side effects, such compounds are administered to the affected tissue. Consideration should be given to designing a delivery system that targets the target site. Data obtained from laboratory and animal studies are used to develop a range of dosages for human use. The dosage of such compounds may be such that they provide circulating concentrations that include the ED50 with little or no toxicity. The dosage will vary depending on the dosage form employed and the route of administration utilized. For any compound used in the disclosed method, A therapeutically effective dose can be estimated initially from cell culture assays. IC50 determined in cell culture (i.e., the concentration of the test compound that achieves 50% inhibition of symptoms) Effective doses can be formulated in animal models. Such information can be used to refine useful doses in humans. Plasma levels can be determined more accurately, for example, by high performance liquid chromatography. It may be measured.

[0258] The compositions of the present disclosure can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. These pharmaceutical compositions may be formulated and administered in controlled release formulations. Possible pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, Aluminum stearate, lecithin, serum proteins such as human serum albumin, buffers, such as phosphates, glycine, sorbic acid, potassium sorbate, saturated vegetable fats Acid partial glyceride mixture, water, salt or electrolytes, e.g., prolamin sulfate, dihydrogen phosphate Sodium, potassium hydrogen phosphate, sodium chloride, zinc salt, colloidal silica, trisilicic acid Magnesium acetate, polyvinylpyrrolidone, cellulose-based materials, polyethylene glycol, Sodium carboxymethylcellulose, polyacrylate, wax, polyethylene Examples include polyoxypropylene block polymers, polyethylene glycol, and wool fat. can be done.

[0259] The active compound is sufficient to deliver to the patient a therapeutically effective amount for the desired indication. , in an amount that does not cause serious toxic effects in the patient being treated, in a pharmaceutically acceptable carrier or The diluent contains the active compound. A preferred dose of the active compound ranges from about 10 ng / kg to 300 mg / kg, preferably 100 mg / kg per day. In the range of 0.1-100mg / kg, more commonly 0.0 mg / kg of recipient / patient body weight per day. Typical topical doses range from 0.01 to 5% wt / wt in a suitable carrier. It is possible.

[0260] The compound contains less than 1 mg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. It may be conveniently administered in any suitable unit dosage form, including, but not limited to, about 25 to 250 mg An oral dose of is often convenient.

[0261] The active ingredient is administered to a patient in need thereof at a peak plasma concentration of the active compound of about 0.00001 to 30 mM, preferably about 0.1 to 30 μM. This is preferably done by administering a solution of the active ingredient or The formulation is administered by intravenous injection, optionally in saline solution or in an aqueous medium. Oral administration can be achieved by bolus administration of the active ingredient. It is also suitable for producing degrees.

[0262] The concentration of the active compound in the drug composition affects the absorption, distribution, inactivation, and excretion rates of the drug, and other factors known to those skilled in the art. Please note that the amount of time spent on any particular For a given subject, the particular dosing regimen will depend on the individual's needs and the administration of the composition. or should be adjusted over time according to the professional judgment of the person administering the dose; The concentration ranges described herein are exemplary and are not intended to be exhaustive or to be limiting of the ranges of the claimed compositions. It should be understood that this is not intended to limit the scope or practice of the present invention. The dose may be given in one dose or may be divided into a number of smaller doses to be administered at varying intervals of time. Good too.

[0263] When administered intravenously, preferred carriers are saline or phosphate buffered saline (PBS )

[0264] In one embodiment, the active compounds are delivered via, for example, implants and microencapsulated delivery systems. controlled-release formulations, including delivery systems, that protect the compound from rapid elimination from the body. The carriers are prepared using a variety of materials, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, Biodegradable and biocompatible polymers such as elagens, polyorthoesters, and polylactic acid Methods for the preparation of such formulations will be apparent to those skilled in the art.

[0265] Liposomal suspensions may also be pharmaceutically acceptable carriers. These are described, for example, in U.S. Pat. No. 4,522,811 (incorporated herein by reference in its entirety). For example, liposome preparations may be prepared according to methods known to those skilled in the art. Suitable lipids (e.g., stearoylphosphatidylethanolamine, stearoylphosphatidylethanolamine, Phosphatidylcholine, arachadoyl phosphatidylcholine, and cholesterol The lipids (such as ethanol) are dissolved in an inorganic solvent and then evaporated to leave a thin film of dried lipid on the surface of the container. The membrane may be left in place. An aqueous solution of the active compound is then placed in the container. Rotate the container by hand to remove lipid material from the sides of the container, disperse lipid clumps, and remove the liposomes. A rubber suspension is formed.

[0266] Mode of administration In any of the aspects or embodiments described herein, the compounds described herein The therapeutic composition containing the compound may be any suitable composition adapted to be delivered by any suitable route. The compound may be administered in any suitable dosage form, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or It can be administered by any suitable route, such as topically, e.g., as a liquid, cream, or gel. or in solid form transdermally, rectally, nasally, orally, vaginally, or via an implanted container; Alternatively, it can be administered in aerosol form.

[0267] The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, and synovial administration. Includes intrathecal, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques Preferably, the compositions are administered orally, intraperitoneally, or intravenously.

[0268] The compounds described herein may be administered orally, parenterally or topically in a single dose, or The active compound may be administered in divided doses. The administration of the active compound may range from continuous (intravenous drip) to several doses per day. These may range from multiple oral doses (e.g., QID) to multiple oral doses (e.g., QID), among other routes of administration. Oral, topical, parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may contain penetration enhancers), Administration may include intravenous, sublingual, and suppository administration. may be used to enhance the bioavailability of the compound from the oral route of administration. will depend on the pharmacokinetics of the particular agent selected, as well as the severity of the patient's disease .

[0269] As a spray, mist, or aerosol for nasal, intratracheal, or pulmonary administration Administration of the compounds described herein may be used in immediate release or sustained release form. The sustained release or controlled release formulations may be administered orally. is preferred, but may also be administered in suppository and transdermal or other topical forms. Intramuscular injection of the compound may be used to control or sustain the release of the compound at the injection site.

[0270] Sterile injectable forms of the compositions described herein may be aqueous or oleaginous suspensions. These suspensions can be formulated using suitable dispersing or wetting agents and suspending agents, as known in the art. The sterile injectable preparation may be prepared by conventional techniques, for example, by dissolving in 1,3-butanediol. A sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as Among the acceptable vehicles and solvents that may be employed are Ringer's solution, sodium chloride solution, and the like. In addition, sterile, fixed oils can be used as solvents or suspending media. For this purpose, synthetic monoglycerides or diglycerides are used. Any bland fixed oil may be employed, for example olive oil or castor oil, especially As are natural pharmaceutically acceptable oils, e.g., polyoxyethylated versions thereof. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables. These oil solutions or suspensions may be prepared using a long-chain alcohol diluent or dispersant, such as Ph. Helv or may contain similar alcohols etc.

[0271] The pharmaceutical compositions described herein may be in the form of, but not limited to, capsules, tablets, aqueous suspensions or water. It may be administered orally in any orally acceptable dosage form, including a solution. In the case of tablets for oral administration, carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring, or coloring agents may also be added. Oral compositions generally contain The composition may contain an inert diluent or an edible carrier. The composition may be encapsulated in a gelatin capsule. For the purpose of oral therapeutic administration, the active compound or its prodrug may be administered intravenously or in a tablet form. The ragweed derivative is combined with an excipient and used in the form of a tablet, lozenge, or capsule. Pharmaceutically compatible binding agents, and / or adjuvant materials may be added to the composition. Included as part of

[0272] Tablets, pills, capsules, troches, etc. may contain the following ingredients, or compounds of a similar nature: It may contain any of: e.g. microcrystalline cellulose, gum tragacanth or gelatin binders such as starch or lactose; excipients such as alginic acid, Prim dispersing agents such as ogel or cornstarch; e.g., magnesium stearate or Sterot lubricants, such as colloidal silicon dioxide; glidants, such as sucrose or or sweeteners such as saccharin; or sweeteners such as peppermint, methyl salicylate or oat flakes; Flavoring agents, such as microwave flavorings. If the dosage unit form is a capsule, the above types of substances may be used. Additionally, it can contain a liquid carrier, such as a fatty acid. For example, various additives that modify the physical form of the dosage unit, such as sugars, shellac, or enteric agents. It may contain other substances such as:

[0273] The active compound or a pharmaceutically acceptable salt thereof may be administered in the form of an elixir, suspension, syrup, water, or the like. It can be administered as a component of a syrup, chewing gum, etc. In addition to the lactic acid compounds, sucrose as a sweetener and / or certain preservatives, dyes and colorings , as well as flavoring agents.

[0274] Alternatively, the pharmaceutical compositions described herein may be administered in the form of suppositories for rectal administration. These are mixed with suitable non-irritating excipients that are solid at room temperature but liquid at rectal temperature. It can be prepared by mixing a steroid with a steroid compound, which will melt in the rectum and release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols. can be.

[0275] The pharmaceutical compositions of the present disclosure may be administered topically. Suitable topical formulations are available for each of these areas. Topical application for the lower intestinal tract may be effected by rectal suppository formulations, which are easily prepared for each area or organ. This can be achieved by administering the formulation (see above) or a suitable enema. For topical application, the pharmaceutical compositions may be administered in one or more carriers. They may also be formulated in a suitable ointment containing the active components suspended or dissolved therein. Carriers for topical administration of the compound include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propolis, Pyrene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and In certain preferred aspects of the present disclosure, the compound is surgically implanted in a patient. The drug may be coated onto a stent, thereby preventing blockage of the stent in the patient. The possibility of this occurring is prevented or reduced.

[0276] Alternatively, the pharmaceutical compositions may be suspended or dissolved in one or more pharmaceutically acceptable carriers. The active ingredient may be formulated in a suitable lotion or cream. Examples include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, ceteth-1 ... Chile Ester Wax, Cetearyl Alcohol, 2-Octyldodecanol, Benzyl Alcohol Coal and water.

[0277] For ophthalmic use, the pharmaceutical composition is a micronized suspension in isotonic, pH-adjusted, sterile saline. as a suspension or, preferably, with a preservative, such as benzylalkonium chloride It is formulated as a solution in isotonic, pH-adjusted, sterile saline, with or without Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated in an ointment, such as petrolatum. This may also be done.

[0278] The pharmaceutical compositions of the present disclosure may also be administered by nasal aerosol or inhalation. The composition is prepared according to techniques known in the pharmaceutical formulation art and administered as a solution in saline: Benzyl alcohol or other suitable preservative, absorption to improve bioavailability promoters, fluorocarbons, and / or other conventional solubilizing or dispersing agents It may be prepared by employing an agent.

[0279] Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application shall contain: Components may include: e.g., water for injection, saline solution, fixed oils, polyethylene glycols a sterile diluent such as alcohol, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methylparaben; or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid buffering agents such as acetate, citrate, or phosphate, and buffers such as sodium chloride Tonicity adjusters such as cereals or dextrose. Parenteral preparations should be prepared with glass or plastic Packaged in a custom-made ampoule, disposable syringe, or multi-dose vial. That's fine.

[0280] The specific dosage and treatment regimen for any particular patient will depend on the specific Activity of the compound, age, body weight, general health condition, sex, diet, administration time, excretion rate, drug composition The combination of the two, as well as the judgment of the treating physician and the importance of the particular disease or condition being treated It should also be understood that this will depend on a variety of factors, including the severity of the condition.

[0281] A patient or subject in need of treatment with the compounds described herein may be a patient of the pharmaceutically acceptable salt thereof. An effective amount of the compound, including an acceptable salt, solvate, or polymorph, is administered in a pharmaceutically acceptable carrier. It can be administered to a patient (subject) alone or in combination with other known agents in a suitable carrier or diluent. It can be treated by:

[0282] Coadministration Symptom conditions that may be treated using the compounds or compositions herein include, but are not limited to: Examples of cancers that may be present include, but are not limited to, cancer (e.g., prostate cancer) and Kennedy's disease. In this context, therapeutic or pharmaceutical compositions may contain additional biological or bioactive agents, e.g. , including an effective amount of a co-administered agent effective in treating cancer.

[0283] The term "co-administration" or "combination therapy" refers to the administration of at least two compounds or compositions. are administered to a patient simultaneously, thereby providing an effective amount or effective doses of each of the two or more compounds. It is intended to mean that a concentration of α- and β-actin can be present in a patient for a given period of time. Although the compounds may be co-administered to a patient at the same time, the term does not include all co-administered compounds or compositions. The two may be administered simultaneously or at different times, provided that an effective concentration of each is present in the patient at a given time. In a specific preferred embodiment of the present disclosure, the above-mentioned agents are administered simultaneously. One or more of the compounds may be administered in combination with at least one additional bioactive agent, including, in particular, an anti-cancer agent. In particularly preferred embodiments of the present disclosure, the co-administration of compounds provides therapeutic benefits, including anti-cancer treatment. This results in a synergistic treatment that

[0284] In another aspect, the present disclosure provides a method for treating a cancer, comprising administering to a patient a therapeutically effective amount of two or more of the PROTAC compounds described herein, and and a pharmaceutically acceptable carrier. In certain embodiments, the composition comprises P It further includes an effective or synergistic amount of another bioactive agent that is not a ROTAC compound.

[0285] An effective amount of at least one bifunctional compound according to the present disclosure and as otherwise described herein A combination of one or more of the compounds described in effective amounts is administered in a pharmaceutically effective amount. Pharmaceutical compositions comprising the compounds of the present invention in combination with an active ingredient, additive, or excipient represent a further aspect of the present disclosure.

[0286] The term "bioactive agent" describes an agent other than the PROTAC compounds described herein. and the compounds are used to treat, inhibit, and / or control / Used in combination with the compound as a biologically active agent to aid in the prevention of Preferred bioactive agents for use herein are those in which the compounds are used or administered. Examples of such agents include those having pharmacological activities similar to those of the administered agent, such as anti-cancer agents.

[0287] The term "additional anti-cancer agent" refers to an agent that may be administered in combination with a PROTAC compound according to the present invention to treat cancer. This is used to describe anti-cancer drugs that may be used. These drugs include, for example, everolim. everolimus, trabectedin, abraxane, TLK 2 86, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin(en zastaurin), vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, FLT-3 inhibitor, androgen receptor inhibitor, VEGFR inhibitor, EGFR TK inhibitor agents, aurora kinase inhibitors, PIK-1 inhibitors, Bcl-2 inhibitors, HDAC inhibitors, c-ME T inhibitors, PARP inhibitors, Cdk inhibitors, EGFR TK inhibitors, IGFR-TK inhibitors, anti-HGF antibodies, PI3 kinase enzyme inhibitors, AKT inhibitors, JAK / STAT inhibitors, checkpoint 1 or 2 inhibitors, focal adhesion Kinase inhibitors, Map kinase kinase (mek) inhibitors, VEGF trap antibodies, pemetrexed (pemetrexed), erlotinib, dasatinib, nilotinib nilotinib, decatanib, panitumumab, amrubicin amrubicin, oregovomab, Lep-etu, nolatrexed , azd2171, batabulin, ofatumumab, zanolimumab zanolimumab, edotecarin, tetrandrine, rubite Can (rubitecan), tesmilifene, oblimersen, Ticilimumab, ipilimumab, gossypol , Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide ), gimatecan, IL13-PE38QQR, INO 1001, IPdR1KRX-0402, lucanton (lucanthone), LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311 , romidepsin, ADS-100380, sunitinib, 5-fluorouracil fluorouracil, vorinostat, etoposide, Gemcitabine, doxorubicin, liposomal doxorubicin liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine (v incristine, temozolomide, ZK-304709, seliciclib ), PD0325901, AZD-6244, capecitabine, L-glutamic acid, N-[4-[2-( 2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzyl [zoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled iridium Notecan (irinotecan), tamoxifen (tamoxifen), toremifene citrate (tor emifene citrate, anastrazole, exemestane , letrozole, DES (diethylstilbestrol )), estradiol, estrogen, conjugated estrogens bevacizumab, IMC-1C11, CHIR-258; 3-[5-(methylsulfonylpiperidine) (radicalmethyl)-indolyl-quinolone, vatalanib, AG-013736, AVE-0005 , [D- Ser(Bu t ) 6 ,Azgly 10 ] (Pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t )-Leu-Arg-Pr o-Azgly-NH2 Acetate [C 59 H 84 N 18 Oi4-(C2H4O2) X , where x = 1 to 2.4] acetate, Gosserely goserelin acetate, leuprolide acetate, triptorelin medroxyprogesterone pamoate, medroxyprogesterone acetate, hydroxyprogesterone Cyprogesterone caprylate, megestrol acetate, raloxifene (raloxifene), bicalutamide, flutamide, nilutamide Nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272 , erlotinib, lapatinib, canertinib , ABX-EGF antibody, Erbitux, EKB-569, PKI-166, GW-572016, Lonafa Ionafarnib, BMS-214662, tipifarnib, amifostine ( amifostine), NVP-LAQ824, suberoyl analide hydroxamic acid roximic acid), valproic acid, trichostatin A, FK-228, SU11248, sorafenib fenib), KRN951, aminoglutethimide, arunsacrine crine), anagrelide, L-asparaginase, bacillus Calmette-Guerin BCG vaccine, adriamycin, bleomycin, buce Buserelin, busulfan, carboplatin, Carmustine, chlorambucil, cisplatin n), cladribine, clodronate, cyproterone roterone, cytarabine, dacarbazine, dactinomycin Dactinomycin, daunorubicin, diethylstilbestrol (diethylstilbestrol), epirubicin, fludarabine , fludrocortisone, fluoxymesterone , flutamide, Gleevec, gemcitabine, Hydroxyurea, idarubicin, ifosfamide amide), imatinib, leuprolide, levamisole isole, lomustine, mechlorethamine, melfala Melphalan, 6-mercaptopurine, mesna, methotrexate methotrexate, mitomycin, mitotane, Mitoxantrone, nilutamide, octreotide eotide, oxaliplatin, pamidronate, pentoxin Statins (pentostatin), plicamycin, porfimer , procarbazine, raltitrexed, rituximab (rituximab), streptozocin, teniposide, tes Testosterone, thalidomide, thioguanine ne), thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard alanine mustard, uracil mustard, estramustine mustine, altretamine, floxuridine, 5-de Oxyuridine (5-deooxyuridine), cytosine arabinoside, 6-mecaptopurine (6-mec aptopurine, deoxycoformycin, calcitriol triol), valrubicin, mithramycin, vinblastine vinblastine, vinorelbine, topotecan, razoxin Razoxin, marimastat, COL-3, neovastat ), BMS-275291, squalamine, endostatin, SU5416 , SU6668, EMD121974, interleukin-12, IM862, angiostatin , vitaxin, droloxifene, idoxifene ene), spironolactone, finasteride, simici Cimitidine, trastuzumab, denileukin diftitox Ileukin diftitox, gefitinib, bortezimib, Parkinson disease Paclitaxel, cremophor-free paclitaxel litaxel), docetaxel, epothilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen oxytamoxifen), pipendoxifene, ERA-923, arzoxifene arzoxifene, fulvestrant, acolbifene, la Lasofoxifene, Idoxifene, TSE-424, HMR-3339 , ZK186619, topotecan, PTK787 / ZK222584, VX-745, PD184352, rapamycin rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus rolimu), AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293 684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgra Filgrastim, darbepoetin, erythropoietin, granulocyte colony Ronnie's stimulator, zoledronate, prednisone, cetethone Cetuximab, granulocyte-macrophage colony-stimulating factor, histrelin elin), pegylated interferon alfa-2a, interferon alfa-2a, pegylated interferon Interferon alfa-2b, interferon alfa-2b, azacitidine e), PEG-L-asparaginase, lenalidomide, gemtuzumab mab), hydrocortisone, interleukin-11, dexrazoxane (dexrazoxane), alemtuzumab, all-trans retinoic acid (all- transretinoic acid, ketoconazole, interleukin-2, Megnesium megestrol, immunoglobulin, nitrogen mustard d), methylprednisolone, ibritumomab tiuxetan (ibr itgumomab tiuxetan, androgen, decitabine, hexamethylmelamine hexamethylmelamine, bexarotene, tositumomab ), arsenic trioxide, cortisone, etidronate, mitotane, Cyclosporine, liposomal daunorubicin ), Edwina-asparaginase, Strontium-89, Cassopi Casopitant, netupitant, NK-1 receptor antagonist, palonosetro palonosetron, aprepitant, diphenhydramine amine), hydroxyzine, metoclopramide, Lora Lorazepam, alprazolam, haloperidol , droperidol, dronabinol, dexamethasone xamethasone, methylprednisolone, prochlorperazine (p rochlorperazine, granisetron, ondansetron ), dolasetron, tropisetron, pegfilgras pegfilgrastim, erythropoietin, epoetin alfa (e poetin alfa, darbepoetin alfa, and mixtures thereof Examples include:

[0288] Treatment method In another aspect, the present disclosure provides a method for detecting a cellular component of a cell in a subject, e.g., a cell, tissue, mammal, or human patient. A method for regulating protein ubiquitination and degradation is provided, the method comprising: , an effective amount of a PROTAC compound described herein, or an effective amount of such a compound. administering a composition to a subject, wherein the compound or a composition comprising the compound The compound is effective in modulating protein ubiquitination and protein degradation in the subject. In certain embodiments, the protein is the androgen receptor (AR).

[0289] In certain embodiments, the present disclosure provides a method for administering to a patient an amount of a compound described herein. androgen receptor protein activity in patients in need thereof, including administering This provides a way to

[0290] In yet additional embodiments, the present disclosure provides a method of treating a symptom or condition in a patient. wherein deregulated protein activity is associated with the symptom or condition. and the method comprises administering to the patient an effective amount of a compound described herein. and regulating the activity of the protein in the patient. In the example, the protein is AR.

[0291] As used herein, "treat," "treating," and "treatment" The term refers to any action that benefits a patient and for which the compound The compounds may be administered to treat any condition or condition that is modulated via the protein to which they bind. Symptoms or conditions that can be treated using compounds according to the present disclosure, including cancer. is described herein above.

[0292] In another aspect, the present disclosure provides a method for detecting a cellular component of a cell in a subject, e.g., a cell, tissue, mammal, or human patient. A method for regulating ubiquitination and degradation of AR proteins is provided. is an effective amount of a compound described herein, or wherein the compound or a composition comprising the compound is administered to a subject. The composition is effective in modulating AR protein ubiquitination and proteolysis in the subject. be.

[0293] In another aspect, the present disclosure provides a method for detecting a cellular component of a cell in a subject, e.g., a cell, tissue, mammal, or human patient. A method for treating or ameliorating symptoms of a disease associated with AR activity is provided, The present invention relates to a method for treating a rheumatoid arthritis, and a method for treating a rheumatoid arthritis, comprising administering an effective amount of a compound described herein or a composition containing an effective amount of the compound to a patient. wherein the compound, or a composition comprising the compound, is administered to a subject in need thereof. The composition is effective in treating or ameliorating symptoms of a disorder associated with AR activity in the subject.

[0294] In certain embodiments, the disease or disorder is asthma, multiple sclerosis, cancer, prostate cancer, Kennedy's disease, or a combination of these. Diseases, ciliopathies, cleft palate, diabetes, heart disease, high blood pressure, inflammatory bowel disease, mental retardation, mood disorders Disability, obesity, refractive errors, infertility, Angelman syndrome, Canavan syndrome, celiac disease, Charcoal-Marie-Tooth disease, cystic fibrosis, Duchenne muscular dystrophy, hemochromatosis , hemophilia, Klinefelter's syndrome, neurofibromatosis, phenylketonuria, polycystic ulcers Kidney, (PKD1) or 4(PDK2) Prader-Willi syndrome, sickle cell disease, Tay-Sachs disease and Turner syndrome. The cancers include squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinoma, and renal cell carcinoma, bladder cancer, intestinal cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, head cancer, kidney cancer, liver cancer, lung cancer Cancer, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer and gastric cancer; leukemia; benign and malignant lymphoma, especially Burkitt's lymphoma and non-Hodgkin's lymphoma; benign and malignant melanoma; bone marrow Proliferative diseases; Ewing's sarcoma, angiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcoma, peripheral neuroma, Synovial sarcoma, glioma, astrocytoma, oligodendroglioma, ependymoma, glioblastoma, neuroblastoma, Ganglioneuroma, ganglioglioma, medulloblastoma, pineal cell tumor, meningioma, meningeal sarcoma, nerve fiber tumor sarcomas, including schwannomas and neurilemmomas; colorectal cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer Neoplasms, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma carcinosarcoma, Hodgkin's disease, Wilms' tumor, or teratocarcinoma. In certain embodiments, the treatment The disease of interest is cancer, e.g., prostate cancer, or Kennedy's disease. The subject is a human.

[0295] In another aspect, the present disclosure provides a method for detecting a cellular component of a cell in a subject, e.g., a cell, tissue, mammal, or human patient. A method for treating or ameliorating symptoms of a disease associated with AR activity is provided, an effective amount of a compound described herein, or a composition comprising an effective amount of said compound; administering to a subject in need thereof an effective or synergistic amount of another bioactive agent; wherein a composition comprising the compound is used to treat symptoms of a disease associated with AR activity in the subject. In certain embodiments, the disease being treated is cancer, e.g., prostate cancer. or Kennedy's disease. In a preferred embodiment, the subject is a human. In an additional embodiment, the additional bioactive agent is an anti-cancer agent.

[0296] In another aspect, the present disclosure provides a method for treating a condition by degrading a protein or polypeptide. and a method of treating a subject with a steroid hormone via the protein or polypeptide. The symptom or condition is modulated, and the method comprises administering to the patient or subject at least one of the above-described and optionally administering an effective amount of another compound, and optionally an additional bioactive agent. The disclosed methods are used to administer an effective amount of at least one compound described herein. By doing so, many symptoms or conditions can be treated, including cancer.

[0297] In another aspect, the present disclosure provides a method for treating a disease in a biological system using a compound according to the present disclosure. A method for identifying the degradative effects of morphine proteins is provided.

[0298] kit In another aspect, the present disclosure provides kits comprising the compounds or compositions described herein. Kits may be advertised, distributed, or sold as a unit for performing the disclosed methods. Additionally, kits of the present disclosure preferably include instructions for proper use. Such kits may be used, for example, in clinical settings, e.g., to treat cancer, Patients presenting with conditions such as prostate cancer or Kennedy's disease can be treated. [Example]

[0299] Overall Chemistry - Analysis and Synthesis Unless otherwise stated, all materials / reagents were obtained from commercial suppliers and used without further purification. The reactions were monitored by LC-MS and / or by pre-covering the reaction mixture in aluminum foil or Glass-reinforced silica gel 60F 254 by thin layer chromatography (TLC) on a 0.2 mm The chromatographic analysis was monitored by flash chromatography (also known as "flash chromatography") and visualized with UV light. ISCO chromatography (also known as "ISCO chromatography") was performed using RediSep normal phase silica gel cartridges. Preparative TLC was performed using an ISCO CombiFiash RF 75 PSI or equivalent equipped with a A 20x20cm plate of Whatman LK6F Silica Gel 60A, 1000µm thick, or equivalent So I went.

[0300] 1 HNMR (300 or 400 MHz), and 13CNMR (100.6 MHz) spectra were obtained at room temperature. Recorded on a Bruker spectrometer using TMS or residual solvent peak as standard. The position or overlap is given by (δ), and the coupling constant (J) is given as an absolute value in Hertz (Hz). Multiplicities in 1H NMR spectra are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br or broad.

[0301] Preparative HPLC purification is performed using the 2545 Binary Gradient Module, 2767 Sample Manager, and 2489 Waters equipped with a UV / Visible Detector (登録商標) On UV-Directed Purification System The following columns were used for all the experiments: The purification work was completed using: Atlantis Prep T3 OBD column, SunFire Prep C18 OBD column, and an XBridge Prep Phenyl OBD column. The mobile phase was water (with 0.1% TFA or 0.01% NH4HCO3). The reagents used were HPLC grade. The flow rate was 30 ml / min. After the column, a 1:1000 LC packing flow splitter was used. A small portion of the eluent was transferred to the UV detector. The electrospray source was capillary-coupled at 3.0 kV. -voltage, 30 V cone voltage, 110 °C source temperature, 350 °C desolvation temperature, 600 L / h desolvation The analyzer was set at 1000 kJ / h for the saturation gas flow and 60 L / h for the cone gas flow. The magnification was set to 550 for the preparative method.

[0302] Analytical LC-MS data were obtained from 0.05% TFA in acetonitrile (A) and 0.05% TFA in HPLC gray water (B). 0.1% FA in acetonitrile (A) and 0.1% FA in HPLC-grade water (B) ); mobile phase of acetonitrile (A) and 5 mM ammonium bicarbonate in HPLC-grade water (B) and collected on a Shimadzu LCMS-2020.

[0303] The Shimadzu LCMS-2020 is equipped with an LC-20AD or 30AD pump, an SPD-M20A PDA, and an Alltech 3 Equipped with a 300 ELSD, the system was configured for runs of 2.0, 2.6, 3, 3.6, 5, or 5.6 minutes. The following conditions are used for the times:

[0304] 2.0 min run: Kinetex XB-C 18 100A column, 2.6 μm, 3.0 × 50 mm. Flow rate: 1.5 mL / min. The run time was 2.0 min, and the gradient profile was 0.01 min 10% A, 1.10 min 100% A, and 1.60 min 100% A. , 1.70 min 10% A, 2.00 min 10% A.

[0305] 2.6 min run: Shim-pack VP-ODS column, 2.2 μm, 3.0 × 50 mm. Flow rate: 1.5 mL / min. The time was 2.6 min, and the gradient profile was 0.01 min 5% A, 1.20 min 100% A, 2.20 min 100% A, 2.30 min 5%A, 2.60 min 5%A.

[0306] 3.0 min run: ACE UlTracore SuperC18 column, 2.5 μm, 3.0 x 50 mm. Flow rate: 1.5 mL / min , runtime 3.0 min, gradient profile 0.01 min 10% A, 2.00 min 95% A, 2.60 min 95% A , 2.70 min 10% A, 3.00 min 10% A.

[0307] 3.6 min run: Shim-pack VP-ODS column, 2.2 μm, 3.0 × 50 mm. Flow rate: 1.5 mL / min. The time was 3.6 min, and the gradient profile was 0.01 min 5% A, 2.20 min 100% A, 3.20 min 100% A, 3.30 min 5% A, 3.60 min 5% A.

[0308] 5.0 min run: ACE UlTracore SuperC18 column, 2.5 μm, 3.0 x 50 mm. Flow rate: 1.5 mL / min , runtime 5.0 min, gradient profile 0.01 min 10% A, 4.00 min 60% A, 4.70 min 60% A, 4.80 min 10% A, 5.00 min 10% A.

[0309] 5.6 min run: Shim-pack VP-ODS column, 2.2 μm, 3.0 × 50 mm. Flow rate: 1.5 mL / min. The time was 5.6 min, and the gradient profile was 0.01 min 5% A, 3.00 min 50% A, 5.00 min 50% A, 5.20 min 5% A, 5.60 min 5% A.

[0310] or Analytical LC-MS data were obtained using an Agilent infinity 1260 LC and an Agilent 6230 TOF mass spectrometer. The analysis was carried out at 45°C on a Poroshell 120 EC C18 column (50 mm x 3.0 mm internal The diameter is 2.7 μm (packing diameter). The solvents employed were: A = 0.1% v / v formic acid in water. B = 0.1% v / v formic acid in acetonitrile. The gradient used is:

[0311] [Table 1]

[0312] UV detection was the average signal from wavelengths of 210 nm to 350 nm, and mass spectra were obtained from positive models. The ions are recorded on a mass spectrometer using electrospray ionization of the ion beam.

[0313] Unless otherwise stated, all compounds were prepared with LC-MS purity >95%. chemical synthesis A PROTAC of ABM-L-ULM, or a pharmaceutically acceptable salt, polymorph, or prodrug thereof; Solvated, isotope-containing derivatives can be prepared using the general methods described below (Scheme 1 and and 2, and general schemes 1–122, 1A–22A, and 1B–25B) have been published in the field of organic chemistry. They may be prepared using known synthetic methods, as well as modification and derivatization methods known to those skilled in the art.

[0314] Scheme 1:

[0315] [ka]

[0316] Scheme 2:

[0317] [ka]

[0318] General Scheme 1:

[0319] [ka]

[0320] General Scheme 2:

[0321] [ka]

[0322] General Scheme 3:

[0323] [ka]

[0324] General Scheme 4:

[0325] [ka]

[0326] General Scheme 5:

[0327] [ka] 【0328...

Claims

1. 【Fig. 1】 A compound represented by the formula:

2. 【Fig. 2】 A pharma- ceutically acceptable salt of a compound represented by the formula:

3. A pharmaceutical composition comprising the compound of claim 1 and a pharma- ceutically acceptable carrier.

4. A pharmaceutical composition comprising a pharma- ceutically acceptable salt of the compound of claim 2 and a pharma- ceutically acceptable carrier.

Citation Information

Patent Citations

  • Androgen Receptor Modulating Compounds

    JP2013508447A

  • Androgen Receptor Modulated Carboxamide

    JP2014511895A

  • JPP6972210B

  • JPP7009466B

  • JPP7178532B

Cited By

  • Compounds and methods for targeted degradation of androgen receptor

    JP2025026916A